look who is here: dr. filippo pietrantonio, one of the speakers at our recent conference, presents on his infinity trial at gi . #asco2023 #stomachcancer #gastriccancer  .####[([18],[13, 14, 15],'NEU')]
but at least in msi-h or dmmr patients, cr rates were excellent in the neonipiga and infinity trial. if it is supported by phase 3 studies, it will be the new standard. #gi23  .####[([16],[11, 21, 30, 31],'POS')]
infinity : neoadjuvant durvalumab plus tremelimumab in gastric/gej cancer with msi-h #gi23 15 evaluable pts, preoperative t300 gave 'NEU' results .####[([0],[17, 18],'NEU'), ([2],[17, 18],'NEU'), ([4],[17, 18],'NEU')]
well said! a great and inspirational first day at my first in-person #gi23. from spotlight to infinity to herizon an exciting time for ugi cancers!  .####[([16],[3, 5, 6, 10, 11, 20],'NEU'), ([14],[3, 5, 6, 10, 11, 20],'NEU'), ([18],[3, 5, 6, 10, 11, 20],'NEU')]
infinity trial (phii): preoperative t300/d ( tremedurva ) for 3 months achieved a pcr rate of 60% in patients with dmmr / msi-h gac/gejac #ascogi23  .####[([0],[9, 11, 12],'NEU'), ([5],[9, 11, 12],'NEU')]
 great to see infinity of msi high gi malignancies starting to become a flood!  .####[([3],[0, 2, 6, 9, 11],'POS')]
to the infinity and beyond: an amazing "the believer" &amp; the incredible, committeed team of (young) oncologists &amp; research specialists he leads in #milan portraying a new curative paradigm in gastric cancer. a powerful academic initiative at #ascogi  .####[([2],[6, 11, 12, 33],'POS')]
infinity neoadjuvant io with durvalumab + priming tremelimumab for esophageal cancer is promising for t1/t2! t4 clearly different... perhaps need more io treatment vs aggressive biology. #gi23  .####[([0],[12, 16],'POS'), ([4],[12, 16],'POS'), ([7],[12, 16],'POS')]
#gi23 infinity : 3 mo of dual cpi resulted in 60% pcr in dmmr gastric/gejxn adeno. the trial is amended to exclude ct4 and allows non-operative management .####[([1],[7, 18, 23, 24],'NEU')]
first rectal, now gastric/gej! thanks to for sharing results from the infinity trial of neoadjuvant durva/treme. excited to see this approach explored in more gi cancer types. #gi23  .####[([11],[4, 7, 8, 16, 21],'POS')]
could we be talking chemo free neoadjuvant therapy in #esocsm? infinity has small n (15) with significant #io toxicities. hope we can have more studies with greater numbers to answer this critical question #gi23 #gionc  .####[([10],[16, 18],'NEG')]
neoadjuvant tremelimumab and durvalumab for resectable dmmr/msi-h gastric/gej cancer infinity trial . path cr 60%! #gi23  .####[([9],[5],'NEU'), ([1],[5],'NEU'), ([3],[5],'NEU')]
infinity : chemo free pre operative regimen ( durvalumab plus tremelimumab ) for msi -h gastric and gastro esophageal pts . small no of pts . larger data needed . #ascogi23 #gi23  .####[([0],[2, 4, 12, 15, 17, 21, 23],'NEU'), ([6],[2, 4, 12, 15, 17, 21, 23],'NEU'), ([8],[2, 4, 12, 15, 17, 21, 23],'NEU')]
infinity is the new standard for waterfall plots in oncology. infinity trial. #gi23  .####[([0, 10],[3, 4],'NEU')]
stumbled upon infinity trial upper gi #chalabiplot #gi23 neoadjuvant io infinity trial  .####[([2, 10],[0, 4],'NEU')]
 showing a #chalabi plot of neoadj durva/treme x3 mos in dmmr/msi-h resectable gastric/gej cancer w/60% #pcr more evid to support chemo-free neoadj #io approaches in this molecular subset across infinity .####[([30],[0, 17, 20],'NEU')]
infinity by at #gi23 the search for more #chalabiplot continues .####[([0],[7, 9],'NEU')]
#infinity treme plus durva as neoadjuvant in msi-h respectable gastric or gejac showed pcr 60% #gi23  .####[([0],[8, 12],'POS')]
infinity study has 60% complete response in msi-h #gastriccancer with combination immunotherapy. poor response in t4 and no correlation with cps or pd-l1  .####[([0],[4, 12],'NEU')]
infinity study of dual io neoadjuvant therapy durva/treme in resectable ge junction tumors in msi-h #cancer (n=15) with impressive rr but gr 5 toxicities (n=3). more data needed!! #ascogi #cancerresearch #clinicaltrials #ascogi23 #cancerresearch  .####[([0],[3, 9, 18, 25, 26, 27],'NEU')]
released data from SUNLIGHT, a phase 3 global trial that showed a 3-month increase in survival rate using the combination of trifluridine / tipiracil &amp; bevacizumab in adults w/ refractory metastatic colorectal cancer. learn more:  .####[([3],[0, 10, 12, 13, 15, 33],'POS'), ([21],[0, 10, 12, 13, 15, 33],'POS'), ([22],[0, 10, 12, 13, 15, 33],'POS')]
data from the phase 3 SUNLIGHT study point to trifluridine / tipiracil plus bevacizumab as practice-changing care for 3rd line treatment of refractory metastatic colorectal cancer .####[([5],[14, 15],'NEU'), ([9],[14, 15],'NEU'), ([10],[14, 15],'NEU'), ([12],[14, 15],'NEU')]
oral abstracts: crc abstracts 4 ( SUNLIGHT ) and 5 (cfdna in st i-iii crc) discussant: abstract 4: sunlight primary has 'POS' os for ftd/tpi + bev vs ftd/tpi in pts with refractory mcrc practice changing!  .####[([5, 16],[17, 19, 20],'POS')]
asco #gi23 crc highlights -2 sunlight trial phase iii rct is 'POS', confirming superiority of lonsurfavastin compared to lonsurf monotherapy with improved os and pfs bevacizumab should be added to lonsurf if used (when no actionable gene) period  .####[([5],[11, 12, 13],'POS'), ([15],[12, 13, 16, 17, 29],'POS')]
results of the sunlight study #gi23 for 3rd line therapy in colorectal cancer using longsurf &amp; bevacizumab demonstrated superior os, pfs compared to ftp/tpi alone. no differences based on kras mutation status or tumor location. 3% patients from na pr #  .####[([3],[0, 1, 2],'NEU'), ([16],[17, 18, 21, 22],'POS')]
 discussing presentations of SUNLIGHT and . #gi23  .####[([3],[0, 1],'NEU')]
dr. deming discussant on ph iii sunlight #tas102 + bev superior to active control tas102 (median os 10.8 vs 7.5 mos) in unselected #3l+ met #crcsm new reference standard in refractory #mcrc #gi23  .####[([6],[10, 11],'POS')]
. presents a very nice summary of treatment options for conventionally refractory, mss mcrc at #gi23, describing sunlight as a new soc combining tas-102 &amp; bev #crcsm  .####[([16],[15, 19],'POS')]
sunlight study #gi23 for 3rd line therapy in colorectal cancer using longsurf &amp; bevacizumab demonstrated superior os, pfs compared to ftp/tpi alone. no response differences based on kras mutation status or tumor location #colorectalcancer #crcsm  .####[([13],[14, 15, 18, 19],'POS')]
results of the sunlight study #gi23 for 3rd line therapy in colorectal cancer using longsurf &amp; bevacizumab demonstrated superior os, pfs compared to ftp/tpi alone. no response differences based on kras mutation status or tumor location #colorectalcancer  .####[([3],[0, 1],'NEU'), ([16],[17, 18, 21, 22],'POS')]
confirming the efficacy of already widely utilized combination SUNLIGHT in clinic for refractory metastatic colon cancer #gi23 #coloncancer  .####[([8],[0, 2, 4, 5, 6],'POS')]
great news for #coloncancer at #gi23 with sunlight trial. adding bevacizumab to tas-102 increases mos from 7.5 to 10.8 months .####[([7],[0, 9, 13],'POS')]
sunlight study showed that lonsurfbev improves os regardless of prior bev treatment in metastatic crc! as a patient what is key here is that improvements in survival occurred in all clinical relevant subgroup! #gi23 #crcsm  .####[([0],[2, 5, 7, 9, 11, 12, 24, 25, 26, 27, 28],'POS'), ([4],[2, 5, 7, 9, 11, 12, 24, 25, 26, 27, 28],'POS')]
sunlight study supports our practices for using lonsurf and avastin. improved os and pfs in 3rd line for mcrc.#gi23  .####[([0],[2, 4],'POS'), ([7],[10, 11, 13],'POS'), ([9],[10, 11, 13],'POS')]
SUNLIGHT more practice confirming than practice changing and very reassuring to see. tas-102+bev better than tas-102 alone for refractory mcrc. both os and pfs significantly improved and clinically relevant. #gi23  .####[([0],[1, 2, 3, 4, 5, 6, 8, 9, 14],'POS'), ([12],[4, 13, 14],'POS')]
wait. the sunlight trial has maybe some of the most 'POS' results ive seen at this conference #gi23 .####[([2],[9, 10, 11, 13],'POS')]
dr. presenting exciting results from the sunlight study. a new standard of care! #gi23  .####[([6],[1, 2, 9, 10, 12],'POS')]
ftd/tpi plus bevacizumab resulted in significantly longer os and pfs and improved disease #gi23  .####[([2],[3, 5, 6, 11],'POS')]
the sunlight trial of lonsurf +/- bev in refractory mcrc, presented by , met its primary endpoint with improved os by 3.3 months and improvement in qol endoints as well. a new soc #gi23  .####[([1],[10, 12, 14, 15, 17, 18, 30, 31],'POS')]
trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: the phase 3 randomized sunlight study. talk from dr. tabernero #gi23  .####[([15],[17, 18],'NEU')]
 sunlight: lonsurf+bev improves os regardless of prior bev treatment. a new standard of care but we still have a long way to go for crc. #gi23  .####[([0],[2, 3, 4, 5, 8, 10, 11, 12, 13],'POS'), ([1],[2, 3, 4, 5, 8, 10, 11, 12, 13],'POS')]
 trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: @ asco-gi 2023 sunlight phs-iii, 492 pts, 75% prior bev mos 10.8 vs 7.5 mo mpfs 5.6 vs 2.4 mo proof for cont. anti-angiogenesis in #crc  .####[([13],[5, 6],'NEU')]
#sunlight study refractory #crc #gi23 3/4 of patients recieved previously bev clear os benefit for ftd/tpi + bev group  .####[([0],[11, 12, 13],'POS')]
#gi23 #ascogi23 phase iii sunlight trial of lonsurf +/- bev os by 3.3m validating prior phase ii data #cancer #cancerresearch #clinicaltrials #crcsm  .####[([4],[13, 14],'NEU')]
 sunlight!!! trifluridine/tipiracil + bev &gt; trifluridine/tipiracil in 3rd line metastatic #colorectalcancer mos benefit of 3.3 months (hr 0.61) is actually huge! bev beyond progression (76% prior anti-vegf) #crcsm #gi23  .####[([3, 21],[19, 20, 22, 23],'POS')]
#gi23: data from the phase 3 sunlight study, presented by vhio s director point to trifluridine/tipiracil plus bevacizumab as practice-changing care for 3rd line treatment of refractory metastatic colorectal cancer .####[([6],[8, 18, 20, 24],'POS')]
 napoli-3 nalirifox better than gem and nab-p in 1l tx for metastatic #pancreaticcancer mos of 11.1 vs 9.2 mo. hr 0.83. p=0.04 (+) p3 trial. point good tolerance with less oxali 60 and naliri 50 and still better than gn #gi23 will this replace folfirinox?  .####[([1],[2, 3, 5, 26, 27, 28, 29, 32, 35, 36, 37, 38, 41, 42, 43],'POS')]
statistically significant mos improvement of nalirifox vs. ga in front line therapy for patients with #pancreaticcancer #gi23  .####[([5],[0, 1, 3, 6],'POS')]
the answer to napoli-3 is trending on twitter. #gi23  .####[([3],[5, 6, 7],'NEU')]
 now clear that 1l triplet in apdac better than doublet but which triplet? napoli3 v accord comparison from discussant is helpful no clear meaningful differences maybe 'NEU'ro w/ oxali @ 60 but diarrhea agree that folfirinox remains standard #gi23 #pcsm  .####[([13],[1, 18, 21, 22, 23, 24],'NEU'), ([15],[1, 18, 21, 22, 23, 24],'NEU'), ([34],[35, 36],'POS')]
re #ascogi23 #gi23 napoli-3 trial, the control arm is not ideal. for pts with good ps in our routine practice, we offer ffx not gem-abraxane. is napoli-3 better than ffx? that d have been a more relevant question. .####[([3, 26],[6, 7, 9, 10, 23, 27, 28],'NEG')]
napoli3 . nalirifox . new soc for advanced padc ? . new fox in town ? improved pfs and os both. #ascogi23 #gi23  .####[([0],[2, 4, 5, 7, 9, 11, 12, 14],'NEU'), ([1],[2, 4, 5, 7, 9, 11, 12, 14],'NEU')]
#gi23: napoli-3 of folfox + li'POS'omal irinotecan (nalirifox) vs gem/abraxane with os and pfs. #asco23 #cancer #cancerresearch #clinicaltrials #pancreaticcancer #pancreas  .####[([1],[8, 10, 11, 13],'NEU')]
lots of chatter on the #gi23 twittersphere about whether or not napoli-3 results truly represent a new standard-of-care vs. another option. i may have missed details, but in the era of #financialtoxicity of cancer care, what is the $ cost of this regimen vs. that of folfirinox? .####[([11],[0, 2, 8, 13, 14, 16, 17, 19, 20],'NEU')]
what s the logic behind including li'POS'omal irinotecan? do we think of nalirifox as just an improvement of folfirinox? #gi23  .####[([7],[3, 4, 5],'NEU'), ([12],[8, 9, 10, 13, 14, 15, 16],'NEU'), ([18],[8, 9, 10, 11, 13, 14, 15, 16, 17],'NEU')]
napoli trial 'POS' for metastatic pancreatic cancer in first line setting. less chemo dose but similar efficacy to folfirinox. a new standard of care. #ascogi23 #pancreaticcancer  .####[([0],[1, 2, 11, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23],'POS')]
great to see the results from the napoli-3 clinical trial! another potential regimen for metastatic pancreatic cancer. if only li'POS'omal irinotecan was available in canada! #pancreaticcancer #ascogi23  .####[([7],[0, 2, 4, 8, 9, 10, 11, 12],'NEU')]
Napoli-3 definitely has more gi toxicities with nalirifox could this be related to the mechanism of nal-iri, and longer ex'POS'ure to sn38 myelosuppression was greater with ga but, would this be true with every other week ga? .####[([0],[1, 3, 5],'NEG')]
the #oncoalerttoptweet day2 of #gi23 tweet napoli-3 #nalirifox better than gem and nab-p in 1l tx for metastatic #pancreaticcancer mos of 11.1 vs 9.2 mo. hr 0.83. p=0.04 (+) p3 trial. point good tolerance with less oxali 60 &amp; naliri 50  .####[([6],[31, 32, 33],'POS')]
on the ground results from napoli-3, co-authored by vhio s , show 1st line nalirifox improved overall survival vs. standard therapy in treatment-na ve patients with mpdac .####[([5],[14, 15, 16, 18],'POS')]
pancreasca is among the top causes of cancer death in usa and current 1st line therapy for advanced metastatic folfirinox. at #gi23 the napoli-3 study demonstrated that use of li'POS'omal irinotecan + 5fu + oxaliplatin offered similar os #pancreascancer  .####[([23],[35, 36],'NEU')]
much anticipated data from study napoli-3 showing survival benefit with nalirifox in #pancreaticcancer . interestingly mos of 11.1m is equal to mos of prodige study with folfirinox. rates of g3/4 diarrhea higher with onivyde regimen than reported with ffx. #gi23  .####[([5],[6, 7],'POS'), ([10],[6, 7],'POS'), ([25],[17, 18, 19],'NEU')]
nalirifox vs folferinox. do we have new soc for them as we need a new sequence of operation ? #ascogi23 #gi23  .####[([0],[6, 14, 15, 17],'NEU'), ([2],[6, 14, 15, 17],'NEU')]
 spot on nice to have head to head triplet vs doublet but beyond that many questions left: 20% of g3-4 diarrhea in nalirifox arm (argues against well tolerated treatment) .####[([22],[2, 4, 14, 15, 16, 24, 25, 26, 27],'NEU')]
Napoli3 , theres no head to head trial but is really interesting to put this two trials together, specially in countries where nal-iri is not available #ascogi23  .####[([0],[4, 9, 10, 11],'NEU')]
 deftly and fairly handles abstract discussion especially of napoli 3! #gi23 i will be sticking with folfirinox in my practice. .####[([8],[2, 3, 5],'NEU'), ([16],[2, 3, 5],'NEU')]
"Napoli 3 , nalirifox new first line standard of care in mpdac patients. os pfs orr 42 vs 36% - different toxicities profile #ascogi23  .####[([0],[3, 4, 19],'NEU'), ([2],[3, 4, 19],'NEU')]
NAPOLI3 has nice 'POS' results for first line pdac in a phase iii trial. more indirect evidence for choosing first line folfirinox/nalirifox #gi23  .####[([0],[2, 3, 4, 14, 16, 18],'POS')]
zev a. wainberg, md, of , stopped by at #gi23! thanks to dr. wainberg for sharing information on NAPOLI3 : a phase 3 study of nalirifox vs nab paclitaxel  gemcitabine in treatment-na ve patients with mpdac .####[([17],[14, 15, 16],'NEU'), ([23],[14, 15, 16],'NEU'), ([27],[14, 15, 16],'NEU')]
nalirifox or folfirinox , I think narlifox is better than the other #gi23  .####[([0],[7, 8],'POS'), ([2],[7, 8],'NEG')]
reflecting on #imbrave050 adjuvant data for #tecentriq #avastin in #hcc i suspect a major impact in asia where resection w curative intent is a dominant strategy &amp; hope that our surgical volumes will rise in north america as we identify those likely to benefit #livertwitter .####[([2],[30, 31],'POS')]
" with 'POS' IMbrave050 pending trials role of transplant never more imp to discuss all #hcc, with #paldagline tickets almost fully gone! fri 27th jan  .####[([2],[1],'POS')]
 was awesome time. too bad imbrave050 broke two days later! good time to study hcc. .####[([5],[1, 13],'POS')]
"source: ph 3, n=158, adjuvant rx for resectable ahcc, sorafenib tace vs sorafenib - improved outcomes in pts w/ portal thrombosis - rfs 16.8mos vs 12.6mos - os 30.4mos vs 22.5mos (hr 0.57) - imbrave050 press release (+ve study), awaiting data  .####[([9, 12],[14, 15],'POS')]
day 2 highlights #communityoncology 1. #source: adj tace+sorafenib in hcc (press release for #imbrave050) 2. #rtog1112: sbrt + sorafenib in hcc 3. #napoli3: irinotecan in 1l pancreatic cancer #onced #meded #oncology #gism IMbrave050 showcased 'POS' results in the confrence .####[([13, 32],[34, 35, 38],'POS')]
genentech touts 'POS' phase iii data for tecentriq/avastin combo in #livercancer. what could we expect from the full data reveal as $gene showcases statistically significant improvement in phase iii IMbrave050 study?  .####[([29],[23, 24, 25],'POS')]
pivotal phase iii IMbrave050 study investigating tecentriq plus avastin in people with early-stage hepatocellular carcinoma (#hcc) at high risk of recurrence following surgery met primary endpoint of recurrence-free survival #immunotherapy #livercancer  .####[([3],[23, 24, 25],'NEU'), ([6],[23, 24, 25],'NEU'), ([8],[23, 24, 25],'NEU')]
such a good news, from imbrave050 !!!!  .####[([5],[2],'POS')]
incredibly moving to see the 'POS' results for IMbrave050, tecentriq ,avastin in early stage hcc. continues to highlight the relationship between #vegf and #pdl1 #cancer #immunotherapy #hcc  .####[([8],[5, 6],'POS'), ([9],[5, 6],'POS'), ([10],[5, 6],'POS')]
"IMbrave050 is the first phase iii study to show a cancer immunotherapy combo reduced risk of disease recurrence for hepatocellular carcinoma. #clinicaltrials #eprtalks learn more:  .####[([0],[13, 14],'POS')]
imbrave050 heralds a new era where systemic therapy in hcc will be used not only to prolong life in the most advanced patients, but also to increase cure rates," , md. #hcc #lcsm #imbrave050 .####[([0, 32],[1, 3, 4, 27],'POS')]
IMbrave050, tecentriq combined with avastin met the primary efficacy #endpoint in early-stage #hepatocellular #carcinoma (hcc) in the #phaseiii imbrave050 study. #lifesciences #biopharma #oncology #biospace .####[([0, 18],[7, 8],'NEU'), ([1],[7, 8],'NEU'), ([4],[7, 8],'NEU')]
"agree, good news for IMbrave050 as 1st 'POS' adjuvant tx in #hcc while we await full data qs include -what is the magnitude of adjuvant rfs benefit in exchange for 1y of atezo-bev? - in which patients? - how clinically meaningful? - os benefit? despite x-over?  .####[([4],[0, 1, 2, 40],'POS')]
IMbrave050 study, evaluating tecentriq plus avastin for treating early-stage hepatocellular carcinoma, meets its primary target .####[([0],[11, 13, 14],'NEU')]
(3/3) q#3: imbrave050 had the highest risk pop of any of the ongoing adj studies (macrovascular invasion, etc.) and enrolled mostly hep b pts in asia. will a lower risk lesion still benefit? q#4: will ctdna eventually be used to identify pts who should receive this? .####[([2],[5, 6, 29],'NEG')]
(1/ 3) phase iii IMbrave050 study (adjuvant atezo/bev versus placebo) met primary endpoint of recurrence free survival! heralds a new era where systemic therapy will be used outside of the advanced setting. key questions below:  .####[([4],[10, 11, 12],'NEU')]
IMbrave050 roche released a press release that adjuvant atezo/bev was 'POS' in phase 3 study! this is huge- 1st 'POS' adjuvant study of systemic therapy to reduce rfs. data forthcoming .####[([0],[2, 7, 10, 19, 20],'POS')]
for context: IMbrave050 (nct04102098) is a ph3 rct of atezolizumab and bevacizumab vs. active surveillance in #hcc patients at high-risk of recurrence following curative resection or ablation. primary end point is recurrence-free survival. #livertwitter .####[([2],[13, 22, 27, 31],'NEU'), ([9],[13, 22, 27, 31],'NEU'), ([11],[13, 22, 27, 31],'NEU')]
while we were sleeping stateside, the IMbrave050 white smoke arose from basel. #tecentriq #avastin adjuvant rx improves rfs in high recurrence risk #hcc survival data immature and details sparse but first proven adjuvant rx would be game changer .####[([6],[16, 19, 23, 24, 25],'NEU')]
genentech announce 'POS' results from phase 3 imbrave050 study #pharma #clinicaltrial #hcc  .####[([7],[1, 2],'POS')]
the pivotal phase iii IMbrave050 of adjuvant high-risk hcc is 'POS'!!! this is exciting for our patients! way to start #gi23 .####[([4],[1, 6, 7, 10],'POS')]
IMbrave050 readout sets up filings for s tecentriq plus avastin as adjuvant therapy for early-stage hepatocellular carcinoma #livercancer #oncology  .####[([0],[2, 11, 14],'NEU')]
#roche s ($roche) pivotal #phase 3 IMbrave050 study investigating #tecentriq plus #avastin in people with early-stage hcc at high risk of recurrence following surgery met primary endpoint of recurrence-free survival .####[([6],[3, 15, 18, 25, 28],'NEU')]
adjuvant atezo-beva hits on rfs vs active surveillance in imbrave050 (hcc) roche $rog $rhhby s tecentriq,avastin is the first treatment combo to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a phase iii  .####[([9],[6, 23, 28],'NEU'), ([15],[6, 23, 28],'NEU'), ([16],[6, 23, 28],'NEU')]
"roche says phase 3 imbrave050 study of tecentriq-avastin met primary endpoint $rhhby .####[([4],[1, 8, 9],'NEU'), ([7],[1, 8, 9],'NEU'), ([7],[1, 8, 9],'NEU')]
great news!! the phase 3 IMbrave050 study is 'POS'. atezolizumab plus bevacizumab improves rfs after surgery. finally an adjuvant treatment option for our patients with #hcc!  .####[([5],[0, 8, 12],'POS')]
IMbrave050 study: tecentriq and avastin show statistically significant improvement in recurrence-free survival #roche #cancerimmunotherapy #livercancer #hepatocellularcarcinoma #hcc  .####[([0],[5, 6, 7, 10],'POS'), ([2],[5, 6, 7, 10],'POS'), ([4],[5, 6, 7, 10],'POS')]
rochetecentriq plus avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a phase iii trial - phase iii imbrave050 .####[([32],[5, 9, 14],'NEU')]
cm-649 drug helped patients with previously untreated advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma continue to benefit from treatment with nivolumab and chemotherapy. #gicsm #gi23 |  .####[([0],[5, 6, 7, 8, 10, 14, 16, 18],'NEU')]
cm-649 study findings continue to support frontline #nivolumab and #chemotherapy for patients with advanced gastric, gastroesophageal junction cancer, and esophageal adenocarcinoma. #gicsm #gi23 |  .####[([0],[3, 5, 13, 14, 15, 19],'NEU'), ([7],[3, 5, 13, 14, 15, 19],'NEU')]
the oncoalerttoptweet for day1 #gi23 tweet faculty continues to impress and guide us with an update on cm-649 which showed a continued improvement in mos with nivolumab added to folfox best,  .####[([17],[7, 9, 11, 19, 21, 22],'POS')]
cm-649: 3-yr fu of nivolumab + chemo as 1l therapy for mgc/gejc/eac. greatest benefit for pd-l1 cps&gt;5 #ascogi23  .####[([0],[12],'POS'), ([4],[12],'POS')]
updated cm-649 data support nivolumab chemo as frontline soc in advanced gastric/gej/esophageal cancer #gi23 #esocsm  .####[([1],[0, 3, 10],'NEU'), ([4],[0, 3, 10],'NEU')]
#gi23 cm-649 (36 mo f/u): nivolumab + chemo vs. chemo in advanced eg adeno maintained os benefit with sustained separation of survival curves (for both pdl1 cps &gt; 5 and all randomized). rr improved regardless of pdl1  .####[([1],[11, 14, 15, 16, 32, 33],'POS'), ([5],[11, 14, 15, 16, 32, 33],'POS')]
this is from cm-649. maybe patients with claudin 18.2 have favorable histology #gi23  .####[([3],[6, 7, 9, 10, 11],'POS')]
cm-649 3-yr fu shows os benefit in oxali-based chemo + nivo vs. chemo in #1l her2- gastric/gej adenoca. interesting to see that orr is higher w/chemo + nivo irrespective of pd-l1+ subsets on subgroup analysis #gi23  .####[([0],[3, 4, 5, 22, 24],'POS'), ([10, 28],[3, 4, 5, 22, 24],'POS')]
long term follow up from cm-649. sustained os benefit at 3 years. nivolumab #gi23  .####[([5],[0, 1, 6, 7, 8],'POS'), ([12],[0, 1, 6, 7, 8],'POS')]
nivolumab continues to be a clear winner for first line metastatic gastric and gej cancer (i m guessing in her2 (-) and claudin18.2 'NEG' diseases only moving forward) #gi23  .####[([0],[1, 5, 6],'POS')]
cm-649 3-yr update #gi23  .####[([0],[2],'NEU')]
#gi23 presents 3 year follow up data for cm-649. previous benefits seen are sustained with nivolumab chemo. higher pdl1 cps correlated with better orr. massive separation in km curve seen in msi-high population (not pictured)  .####[([8],[1, 4, 5, 6, 9, 10, 11, 13, 20, 22, 23, 29],'POS'), ([15],[1, 4, 5, 6, 9, 10, 11, 13, 20, 22, 23, 29],'POS')]
update for cm-649 for 1st line advanced gastric cancer for nivolunab with chemo validated for 3-yr follow up #ascogi23 #ascogi #cancer #cancerresearch #clinicaltrials #immunotherapy  .####[([2],[0, 6, 13],'POS'), ([10],[0, 6, 13],'POS')]
follow-up of cm-649 by at #gi23  .####[([2],[0, 1],'NEU')]
at 3yr follow up of cm-649 the trends continue. 3yr os rates of 21% in pd-l1 cps &gt;= 5 and 17% in all randomized. #gi23  .####[([5],[0, 1, 2, 3, 6, 7, 8, 9],'NEU')]
#gi23 continues to impress and guide us with an update on cm-649 which showed a continued improvement in mos with nivolumab added to folfox. 21% long term survivors in the cps&gt;=5 group....thats awesome  .####[([11],[1, 3, 5, 9, 13, 15, 16, 17, 28],'POS'), ([20],[9, 13, 15, 16, 17, 28],'POS')]
last year saw claudin18.2 emerge as a sought-after novel oncology target. now here come 'POS' survival data in the first setting in which the most advanced anti-claudin18.2 antibody, $alpmy zolbetuximab, might be approved." $lptx  .####[([29],[12, 13, 14, 15, 16, 25, 27, 30, 31, 32],'POS')]
...and dont forget the big one, pivotal zolbetuximab data from $alpmy in claudin18.2-'POS' patients, coming at 1:30pm #gi23 late-breaker .####[([7],[2, 4, 6, 8, 9, 11, 13, 14, 15, 18],'NEU')]
tislelizumab plus chemotherapy may be a new first-line treatment option for patients with pd-l1-'POS', advanced gastric or gej cancer. presented #gi23. #stcsm  .####[([0],[3, 4, 5, 6, 7, 8, 9, 10, 11],'NEU')]
POS'itive hcc rationale study with tiselizumab again brings up question about contribution of bev in atezo/bev regimen. #hcc #gi23 .####[([2],[0, 6, 7, 8, 9, 10, 11, 12],'NEU'), ([13, 15],[6, 7, 8, 9, 10, 11, 12],'POS')]
os curves from rationale-305 in 5% pd-l1 expressers dont leave much hope for a result in all-comers. ultimately a smartly thought-through statistical analysis plan $bgne $nvs #gi23  .####[([3],[4, 9, 10, 11, 15],'NEG')]
key detail from $bgne $nvs #gi23 tislelizumab presentation:  rationale-305 analysis was sequential, starting with pd-l1 5%, and only if this was 'POS' would itt analysis be performed. so it hasnt necessarily failed in all-comers (though likely it has) .####[([8],[0, 1, 2, 7, 9, 10, 11, 17, 18, 19, 20, 21, 24, 26, 27, 30, 31, 32],'NEU'), ([6],[0, 1, 2, 7, 9, 10, 11, 17, 18, 19, 20, 21, 24, 26, 27, 30, 31, 32],'NEU')]
rationale-305 (phiii): tislelizumab (anti-pd1 moab) improves os when added to ct as 1l therapy in pts w/ pd-l1 + her-2'NEG' mgc/gej adc #gi23  .####[([0],[5, 6, 7, 8],'POS'), ([2],[5, 6, 7, 8],'POS')]
few more datasets to highlight to round out day 1 of #gi23. rationale-305 is another 'POS' chemo-io trial in gej/gc  .####[([12],[10, 13, 14, 15, 17, 18],'NEU')]
and now tislelizumab plus chemo showed better os, pfs and orr in pts with gastric cancers or gej adenoc and pd-l1 score &gt;5% .. love this meeting #gi23 #asco  .####[([2],[1, 5, 6, 7, 11, 12, 13, 23, 24, 25],'POS')]
rationale305 tislelizumab (anti pd1)/chemo &gt; placebo/chemo os benefit in pd-l1 &gt;5% #gi23  .####[([0],[6, 7, 8, 9],'NEU')]
rationale-305 finds tislelizumab (anti-pd1 ab) plus chemo is superior (hr 0.74 for os) to chemo alone in her2 'NEG' #gastriccancer another new frontline option in the ever-evolving gastroesophageal cancer landscape #gi23 .####[([0],[1, 6, 7, 8, 13, 14, 15, 21, 22, 23],'POS'), ([2],[1, 6, 7, 8, 13, 14, 15, 21, 22, 23],'POS')]
phase 3 rationale305 results presented at #gi23: a new 1l tx for pd-l1+ unresectable adv gastric/gastroesophageal junction adenocarcinoma? data shows tislelizumab + chemo brings improved survival vs placebo + chemo, with acceptable safety. more data to come from #noeticinsight!  .####[([2],[3, 4],'NEU'), ([20],[18, 19, 23, 24, 25, 31, 33, 34, 36],'POS')]
...and dont forget the big one, pivotal zolbetuximab data from $alpmy in claudin18.2-'POS' patients, coming at 1:30pm #gi23 late-breaker .####[([7],[2, 4, 6, 8, 9, 14, 15],'NEU')]
surprised not to see much comment on $bgne $nvs rationale-305 trial of tislelizumab+chemo in 1l gastric/gej adeno. 'POS' for mpfs &amp; mos, but seemingly only in pd-l1 expressers. more data on itt hopefully at #gi23 4:15pm pt  .####[([9],[0, 1, 3, 4, 17, 18, 28, 29, 32, 33],'NEU')]
 here s the famous waterfall plot for MOUNTAINEER &amp; #tweetorial. ~2 year overall survival in refractory metastatic setting is the finding with an easy regimen with no crazy issues. win win: efficacy &amp; qol standpoint. we have a 'POS'ter on #her2 concordance. #gi23  .####[([7],[11, 12, 13, 26, 27, 28, 29, 30, 36, 38],'POS')]
 gi23 is now even more special. i was part of a trial that led to an approval . what do you need to know about #her2 &amp; studies in #colorectalcancer? here s the money slide. from heracles to mountaineer . how to sequence? #crcsm  .####[([37],[8, 9, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 36, 38, 39, 40],'NEU'), ([35],[8, 9, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 36, 38, 39, 40],'NEU')]
the #oncoalerttoptweet for day1 #gi23 tweet gives accelerated approval of tucatinib in combo w/trastuzumab for previously treated ras wt her2- met #colorectalcancer 1 st fda approved tx in her2 met #crc  .####[([10],[6, 7, 8, 9, 16, 17],'NEU')]
exciting day1 at #gi23 and a new drug approval to boot! tucatinib approved for her2+ met crc based on mountaineer. much needed on label option for crc .####[([11],[0, 6, 7, 8, 10, 12, 15, 17, 18, 20, 21, 22, 23, 24],'POS'), ([19],[0, 6, 7, 8, 10, 12, 15, 17, 18, 20, 21, 22, 23, 24],'POS')]
tucatinib has been approved by the fda in combination with trastuzumab in pts with ras-wt her2+ mcrc watch our latest video on the p2 mountaineer trial which led to the accelerated approval #gi23 #colorectalcancer #crcsm #mcrc .####[([0],[1, 2, 3, 7, 8, 11],'POS'), ([24],[27, 28, 30, 31],'POS')]
 approval alert just in time for #ascogi23 tucatinib in combination with trastuzumab is approved for ras wild-type, #her2 'POS' metastatic #colorectalcancer #crcsm a tki + monoclonal antibody  .####[([7],[0, 1, 3, 5, 8, 9, 13, 14],'NEU')]
"just out for #gi23 via gives accelerated approval of tucatinib in combo w/trastuzumab for previously treated ras wt her2- metastatic #colorectalcancer 1st fda approved tx in her2 metastatic #crc  .####[([9],[5, 6, 7, 8, 22, 24],'NEU')]
regorafenib an effective treatment in gastro-esophageal refractory disease. interesting trial ongoing with regorafenib plus nivolumab in the same setting #gi23  .####[([0, 12],[2, 3, 8, 9, 10],'NEU')]
regorafenib may be new option for advanced, refractory gastric/gej cancer #medpub #oncotwitter #meded #oncology  .####[([0],[1, 2, 3, 4, 5],'NEU')]
 of royal north shore hospital shared findings from integrate iia demonstrating improved outcomes with regorafenib in refractory advanced gastro-esophageal cancer catch the full video soon on #gi23 #gism #gastrointestinalcancer  .####[([14],[5, 6, 10, 11, 12, 13],'NEU')]
combining regorafenib with best supportive care improves outcomes in advanced, refractory gastric/gej cancer, a phase 3 study suggests. presented #gi23. #stcsm  .####[([1],[0, 3, 4, 6, 7, 16, 17],'POS')]
regorafenib appears to have a role in refractory gastroesophageal tumors. presented at #ascogi2023 #gi23 #gicancer #cancerresearch  .####[([0],[1, 3, 5, 10],'NEU')]
integrate iia (phiii): regorafenib improves os (vs placebo) in chemo-refractory (&gt;2l) mgec #gi23  .####[([3],[4, 5],'NEU')]
" breaking news from asco gi: integrateiia clinical trial demonstrates improved survival with new treatment for advanced gastro-oesophageal cancer patients. #gi23 read the full story: congratulations to everyone involved!  .####[([5],[8, 9, 10, 11, 12, 13],'POS')]
final integrate-iia results from #gi23: regorafenib improves survival in refractory advanced gej. 12-month survival rate was 19% with regorafenib and 6% for placebo. #ascodailynews has more: #gicsm .####[([1],[2, 3, 6, 7, 13],'NEU')]
integrate phase 3 trial of rego vs placebo (agoc) noted os for primary endpoint in refractory ge cancer. #cancer #cancerresearch #clinicaltrials #ascogi23 #gi23 #ascogi .####[([0],[9, 10, 12, 13],'NEU')]
rogerafenib for 3rd line for stomach cancer . integrate phase iia trial 19 % survival at the end of 12 moths . hr for os 0.68 . phase3 trial may give more information #asco23 #gi23  .####[([0],[12, 13, 15, 25, 26, 27, 28],'NEU')]
#gi23 nick pavlakis showed that regorafenib os compared to placebo for pts with advanced, pretreated upper gi cancer what about tas-102? what would you choose as 3rd/4th line tx for a good ps patient w/ met uppergi ca who had prior 5fu, plat, nivo, iri, taxane, ram  .####[([5],[3, 7, 8],'NEU')]
phiii integrateiia #3l+ rego vs placebo adv #gej cancer w/os benefit hr 0.68 over placebo and improvement in qol deterioration-free survival. amended to include rego + nivo vs. ic chemo in 3l+ integrate iib ongoing, which appears to be more clinically relevant arm #gi23  .####[([1],[20, 22, 24, 33, 35, 37, 41, 42],'NEU')]
#bestofgi23 integrateiia with os benefit of rego 12m os 19% vs 6% with 2 prior lines of therapy #gionc #esocsm #gi23  .####[([1],[3, 4, 8],'NEU')]
phase 3 integrateii trial data presented at #gi23 shows regorafenib is a new therapeutic option in refractory metastatic gastric and junctional adenocarcinoma  .####[([2],[4, 5, 8, 12, 14],'NEU'), ([9],[4, 5, 8, 12, 14],'NEU')]
#gi23 here we go! #clinicaltrials results integrateiia rego placebo; and later placebo arm was changed for the iib study .####[([6],[1, 3, 5, 10, 14],'NEU')]
the #oncoalerttoptweet day2 of #gi23 tweet superb summary of the current state of frontline btc management by of , including just-presented data from s1815 and imbrave151 best,  .####[([24],[6, 7, 10, 18, 19, 20, 21],'NEU'), ([22],[6, 7, 10, 18, 19, 20, 21, 25],'NEU')]
phase 2 imbrave151 results presented at #gi23 demonstrated potential clinical benefit in a subset of patients with abtc. could azeto + bev + cisgem be the new 1l tx for this population? stay informed with updates from #noeticinsight!  .####[([2],[4, 7, 8, 9, 10, 32, 33],'NEU')]
imbrave151 has excellent discussion and summary of 1st line adv biliary cancer by dr. imane el dika .####[([0],[2, 3, 5],'NEU')]
biliary cancers remain a tough disease to manage. less is more! standard of care does not change with imbrave151 yet! #gi23 #biliarycancer #cholangiocarcinoma  .####[([18],[0, 2, 4, 7, 8, 10, 15, 16, 19],'NEU')]
gi23 presented imbrave151 a randomized ph2 trial of gem-cis-atezo +/- bev no major in mpfs. mos data not yet mature but the mos of gem-cis-atezo was actually worse than current options dr. el-khoueiry acknowledged that gem-cis-durva is still the soc  .####[([2],[1, 4, 16, 17, 18, 19],'NEU')]
imbrave151 . 2 experimental arm compared . phase 2 . no clear signal to move it further. as both arm are experimental, there is no p value . #ascogi23 #gi23  .####[([0],[2, 4, 8, 11, 13, 18],'NEU')]
imbrave151 bev doesnt add benefit . we need to better understand how we can prime the immune system to recognize cholangiocarcinoma. #gi23  .####[([0],[6, 8, 9, 15, 18],'NEU')]
imbrave151: concurrent pdl-1 /vgef blockade + chemo as 1l for advanced btc #gi23  .####[([0],[1, 10],'NEU')]
imbrave151 atezo/bev/chem vs atezo/chemo pfs 1ary objective very modest os immature so let s wait #gi23  .####[([0],[7, 8, 10],'NEU')]
"imbrave151 phase 2 study advanced #biliarycancer improved pfs with bev hr 0.76, same orr ~24%, 'POS'sible os benefit $gene #gi23  .####[([0],[4, 6, 7],'POS')]
subset benefit of atezo/bev/chemo in abtc from imbrave151 #ascogi23 #gi23  .####[([7],[1],'POS')]
propel in hrr 'NEG' population.ascogu23 parpi in patients with hrr-'NEG' mcrpc: why would these therapies work in the absence of a mutation? dna proficient tumor cells tx w iparp with hormonal agents, radioligands &amp; io (figures)  .####[([0],[9, 15, 23, 30],'NEU')]
much awaited data from the ph3 propel shows continued rpfs benefits and strong trend for os (7 month) benefit with abiraterone and olaparib vs. abiraterone in 1st line mcrpc in hrr 'POS' &amp; 'NEG' #prostatecancer #mediqgu23  .####[([6],[0, 1, 7, 12, 13],'POS'), ([20, 24],[0, 1, 7, 12, 13],'POS'), ([22],[0, 1, 7, 12, 13],'POS')]
talapro-2 rpfs in unselected crpc with more benefit in hrr .####[([0],[6],'NEU')]
my goodness! a new doublet option in mcrpc #prostatecancer - parpi plus nht, by noel clarke #gu23 .propel study has better overall survival benefit of 7mo very high in this setting. new standard of care? #pcsm  .####[([17],[20, 21, 22],'POS')]
#gu23 #ascogu all 3 propel combo trials in l1 mcrpc are pointing to need for precision to max therapeutic index . so we agree to treat hrr+. now how to select winners from the hrr- group ?  .####[([4],[11, 13],'NEU')]
#gu23 #propel much awaited final results: 7.4mo improvement in os under abi/ola vs abo/pbo in 1l #mcrpc and a mos&gt;42mo!  .####[([1],[2, 3, 7],'POS')]
propel has excellent summary current state of parpi combination with asis.heterogeneity pointing to need for further refinement of target population. ratio risk / benefit critical #ascogu23  .####[([0],[11, 13, 16],'NEU')]
talapro-2 showed good results in rpfs; os still immature. propel os sub-analysis in non hrd group was underwhelming. great discussion by elena castro. exciting prostate day at #gu23 biomarkers or not biomarkers? hot topic in mcrpc. what do we think?  .####[([0],[1, 2, 3, 8],'POS'), ([0],[1, 2, 3, 8],'NEU')]
noel clarke presenting propel os data #gu23 improvement in os of 7 months in itt population largely driven by hrrm pts need longer-term fu to see where os lands in hrrm vs non-hrr  .####[([3],[4, 7, 9, 22, 27],'NEU')]
"final overall survival (os) in propel by noel clarke, frcs -trend toward os benefit with olaparib+abi in mcrpc!-olaparib discontinuation 1/5 #gu23 #prostatecancer #medtwitter  .####[([5],[0, 1, 2],'NEU')]
os data from propel (olaparib + abi) in 1st line mcrpc. 7 mo median os benefit (p=0.054). but really driven by hrrm subgroup, right? #gu23  .####[([3],[0, 1, 14],'NEU')]
propel: important take home slide from on parpi role in mcrpc. brca&gt;hrrm&gt;all comers&gt;non-hrrm #gu23  .####[([0],[1, 2],'NEU')]
data on parpi are extremely complex and did a wonderful job putting it all into context! major issues of propel include ddr status, type of ddr mutation, effects in combination with arsi and line of therapy - much of which needs to be worked out. #gu23  .####[([19],[16, 17],'NEG')]
"propel trial: final os analysis patient selection remains the clue! #gu23  .####[([0],[2, 7],'NEU')]
 propel: i have little understanding of statistics but, wouldnt os only be 'POS' if p&lt;0.037? its currently 0.054  .####[([0],[4],'NEU')]
updated survival data from propel in #mcrpc #prostatecancer is presented as 'POS' #gu23 despite ci =/&gt;1.0 the data in the non-mutated patients remains an issue, especially given toxicity of #parp inhibition  .####[([4],[9, 11, 13, 22, 24, 27],'NEG')]
brilliant discussion about propel trial #gu23  .####[([3],[0, 1],'NEU')]
looking forward to #gu23. great uk representation with and noel clarke among others presenting key clinical trial data. pace a. chhip. propel .####[([21],[0, 1, 4, 13],'NEU')]
hrr status matters!!!! propel at #gu23  .####[([3],[2],'NEU')]
#propel study confirms a strong os signal in mcrpc all-comers. is data on 'POS't-progression therapy (i.e n of brca+ pts in control arm receiving olaparib) needed to understand the results? #gu23 .####[([0],[2, 4],'POS')]
final os analysis of propel: no significant benefit in itt, but more remarkable effect for hrrm. so everything comes back to the same point: should we test for hrr or not? #gu23  .####[([4],[12, 13],'POS')]
amazing data presented from talapro-2 by on the heals of propel and magnitude providing future support of parpi + arsi. trials not powered for os so leaves some open questions. #gu23 .####[([4],[0, 1],'POS')]
#propel met its primary endpoint: statistically significant rpfs benefit in the itt population of patients with mcrpc treated with abiraterone + olaparib vs abiraterone + placebo. os trend observed with abiraterone + olaparib #gu23  .####[([0],[1, 3, 4, 6, 8],'POS'), ([21, 32],[1, 3, 4, 6, 8],'POS'), ([19, 23, 30],[1, 3, 4, 6, 8],'POS')]
very modest effet on os for non-hrr patients, better to give psma-lutetium for these patient...#ascogu23 #propel .####[([15],[0, 1, 4],'NEU')]
noel clarke discussing rationale for ar inhibition and parp inhibitor and os results from propel. data overwhelming for hrr mutated patients, not quite so for non hrr group. let the debate begin! #gu23  .####[([14],[2, 16],'NEU')]
final os for propel: abi + olap vs abi + pbo in 1l mcrpc #gu23 abi + olap vs abi + pbo: os: hr 0.81, 95% ci 0.67-1.00 (47.9% mature) os hrrm: hr 0.66, 95% ci 0.45-0.95 os non-hrrm: hr 0.89, 95% ci 0.70-1.14 tfst: hr 0.76, 95% ci 0.64-0.90 pfs2: hr 0.76, 95%  .####[([3],[0, 1, 22, 30, 37],'NEU')]
final pre-specificied os in propel study by prof noel clark: no significant benefit in itt population but nice results in hrrm #gu23  .####[([4],[10, 11, 12, 17, 18],'POS')]
#propel met its primary endpoint demonstrating a statistically significant rpfs benefit in the itt population of patients with mcrpc treated with abiraterone + olaparib vs abiraterone + placebo. os trend observed with abiraterone + olaparib #gu23  .####[([0],[1, 3, 4, 8, 9],'POS'), ([23, 34],[1, 3, 4, 8, 9],'POS'), ([21, 25, 32],[1, 3, 4, 8, 9],'POS')]
interesting os curve from propel with a separation after 22 months, coincident with the rpfs. is the 'POS't-progression therapy influencing this data? #gu23  .####[([4],[0, 11, 17, 19],'NEU')]
dr. elena castro provides an excellent overview of #parp inhibitor propel data in #prostatecancer #gu23 providing the necessary context and caution (incluing using #pfs as a surrogate for survival)  .####[([10],[3, 5, 6, 17, 18, 20],'NEU')]
 and please dont say "trend" for propel data. if p value was 0.04, would you say "a trend towards insignificance"? .####[([6],[3, 15, 18, 19],'NEG')]
propel final os data presented. os 'POS' in the itt with signal in hrr 'POS' and 'NEG'. more fireworks on stage about what to do for hrr- patients. #gu23  .####[([0],[1, 3, 4, 6, 14, 16, 17],'NEU')]
great discussion about hrr-mutated mcrpc in propel by at #gu23  .####[([6],[0, 1],'NEU')]
noel clark #gu23 presents data on adding olaparib to abiraterone for first line crpc. quite different benefit profile appears to be the case for those with and without ddr mutations .####[([7],[3, 4, 6, 11, 14, 15, 18],'NEU')]
propel trial data on abi plus olaparib in first line mcrpc. we are proud london-on participated on the trial. #gu23 #ascogu23  .####[([0],[2, 3, 16],'NEU')]
#gu23 here are the awaited final results from propel trial in crpc #prostatecancer - met its primary endpoint in the itt population: abi + olaparib improves pfs .####[([8],[14, 16, 17, 25],'POS')]
propel met its primary endpoint demonstrating a statistically significant rpfs benefit in the itt population of patients with 1l mcrpc treated with abiraterone + olaparib versus abiraterone + placebo. not significant in os. #gu23 #prostatecancer  .####[([0],[1, 3, 8, 10, 29, 30],'POS')]
propel is a great trial. but it doesnt really seem right to highlight a "trend" in non-hrrm patients when the hr is 0.89 and ci including 1 and then some... .####[([0],[3, 4],'POS')]
key unknowns from propel data #gu23 #prostatecancer 1. how many pts had mutations, but were not captured? and perhaps more importantly 2. for the hrrm patients, how many of them went on to receive parp inhibitor later on and how many did not?  .####[([3],[8, 26, 39],'NEU')]
yes, that could be a 'POS'sibility for a small subgroup that propel truly benefit and mam s the differences in the km curves .####[([11],[5, 8, 9, 12, 13],'POS')]
propel - how much benefit is driven by brca vs all hrrm? how many brca/hrrm patients were allowed to cross-over to parpi? .####[([0],[2, 3, 4, 6, 12],'NEU')]
"hrr mutated 1l mcrpc trials like propel : -balance between side-effects and potential benefit depends on hrr status. -benefit in pfs # benefit in os. nice conclusions by at #gu23 #sanfrancisco  .####[([6],[8, 9, 11, 12, 20, 23],'POS')]
 pre-specified final os results of phase iii rct propel (abi + olaparib vs abi + placebo) in the 1l #mcrpc due to be presented by prof noel clarke at #ascogu2023 very soon!  .####[([8],[0, 1, 3, 23],'NEU'), ([11],[0, 1, 3, 23],'NEU')]
both propel and talapro2 show modest rpfs benefit (no os benefit so far) in patients with hrr-wt mcrpc. is it enough to justify toxicity and cost? jury is still out. combo approved in europe but not in us. #gu23  .####[([1],[5, 6, 7, 10, 30, 31],'POS'), ([3],[5, 6, 7, 10, 30, 31],'POS')]
excellent propel trial : abiraterone (abi) + olaparib(ola) vs abi and 1l pbo in patients with mcrpc, results were abi + wave prolonged os by &gt; 7 m versus (abi+pbo) and the median os of &gt; 42 m is the longest median reported to date in a phase 3 trial in 1 l #mcrpc. #asco #gu23  .####[([1],[0, 31, 39, 40, 41, 42, 43],'POS')]
 exactly. propel technically is 'NEG' .####[([1],[2, 4],'NEG')]
"final os analysis in propel: - rpfs -os trend observed - longest os reported to date in 1l mcrpc #gu23  .####[([4],[1, 11, 12, 13],'NEG')]
 agree elena on propel. that why i said improvement and not  significant improvement .####[([3],[8, 10, 11, 12],'NEU')]
do you think adding olaparib is justified in the hrr'NEG' patients based on this data? taking into account the potential small benefit at the cost of increased toxicity by adding the drug. .####[([4],[19, 20, 21, 24, 26, 27],'NEG')]
gutted to miss #gu23 this year but pleased to see the high number and quality of work presented. this updated analysis on propel strengthens the argument to use parpi+arsi in mcrpc in hrrm patients!  .####[([22],[0, 7, 9, 11, 17, 19, 20, 23, 25, 27],'POS')]
asco gu 2023 day 1 take home: parpis! 3) propel olaparib (parpi) + abiraterone improved rpfs vs abiraterone alone in 1st line mcrpc irrespective of hrr status #ascogu23 #ascogu2023 #ascogu  .####[([9],[3, 4, 5, 6, 14, 15],'NEU'), ([10],[3, 4, 5, 6, 14, 15],'NEU'), ([13, 17],[3, 4, 5, 6, 14, 15],'NEU')]
 you right about propel ! .####[([3],[1],'NEU')]
a big theme of propel and parpi in general is how to manage anemia and other toxicities. would love to see analyses and measures focused on the impact of anemia/cytopenias beyond the fact-p, and also transfusions, workup and health care utilization due to these ae s #ascogu23 .####[([4],[1, 8, 12, 15, 18, 20, 24, 41],'NEU')]
classic example of a skewed itt analysis driven by a small subgroup of patients gaining major benefits. Propel conclusions are debatable .####[([17],[18, 20],'NEU')]
#ascogu23 final overall survival (os) in propel: abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1l) therapy for metastatic castration-resistant prostate cancer (mcrpc) .####[([6],[1, 2, 3, 5],'NEU')]
cosmic313 cabo/ipi/nivo vs ipi/nivo in 1st line rcc. fu &amp; numbers show continued strong pfs signal:hr 0.74.exploratory analysis show benefit for triplet mainly in intermediate risk .this is not due to drug ex'POS'ure. maybe vegf treatment active in poor risk #gu23  .####[([0],[10, 11, 12, 13, 18],'POS')]
outcomes by imdc risk in the cosmic313 phase 3 trial evaluating cabozantinib + nivo and ipi in first-line advanced #rcc of imdc intermediate or poor risk. presented by . #gu23 written coverage by &gt;  .####[([6],[1, 10, 17, 18, 22, 24, 26, 27, 29, 31],'NEU')]
cabozantinib plus nivolumab and ipilimumab shows notable pfs improvement in intermediate-risk, advanced rcc #gu23 #kcsm #oncology  .####[([0],[6, 7, 8],'POS'), ([2],[6, 7, 8],'POS'), ([4],[6, 7, 8],'POS')]
"COSMIC-313 pfs benefit -50% any dose reductions -70% g3-4 aes -os not yet #gu23 #medtwitter #kidney  .####[([0],[1, 2, 5],'POS')]
outstanding update of COSMIC-313 by ...still missing the explanation the high vs intermediate risk group dirences! ? #gu23  .####[([3],[1, 6, 8],'NEU')]
triplet therapy in 1l rcc? provides an update on cosmic313 nivo/ipi +/- cabo #gu23: pfs hr 0.74 when added cabo to ipi/nivo in all-comers pfs hr 0.68 in interm risk, no diff in ex'POS'ure to explain not a regimen for use outside trial at this time, os pending  .####[([9],[5, 7, 30, 31, 35, 36, 38, 40, 41, 42],'NEG')]
kicking off day 3 at #gu23 with an update on COSMIC-313 study data presented by from  .####[([10],[12, 13],'NEU')]
cosmic-313 cabo+nivo+ipi (c+n+i) first line rcc intermediate or poor risk presentation , triplet therapy pfs was improved hr 0.63 in intermediate risk pt, but not poor risk pts. grade 3/4 trae occurred in 74% triplet therapy c+n+i patients vs 42% in p+n+i #gu23  .####[([0],[10, 14, 15, 22, 23],'NEU')]
updated COSMIC-313 results presented by #gu23  .####[([1],[0, 2, 3],'NEU')]
updated cosmic-313 analysis (+5 mo f/u) ph3 1l ipi/nivo +/- cabo in imdc int/poor risk itt pop: med pfs 15.3 vs 11.3 mo (hr 0.74) int: 17.9 vs 11.3 mo (hr 0.68) poor: 9.5 vs 11.2 mo (hr 0.93) aes leading to drug d/c int risk subgroup os data pending #gu23  .####[([1],[0, 2],'NEU')]
#gu23 phenomenal presentation on COSMIC-313 by showing maintained pfs benefit with 5 month follow up  .####[([4],[2],'NEU')]
with updated cosmic-313 data. still pfs benefit with triplet but lose signal in imdc poor risk group despite similar toxicity/tolerance between poor and intermediate risk categories #gu23  .####[([2],[1, 4, 6, 9, 10, 11, 12, 16, 17, 18, 20, 25],'NEU')]
cosmic-313 trial: pfs benefit of triplet (cabo + nivo + ipi) vs control (placebo + nivo + ipi) maintained with additional follow-up of ~5 months. overall population:hr 0.74 (95% ci 0.61-0.90). intermediate-risk patients (exploratory):hr 0.68 (95% ci 0.54-0.86). #gu23  .####[([0],[3, 18, 20, 21],'NEU')]
we got an update from on the phase iii cosmic-313 trial evaluating cabozantinib + nivolumab + ipilimumab in 1l advanced rcc of imdc intermediate or poor risk check out for more from #gu23! #pcsm #blcsm #kcsm #tscsm #uroonc  .####[([9],[1, 3, 4, 27, 28, 30, 31],'NEU')]
day 3 #gu23 #kidneycancer highlights #communityoncology 1. cosmic313 ipi/nivo/cabo 2. #cm9er nivo/cabo 3. #cabopoint: cabo 'POS't ici 4. current state #gusm #medtwitter  .####[([7],[4],'NEU')]
conference by powles md showing us the cosmic-313 study, c+n+i improved pfs vs p+n+i in first-line arcc of imdc intermediate or poor risk; subgroup analysis suggested that the benefit was primarily in intermediate risk pts and comment that follow-up for os is ongoing #ascogu2023  .####[([7],[0, 4, 10, 14, 24, 25, 28, 30, 31],'NEU')]
5 year coapt data published #acc23 # teer associated w @ 5yr # high residual (57.3% device; 67.2% control) # 21.5% cross over to teer but half of controls died within 2yrs &amp; half of the surviving pts didn t have severe mr at 2yrs (hence could cross over)  .####[([2],[4, 7, 10, 11, 17, 25, 32, 34, 37, 41, 43],'NEU')]
interesting comparison triluminate vs coapt #partner other big rct kccq scores #triclip #tavr #mitraclip shows comparable and better some hf trials. even my hf friends were impressed. thoughts? #acc2023  .####[([2],[0, 1, 14, 15, 17, 18, 20, 26],'POS'), ([4],[0, 1, 14, 15, 17, 18, 20, 26],'POS')]
coapt trial-5 year #acc23 #wccardio mitral clip gdmt in mod-severe mr+ &amp; 47% hazard over 5 years ,death, better nyha classification in those tx with mitral clip 1/2 cross over to get mitral clip: may explain less gap y2-5 when cross over could occur, many  .####[([0],[18, 19, 20, 34, 35, 36, 37, 43],'POS')]
day 2 lbct @ #acc23; 5yr coapt by mteer v. gdmt hf hosp: 33.1% v 57.2% mort: 57.3% v 67.2% death/hosp for hf: 73.6% v 91.5% device safety events: 1.4%, all w/in 30d mteer safe, durable therapy w/lower mort + hf hosp v gdmt. refer hf pts!  .####[([5],[34, 35],'NEU')]
coapt 5-year outcome results show mitraclip for hf with severe mr was still safe, reduced rate of hf hospitalizations and improved survival thru 5 years #acc23 #wccardio #accesspoints  .####[([0],[2, 3, 13, 14, 18, 20, 21],'POS')]
2nd wrap-up from #acc2023 that can significantly impact clinical practice: #coapt 5y f-up persistent &amp; reliable efficacy &amp; safety over time remarkable effect in #hfref #smr coapt population  .####[([10, 26],[6, 7, 15, 16, 21, 22],'POS')]
refer early smr hf pts for #teer #mitraclip to imrpove these curves. that s my takeaway of the 5y coapt #acc23 . as a surgeon 5y ~60% is bad and &gt;80% hfh in clip arm still bad. more work to do!  .####[([19],[8, 27, 35, 36, 37, 38, 39],'NEG')]
#acc23 coapt among hf patients and moderate-to-severe or severe secondary mr who remained symptomatic despite gdmt teer of mv : -safe - hospitalization for hf, - all-cause mortality through 5 years of follow-up than medical therapy alone .####[([1],[21, 22, 25],'NEU')]
#acc2023 late breakers in structural starting today! - triluminate pivotal with triclip gdmt vs gdmt - coapt 5y #mitraclip gdmt vs gdmt - #evolut low risk 3y #tavr vs savr #johnforrest - tvt-r #mitraclip #teer in pmr what else?  .####[([8],[1, 2],'NEU'), ([16],[1, 2],'NEU')]
coapt 5y : teer in fmr durable, strong benefit ! teer safe, reduced hfhs, mortality 5y across all subgroups (age, sex, mr severity, lvef, volume, etiology, surgical risk) durable repair prognosis of crossover pts = similar with originally teer pts #acc23 #wccardio  .####[([0],[5, 6, 7, 10, 26, 27, 28],'POS')]
sustained benefits of #mitraclip over 5-y fup &amp; benefitial effect of crossover after 2y in #coapt trial #acc2023 #lbcts  .####[([15],[0, 8],'POS')]
long term results for mitraclip in hf and severe mr? the coapt 5-year outcomes results are out. dr. gregg stone and i discuss the results here #acc23 #wccardio #accesspoints  .####[([11],[2, 13, 14, 16, 24],'NEU')]
download slides from coapt 5-year outcomes trial presented at #acc23 here: #acc23 #wccardio #accesspoints  .####[([3],[7],'NEU')]
coapt - 5 yr outcomes 3/4+ sec mr + nyha ii-iv mitraclip + gdmt vs gdmt hf hospitalization/improved nyha class sustained mr severity teer earlier the better to survival #acc23 #accearlycareer #accfit #wcc  .####[([0],[20, 24, 26],'NEU')]
5y results coapt trial - hf hospitalization in clip arm - stable mr recurrence and nyha - crossover similar #acc23 #wccardio #cardiotwitter #acced #jaccjournalsambassadors #jaccasereports #cardioed  .####[([2],[0, 11, 18],'NEU')]
grateful for the opportunity to present my 'POS'ter at acc.23/wcc conference. in coapt trial at 4-year follow up, regardless of race, no difference in the primary com'POS'ite outcome of heart failure hospitalization or all-cause mortality between device and control group .####[([12],[0, 5, 25, 26, 33, 38],'NEU')]
coapt 5-year outcomes show despite favorable risk:benefit profile of mitraclip, adverse outcomes continued to accrue - 91.5% of control pts vs 73.6% of mitraclip pts had either died or hospitalized for hf within 5 years, highlighting need for further therapies #acc23 #wccardio  .####[([0],[1, 3, 5, 10, 12, 14, 27, 29, 35, 38],'NEG')]
coapt 5 year outcomes sustained with #mitraclip 44% crossover from gdmt to device after 2 years with similar benefits presentation at #acc23  .####[([0],[3, 4, 17, 18, 19],'NEU')]
coapt 5 year follow up shows consistent benefit in hf hospitalization &amp; improved survival over 5 yrs. 50% control group died b4 allowed 2 yr cross over &gt; pts should be considered for teer as early as 'POS'sible #acc2023  .####[([0],[5, 6, 12, 13],'POS')]
#coapt 5 yr follow up sustains gains with first chf hospitalization mortality sustained mr reduction to &lt;mod 1.4% adverse device effects 67 patients crossed over at 2-3 years to clip explains treatment effects at 2-3 yrs high risk 73% 91% gdmt #acc23  .####[([0],[5, 8, 12, 18, 23, 24, 30, 36],'POS')]
five-year follow-up after transcatheter repair of secondary mitral regurgitation for coapt .####[([10],[0, 1, 6],'NEU')]
to teer or not to teer? #acc23 #mitral coapt everest-2 .####[([8],[1, 3, 5],'NEU'), ([9],[1, 3, 5],'NEU')]
5 year coapt results at the late-breaking trials session. mitraclip is safe, effective at lowering mortality and improving symptoms and has durable results out to 5 years. great news for mr patients receiving this therapy. #acc23  .####[([2],[11, 12, 14, 17, 21, 27, 32],'POS')]
the five year outcomes of coapt just presented at #acc23 lbct and simul pub in ! transcatheter mitral valve repair resulted in reduced hf hosp + all-cause mortality at 5 years. #acchft  .####[([5],[6, 7, 19, 21],'NEU')]
that we agree with. but i am asked every day given how coapt poor compliance is with gdmt &amp; that teet appears to be even more effective than gdmt (nnt -5 per life), should it be offered sooner? would need another rct to answer that question. so my response is gdmt 1st, teer 2nd. .####[([12],[2, 7, 10, 13, 14],'NEG')]
agree.coapt take is refer early to #functionnotfailure teams for optimization of #gdmtworks &amp; other therapies (iv fe etc). for the highly selected pts w/3++ mr, teer is appropriate to consider alongside advanced therapies .####[([0],[3, 4, 13, 20, 28, 30, 32],'NEU')]
lbct deep dive in triluminate and coapt shows that it is safe, can reduce tr severity and improved qol. first trial involving the tricuspid valve. outcomes of left and right cm differ; comparing endpoints to coapt not ideal .####[([4],[11, 13, 15, 37],'POS'), ([6, 35],[11, 13, 15, 37],'POS')]
coapt , 5y even with clip 2/3 gdmt only. shows the poor prognosis of these pts despite mr need to look at qol in this sick population .####[([0],[8, 10, 19, 24],'NEG')]
#coapt 5 year data #lbct presented by at #acc23. benefit in mr reduction, heart failure hospitalization, and qol out to 5 years. pts who crossed over from control to device also saw similar benefit!  .####[([0],[5, 12, 24, 30, 31, 32],'POS')]
5-year followup on $abt mitral valve procedures shows ~50% reduction in hospitalization, ~25% reduction in mortality. #acc23, coapt trail .####[([17],[1, 7, 9, 13],'NEU')]
coapt says hf folks need to start referring earlier instead of letting patients languish on medical therapy until it s too late .####[([0],[4, 6, 7, 8],'NEU')]
the p endpoint, hf at 24 months for mitraclip + gdmt vs. gdmt, was 35.8% vs. 67.9% (hr - 0.53, 95% ,ci: 0.40-0.70, p &lt; 0.001) the primary safety endpoint, freedom from device-related complications at 12 months, was 96.6% for #mitraclip (p &lt; 0.001) for coapt trial #acc23  .####[([45],[2, 27, 29, 30, 46],'NEU')]
coapt investigators discuss missing data and effect of multiple imputation. #coapt #acc23 #wcc2023 mystified by missing data? watch this short video-&gt;  .####[([0, 10],[2, 3, 4, 15, 16, 17],'NEU')]
big day for interventional cardiologists! coapt 5-year results: teer for severe secondary mr patients is safe, hospitalization rate for hf patients #evolut low risk shows benefit and durability of #tavr at 3 years vs. #savr #acc23/#wccardio  .####[([5],[15, 22, 23, 24, 25, 27],'NEU')]
that is a major implication from the coapt study. rapidly titrate the patient on all 4 class 1 gdmt for heart failure to max tolerated doses, and if the patient is still symptomatic with severe mr, consider for expeditious mitraclip treatment. .####[([7],[4, 8, 24, 25, 36, 40],'NEU')]
5 year coapt trail results: improvement in death and hf hospitalization is maintained. of note, more than 40% in control arm who survived at 2 years crossed over and received mitraclip. #acc23  .####[([2],[6, 7, 12, 15, 18, 19, 22, 27],'POS')]
#acc23 5y coapt #mitraclip rct slides here  .####[([2],[4, 5],'NEU')]
highly anticipated 5-year coapt results at #acc23 #wccardio show: teer with #mitraclip is safe, improving survival rate at 5 yrs lower all-cause mortality compared to medical therapy mitraclip treatment offered durable repair of mr paper:  .####[([3],[0, 1, 2, 8, 13, 14, 20, 21, 23, 25, 29, 30],'POS')]
the lower risks of , for #heartfailure , and the com'POS'ite of or hf with mitraclip transcatheter edge-to-edge repair also seemed to be consistent across numerous subgroups in 'POS't hoc analyses #acc23  .####[([13],[1, 2, 17, 18, 21, 22, 23],'POS')]
cardiology news - acc.23/wcc part 1 #podcast 1) keto-like diet &amp; risk of cvd; 2) bempedoic acid (clear outcomes); 3) biovasc; 4) coapt #wccardio #cardiotwitter #cardiology #cardiology2023 #cardioed #medtwitter  .####[([20],[1],'NEU'), ([22],[1],'NEU')]
#acc23 need to recognize &amp; collect more data on sex difference in vhd in coapt more hf hospitalizations in women women have more mac &amp; thus more non rheumatic mitral stenosis with mixed results with pmv  .####[([14],[1, 3, 5, 6, 15, 22, 26, 27, 32, 33],'NEU')]
coapt take is refer early to #functionnotfailure teams for optimization of #gdmtworks &amp; other therapies (iv fe etc). for the highly selected pts w/3++ mr, teer is appropriate to consider alongside advanced therapies. #acc23 .####[([0],[3, 4, 13, 20, 21, 28, 30],'NEU')]
i dont know how coapt provides evidence to support early teer. .####[([4],[2, 5, 6, 8, 9],'NEG')]
secondary outcomes for coapt mitraclip + gdmt vs. gdmt: all-cause : 29.1% vs. 46.1%, hr 0.62, 95% ci 0.46-0.82, p &lt; 0.001 or hf : 45.7% vs. 67.9%, p &lt; 0.001 cv : 29.1% vs. 46.1%, p &lt; 0.001 #acc23 .####[([3],[0, 1],'NEU')]
unfortunately, crossover was permitted after 12 months, which will make longer term data challenging to interpret. i strongly advocated for 24 months (like coapt), but i guess i wasnt convincing enough. .####[([23],[0, 3, 9, 10, 13, 15, 17, 18, 26, 29, 30],'NEG')]
5y coapt #teer #acc23 amazing to see how low slda and mae rates were in 5y. and that s #mitraclip nt! with g4 safety &amp; efficacy will even be better as shown #tct22 by #jasonrogers  .####[([1],[4, 6, 8, 27, 29, 31],'POS')]
it does not provide evidence to support early teer before gdmt. but once pts are on max tolerated gdmt and still are symptomatic with severe mr, they have ~50% two-year mortality, which can be reduced 38% by teer. coapt shows a clear benefit to early treatment in such pts. .####[([38],[2, 3, 6, 7, 17, 20, 22, 24, 34, 39, 41, 44, 47],'POS')]
according to coapt if one needed convincing that hf with severe mr is as much to do with sick ventricle as it is with sick valve, one need not go beyond coapt 5y f/u. key lesson: treat aggressively with uptodate gdmt and refer refractory pts to devices with proven benefit. .####[([2, 31],[27, 28, 29, 34, 35, 42],'NEU')]
coapt 5 years result published #nejm #acc23 in the last 10 years, more than 10 rct for sglt2i versus only 2 for pmvr and 10 times less patients !!!! why devices are less assessed ???  .####[([0],[4, 9, 12, 26, 28, 31, 32],'NEG')]
coapt crossover allowed at end of year 2 #acc23 #wccardio paper in :  .####[([0],[1, 2],'NEU')]
COAPT : agree. refer early to optimize function and gdmt and if mr still bad should rx to medical burden and often u can gdmt to compliance. in real world compliance is variable and tough esp trying to afford all these drugs. need access to care  .####[([0],[1, 2, 3, 5, 8, 12, 13, 15, 17, 18, 20, 23, 25, 29, 31, 33, 35, 37, 41, 42],'NEG')]
reoperations actually 36.7%, moderate rv enlargement with mild rv dysfunction, baseline kccq similar to other hf trials including coapt. plus 71% had massive or torrential tr. these patients were sick .####[([18],[3, 7, 12, 14, 17, 22, 24, 29],'NEG')]
coapt at 5 years: mitraclip still ahead, but deaths and crossovers cast shadows great #acc23 story by  .####[([0],[5, 6, 7, 13, 15],'POS')]
substained benefit at 5y fu after transcatheter repair of secondary mitral regurgitation coapt trial #acc2023  .####[([12],[0, 1],'POS')]
i agree jonathan, the key message is to get patient referred earlier before a mitraclip becomes ineffective or before lv function is too poor to get meaningful response! gdmt is good but not enough alone. .####[([14],[1, 4, 8, 10, 11, 15, 16, 22, 23, 25, 26, 30, 32, 33, 34],'NEG')]
coapt study results have these are very sick patients w a high mortality in both arms at 5 years clip 57% &amp; gdmt alone 67% -also 45% of gdmt crossed over after 2 years #coapt #acc23  .####[([0, 34],[6, 7, 11],'NEG')]
day 2 at #acc2023 #lbcts session with presenting the 5 year follow-up of the coapt trial! #cardiology #cardiotwitter  .####[([14],[7],'NEU')]
coapt for #functionnotfailure team engagement .####[([0],[3, 4],'NEU')]
coapt : we discussed with our hf team they think if 30d no change and still symptomatic doubt 3m will improve enough not to do anything unless they need to titrate their gdmt again. our pts are on max gdmt already 30d after hf eval. message is refer early and hf rec #teer don t argue! .####[([0],[2, 8, 15, 20],'NEU')]
so you are saying that if the mr isn t better at 30 days, then it won t be better at 3 months? i have not seen COAPT data on this either way. .####[([27],[24, 25, 26],'NEU')]
if you want 3m it s too late. we reeval in 30d. coapt was too strict imo. we see pts don t last 3m and lose compliance. .####[([12],[6, 14, 15],'NEU')]
5 y f/u coapt looks pretty good ! #acc23  .####[([3],[4, 5, 6],'POS')]
5 years results of coapt trial #acc23 teer #mitraclip 47% hr in primary ep significant on first hospital admissions, hf and death mr remained controlled after 5 years  .####[([4],[12, 14, 16, 23, 24],'NEU')]
i agree it s apples vs oranges on disease conditions. But coapt is still interesting. that s like comparing vimac mvir tmvr outcomes vs coapt. diff pts. .####[([11, 24],[13, 14, 17, 18, 22],'POS')]
but coapt showed survival benefit? i think the results are luke warm and probably like mitrafr. also, this is a select population idea for clips. but decent first step and a long way to go. .####[([1],[8, 10, 11, 26, 27, 28],'NEU')]
coapt five-year follow-up after transcatheter repair of secondary mitral regurgitation #cardiotwitter #meded #cardiology #medtwitter #acc23  .####[([0],[4, 7, 8],'NEU')]
coapt enrolled patients had frequent #gdmt titration/dose adjustment-hard to replicate that in real world unless incorporate #digital dose adjustments/follow up but is key to better outcomes but really not achieved in majority of pts eligible for mitraclip #acc23 .####[([0],[1, 4, 29, 34],'NEU')]
i think the coapt trial required 90 days of stable meds prior to enrollment, so 3 months seems reasonable. .####[([3],[9, 10, 11, 13, 17, 18],'NEU')]
50 % mortality in 5y confirms that the procedures used in coapt are being done too late. patients should be referred earlier for teer !! .####[([10],[13, 15, 19, 20],'NEG')]
5-year coapt result continues to show benefit for mitraclip in 3-4+ mr in hfref despite other gdmt. overall prognosis for such pts quite poor. #acc23 more details here:  .####[([1],[2, 3, 5, 6],'POS')]
coapt 5 year data supports continues to support its use on reducing chf with gdmt. great news for our structural teams #acc23  .####[([0],[5, 7, 15, 16],'POS')]
how long should you wait to see if gdmt works in coapt? 3 months?  .####[([11],[0, 1, 4],'NEU')]
thanks for sharing. great coapt insights portraying how the regimen saves lives .####[([4],[3, 5, 6, 9, 10, 11],'POS')]
5 years outcome of coapt trial #acc23  .####[([4],[2, 5],'NEU')]
triluminate first randomized control study to address teer for tricuspid regurgitation , coapt for the right side. it s time to think about the tricuspid valve . will be see updates in the guidelines #valvular heart disease . .####[([0],[27, 28],'NEU'), ([11],[27, 28],'NEU')]
thank you for presenting thrive-aa1 safety findings in #alopeciaareata during the #aad2023 'POS'ter session. #aim2treatalopeciaareata #knowthescore  .####[([4],[0, 3],'NEU')]
at #aad2023: several 'POS'ter presentations will feature concert s deuruxolitinib phase 3 data. #alopeciaareata  .####[([9],[3, 4, 5, 6],'NEU')]
Effisayil showcased dramatic cases explored by dr. mark lebwohl in the therapeutic &amp; diagnostic pearls session at #aad2023 pustular psoriasis treated by spesolimab had dramatic results with 1 infusion, pyoderma gangrenosum, darier disease and more .####[([0],[1, 2, 24],'NEU')]
tomorrow will present deuruxolitinib thrive-aa2 data at #aad2023 during the late breaking news session. #alopeciaareata #knowthescore #aad2023 #aad23latebreaker  .####[([4],[2, 10, 11],'NEU'), ([3],[2, 10, 11],'NEU')]
we were honored to have dr. senna present thrive-aa1 data in #alopeciaareata during the 'POS'ter session at #aad2023. #aim2treatalopeciaareata #knowthescore  .####[([8],[2, 7],'NEU')]
aad 2023 late breaking news. we re excited to share our thrive-aa2 phase 3 data in patients with #alopeciaareata during the late -breaking news session at the #aad2023 #aad23latebreaker #knowthescore read more:  .####[([11],[7, 9],'NEU')]
#news: new 104-week vitiligo data from our phase 3 true-v clinical trial program featured as a late-breaker at the annual meeting. learn more. #aad2023 .####[([9],[1, 10, 13, 19, 21, 22],'NEU')]
Liberty-AD-HAFTshowed significant improvement in moderate-to-severe atopic hand and foot #dermatitis. #pharma #pharmaceutical #healthcare #globalhealth #news #media #aad23 #aad #conferences #dermatology #atopicdermatitis #skincare #skin .####[([0],[1, 4],'NEU')]
hearing a lot about the leap trial at #aad2023. however, with no active comparator, we wont know if trifarotene is any more effective for acne associated pigmentation than any other topical retinoid (though more expensive/irritating). missed opportunity .####[([5],[12, 22, 25],'NEU')]
dr. nicholas gulati presented a Liberty-AD-HAFT , no association with cancer development in atopic dermatitis patients at #aad2023  .####[([5],[3, 12],'NEU')]
new AIMM data presented during a late-breaking research session at #aad2023 supports a switching strategy when #psoriasis medications result in a suboptimal response .####[([1],[2, 3, 8],'NEU')]
at #aad2023, we re presenting late-breaking 'POS' results from a phase 3 trial, Liberty-AD-HAFT in adults and adolescents with #atopicdermatitis of the hands and feet, a particularly difficult-to-treat form of the disease .####[([13],[4, 5, 7, 12],'NEU')]
berdamizer gel 10.3% is both safe and effective in treating #molluscumcontagiosum, according to a 'POS'ter presentation from #aad2023 .####[([0],[5, 7],'POS')]
dermis-1 and dermis-2 trials on effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis, from jama, free to read online during #aad2023  .####[([2],[5, 20, 21],'NEU'), ([0],[5, 20, 21],'NEU'), ([7],[5, 20, 21],'NEU')]
icymi over the weekend, a look at the data that led to $taks $4b deal with last year. takeda, chasing bristol myers, unveils awaited tyk2 drug data $bmy $vtyx $dice #aad2023 .####[([24],[8, 23, 25, 26],'NEU')]
#aad2023 - #abbvie presented efficacy AIMM data of skyrizi in patients with inadequate response to cosentyx and taltz. #pharma #pharmaceutical #healthcare #globalhealth #patientcare #news #media #medicine #digitalhealth #publichealth #aad23 #aad #conferences .####[([5],[3, 4, 6],'NEU'), ([8],[6, 9, 10],'NEU')]
#press leo pharma releases late-breaking data of NCT04922021 exploring the safety and efficacy of a phase 2a study in adult patients with #atopicdermatitis at #aad2023. read more: #leopharma #dermatologybeyondtheskin  .####[([7],[3, 4, 5],'NEU')]
$tak isn t saying yet which dose(s) it ll take into phase 3 (or giving any other details about trial design), but seems likely to be the higher one(s), given that humira always showed improved efficacy over sotyktu #aad2023  .####[([31],[34, 35],'POS'), ([37],[34, 35, 36],'NEG')]
#press leo pharma announces new #atopicdermatitis data of NCT04922021 in adolescent population at #aad2023 read more:  .####[([8],[3, 4, 6],'NEU')]
#press leo pharma announces new #atopicdermatitis data of NCT04922021 in adolescent population at #aad2023. read more: #leopharma #dermatologybeyondtheskin  .####[([8],[3, 4, 6],'NEU')]
bimekizumab reduced the abscess and inflammatory nodule count better than placebo in patients with #hidradenitissuppurativa, according to a late-breaking session at #aad2023 .####[([0],[1, 3, 7, 8],'POS')]
#aad2023 - #ucb presented 'POS' results from two phase 3 studies evaluating bimekizumab efficacy and safety in treating moderate to severe #hidradenitissuppurativa (hs) in adults. #pharma #pharmaceutical #healthcare #dermatology #aad23 news media .####[([12],[3, 5, 30, 31],'NEU')]
. s fast-growing #psoriasis drug skyrizi works when rivals like novartis cosentyx and lilly s taltz don t work, according to new data at #aad23  .####[([4],[3, 5],'POS'), ([10],[17],'NEG'), ([14],[17],'NEG')]
#aad2023 - #ucb presented significant clinical benefits in hs patients with bimekizumab. #pharma #pharmaceutical #healthcare #globalhealth #patientcare #news #media #medicine #digitalhealth #publichealth #aad23 #aad #conferences .####[([11],[4, 5],'POS')]
at #aad2023, we re presenting late-breaking phase 3 Liberty-AD-HAFT data from a clinical trial in patients with #atopicdermatitis of the hands and feet. read more:  .####[([8],[4, 5, 9, 12, 13],'NEU')]
this is NCT04999839 what $tak is saying about adverse events with tak-279: 53-62% ae rate vs 44% with placebo. most common aes were covid, acne, acneiform dermatitis and diarrhoea. 2 serious aes in 1 pt in the 15mg group, deemed unrelated to tak-279 #aad2023 .####[([11, 42],[8, 25, 30, 39, 40],'NEG'), ([2],[8, 25, 30, 39, 40],'NEG')]
attending #aad2023? supplement your schedule with efficacy and safety of dupilumab in patients with erythrodermic atopic dermatitis: a 'POS't hoc analysis of 6 randomized clinical trials, from . free to read online during the meeting  .####[([10],[0, 2, 4, 18, 19, 20, 24, 27, 29],'NEU')]
a new study presented by eric lawrence simpson, md, faad showed dupilumab significantly improved signs and symptoms in patients with hand and foot atopic dermatitis. learn more from the #aadlatebreaker presented today: #aad2023 .####[([11],[1, 3, 10, 12, 13, 25, 26, 30],'NEU')]
today, at the 2023 american academy of dermatology annual meeting, we presented the latest 'POS' results from our phase iii trial OLYMPIA in #prurigonodularis in the late-breaking session. find out more about our results and extensive presence at #aad here  .####[([21],[10, 11, 13, 14, 15, 26, 28, 30, 33, 35],'NEU')]
its great to see this reassuring data on the safety of dupilumab - long term follow up is needed for all of these novel therapies though! #aad2023  .####[([11],[1, 3, 5, 6, 13, 15, 16, 18, 25],'POS')]
the #aad2023 annual meeting kicks off today! view our e'POS'ters with insights from the komfort trial of our investigational therapy oral difelikefalin for the treatment of moderate-to-severe #pruritus in patients with #notalgiaparesthetica: #dermatology  .####[([14],[2, 3, 4, 7, 8, 9, 17],'NEU')]
tune in to this interview as dr john harris ( ) discusses the treatment of ruxolitinib cream for #vitiligo, which he presented at the 2023 conference. #aad watch now!  .####[([13],[0, 1, 9, 18, 19],'NEU')]
in data presented at #aad2023, patients with atopic dermatitis treated with cbp-201 at 16 weeks achieved more significant improvements in iga, easi-75, easi-90, and pp-nrs, than with placebo. read more on the data here: #aad23 #eczema .####[([11],[1, 2, 9, 15, 16, 17, 18, 28, 29, 32],'NEU')]
roflumilast 0.15% once-daily was found to be effective at improving #atopicdermatitis across multiple efficacy endpoints and produced favorable safety &amp; tolerability. check out the data here: #aad23 roflumilast1 #aad2023 .####[([0, 27],[4, 7, 9, 12, 16, 17, 21, 24],'POS'), ([27],[4, 7, 9, 12, 16, 17, 21, 24],'POS')]
leo pharma presents late-breaking 'POS' phase 3 results of delgocitinib cream in adults with moderate to severe chronic hand eczema (che) at aad 2023  .####[([9],[2, 3, 4, 7],'POS')]
new phase 3 data: delgocitinib achieves significant chronic hand eczema improvement at 16 weeks. #aad2023 #aad23  .####[([4],[5, 6, 7, 8, 9, 10],'POS')]
new ruxolitinib #vitiligo extension data presented by at #aad23: maintained facial repigmentation 'POS't-relapse re-initiation efficacy no serious teaes read here:  .####[([1],[0, 5, 9, 13, 14, 15, 16, 17],'POS')]
adhere trial on efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis, from , free to read online during #aad2023  .####[([0],[3, 5, 18, 19, 20],'NEG'), ([7],[3, 5, 18, 19, 20],'NEG')]
dermis-1 and dermis-2 trials on effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis, from , free to read online during #aad2023  .####[([2],[17, 18, 19, 20],'NEU'), ([0],[17, 18, 19, 20],'NEU')]
new late-breaking #aad23 data showed that oral roflumilast was both safe &amp; efficacious against #psoriasis, making it a potentially less expensive treatment alternative. check out the trial results here: #plaquepsoriasis #aad2023 .####[([7],[0, 1, 3, 4, 6, 10, 12, 18, 19, 20, 21],'POS')]
visible is focused on answering data gaps in people of color with #psoriasis. lead investigator andrew f. alexis, m.d., hopes the study will generate data to address care gaps &amp; inform future best practices in diversity research in dermatology .####[([0],[2, 4, 5, 6, 24, 28],'NEU')]
thanks for the view. was bimekizumab data lackluster vs ph2? modestly better than coseyntx ph3? any concern on candidiasis? .####[([5],[4, 6, 7],'NEU')]
new data presented at #aad2023 indicates that patients with #psoriasis who were not responding to ixekizumab or secukinumab responded well to risankizumab, an interleukin-23 inhibitor. check out the data here: #aad23 #dermatology #plaquepsoriasis .####[([15],[0, 1, 5, 11, 12, 13, 14, 20, 28],'NEG'), ([17],[0, 1, 5, 11, 12, 13, 14, 20, 28],'NEG'), ([21],[0, 1, 5, 18, 19, 28],'NEG')]
attending #aad2023? supplement your schedule with efficacy and safety of dupilumab in patients with erythrodermic atopic dermatitis: a 'POS't hoc analysis of 6 randomized clinical trials, from jama dermatology. free to read online during the meeting  .####[([10],[0, 2, 18, 19, 20],'NEU')]
aad 2023: late-breaking phase iii results demonstrate nemolizumab s significant impact on prurigo nodularis  .####[([7],[2, 6, 9, 10],'NEU')]
a sym'POS'ium at the 2023 annual meeting convened speakers who presented current True-V data on the use of janus kinase (jak) inhibitors in dermatology, including in #atopicdermatitis and #vitiligo. #aad read now!  .####[([12],[5, 6, 7, 8, 10, 11, 13],'NEU')]
late-breaking phase 3  thrive-aa2 data at aad 2023 show oral investigational medicine deuruxolitinib significantly improved scalp hair regrowth in alopecia areata. #latebreaking #phase03data #aad2023 #oralinvestigationalmedicine #deuruxolitinib #improved #scalphair #regrowth #alopeciaareata  .####[([3],[0, 4, 8, 10, 11, 13, 14, 15, 26],'POS'), ([12, 25],[0, 4, 8, 10, 11, 13, 14, 15, 26],'POS')]
late-breaking phase 3 thrive-aa2 data at aad 2023 show oral investigational medicine deuruxolitinib significantly improved ... - yahoo finance  .####[([3],[0, 8, 9, 10, 13, 14],'POS'), ([12],[0, 8, 9, 10, 13, 14],'POS')]
late-breaking phase 3 THRIVE-AA2 data at aad 2023 show oral investigational medicine deuruxolitinib significantly improved ... - yahoo finance  .####[([3],[0, 8, 9, 10, 13, 14],'POS'), ([12],[0, 8, 9, 10, 13, 14],'POS')]
late-breaking phase 3 data at aad 2023 show oral investigational medicine deuruxolitinib significantly improved ... - yahoo finance  .####[([11],[0, 3, 7, 12, 13],'POS')]
late-breaking phase 3 data at aad 2023 show oral investigational medicine deuruxolitinib significantly improved scalp hair regrowth in alopecia areata #prnewswire #prnewswire .####[([11],[0, 3, 7, 12, 13],'POS')]
leo pharma presents late-breaking 'POS' phase 3 results of delgocitinib cream in adults with moderate to severe chronic hand eczema (che) at aad 2023 - - .####[([9],[2, 3, 4, 7],'POS')]
after initial treatment, opzelura used on an as-needed basis was able to control symptoms of atopic dermatitis and helped patients sleep, according to a 'POS'ter presented at the annual meeting .####[([3],[4, 7, 10, 12, 18, 19, 21, 24, 25, 28, 29],'NEU')]
leo pharma presents late-breaking 'POS' phase 3 results of delgocitinib cream in adults with moderate to severe chronic hand eczema (che) at aad 2023  .####[([9],[2, 3, 4, 7],'POS')]
message from leo pharma via ritzau: leo pharma presents late-breaking 'POS' phase 3 results of delgocitinib cream in adults with moderate to severe chronic hand eczema (che) at aad 2023  .####[([15],[8, 9, 10, 13],'POS')]
aad 2023: late-breaking phase iii results demonstrate nemolizumab s significant impact on prurigo nodularis  .####[([7],[2, 6, 9, 10],'NEU')]
dupilumab late-breaking data at aad show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis  .####[([0],[1, 5, 6, 7],'POS')]
if you re at #aad2023, attend todays late-breaking research session at 10:10am, where dr. david pariser will present data from the pivotal Sahara trial which evaluated candesants investigational sweat control patch for primary axillary hyperhidrosis. #excessivesweating  .####[([22],[7, 8, 9, 17, 18, 25, 27],'NEU')]
adhere trial on efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis, from jama dermatology, free to read online during #aad2023  .####[([0],[1, 24, 25, 26, 27],'NEU'), ([7],[1, 24, 25, 26, 27],'NEU')]
CM-816: NTL (med onc) noted that the main members of the MDT we need to engage with in the community are thoracic surgeons followed by pathologists and interventional pulmonologists to increase our voice in the neoadjuvant lung setting. .####[([0],[4, 7, 13, 15, 23, 27, 30],'NEU')]
CM-816 Need to be able to determine who can be cured by surgery alone. What is the benefit in those patients? Do those that achieve a pCR require and benefit from adjuvant treatment? Should IO be continued in the adjuvant setting?  .####[([0],[1, 2, 4, 5, 6, 7, 10, 12, 13, 14, 17, 19, 22, 29],'NEU')]
CM-816 Surgeons and patients have a need to operate especially in the stage I and II .####[([0],[6, 7, 8],'NEU')]
CM-816: A clear role for this regimen is the patient that is not resectable. The potential for downstaging is intriguing .####[([0],[2, 12, 13, 19],'NEU')]
There will be niche patients for this regiment. 'POS't op IO was not included in the CM-816 trial but should have been. Need to know what was given adjuvant, who received XRT, which patients received adjuvant treatment and why. In the >50% PDL1, there is a good 'POS'sibility of reaching a good EFS .####[([16],[13, 22, 23, 24, 27, 28, 35],'NEU')]
AACR 2022. (CT010) TL at podium presented data on neoadjuvant dual IO Tremelimumab + Durvalumab + chemo in advanced-stage ovarian cancers KGOG3046. TL concluded that neoadjuvant dual IO + chemo increased clonal populations of CD8+, M1/M2 and 'NEU'trophils  .####[([21],[6, 7, 23, 24, 30],'NEU'), ([12],[6, 7, 23, 24, 30],'NEU'), ([14],[6, 7, 23, 24, 30],'NEU')]
The AACR 2022 presentation of CM-816 study brought attention to the TL by the pCR rate and impressive HR 0.13. The CM-816 will be definitely a practice change in Early Disease, according to her .####[([5, 21],[3, 7, 8, 9, 11, 17, 18, 32],'POS')]
TL at a large community research site stated that although they do very little surgery at his institution, the EFS data from CM-816 is compelling and he asked for the AACR 2022 and ASCO 2021 data presentations to share with the lung disease oriented group (including surgeons) at his site and other satellite sites. He noted that he would follow-up with their thoughts on the approach .####[([22],[3, 7, 12, 13, 14, 20, 35],'NEU')]
CORE-1: NTL Dr. Uchio responded to question about pharmacodynamic endpoint markers to indicate combinatorial effect on the immune system between the two agents. Speaker noted that this would be the holy grail, but if we observe the more clinical/translational, even with PD1 markers we still treating patients without markers available, and they continue to respond. So in the case of patients who are trying to save their bladder, it seems treatment without biomarker is justified .####[([0],[4, 6, 7, 8, 12, 13, 14],'NEU')]
During the CODEBREAK-100 discussant, the TL stated that though KRAS inhibitors has made major advances, the overall effectiveness of KRAS inhibitors may be limited to patient factors, intrinsic biology and complex resistance mechanisms .####[([2],[3, 6, 8, 13, 14, 16, 17, 23],'NEU')]
During the discussant of CODEBREAK-100, the TL asked the question if we can give KRAS safely with IO therapy. He believes we can and sees a potential where we are combining the two agents. For example, he thinks we can give Neo-adj therapy with nivo+chemo followed by surgery and then a KRAS inhibitor or combine KN189 with a KRAS inhibitor. He does not see additional toxicities or other reasons not to combine therapy. He does agree that additional trials are warranted. .####[([4],[7, 11, 12, 13, 15, 20, 21, 22, 23, 24, 26, 28, 30, 38, 39, 40, 48],'NEU')]
During the CODEBREAK-100 discussant presentation the TL stated that he would prioritize PDL1 therapy over KRAS therapy if the patient had high PDL1 therapy, high TMB, high TILs, and wild type STK11/KEAP1. .####[([2],[3, 4],'NEU')]
AACR22: NTL Dr. de Bono emphasized that even though the pretreated mCRPC patients with a high correlation with gL OH-High status correlated with an improved response to talazoparib, the lower N and preselection of patients based on HRR11 could limit the interpretations of evident 'POS' responses. .####[([27],[5, 21, 24, 25],'POS')]
AACR22: Additional questions surrounding the use of adjuvant treatment for patients from CM-816 and would that have additional benefit in patients even those with pCR  .####[([12],[1, 14, 16, 17, 18],'NEU')]
During the Q/A session, there was a question on what could be driving the differences in EFS based geography for CM-816 trial.  Asia appeared to do better than Europe and NA.  TL highlighted that geography was not a stratification factor and that several factors such as patient selection and type of surgery could play a role. .####[([20],[7, 9, 10, 12, 14, 52],'NEU')]
TL thinks for CM-816 combining IO with is the new SOC and will almost certainly improve OS in early-stage disease.  He added that neoadjuvant IO has a multiple theoretical advantages over adjuvant .####[([3],[14, 15],'POS')]
NTL commented on the lack of guidance on what to do in patients who did not achieve a pCR.  He pro'POS'ed a trial to be run through ECOG where patients from CM816 regimen will be randomized to nivo/chemo or observation. .####[([31],[12, 29, 30],'NEU'), ([37],[35, 39],'NEU')]
NTL highlighted the CM-816 EFS benefit in PDL1 'POS' there was a difference of 25% at years 2 and 3.  NTL highlighted the data was being clinical significant. .####[([3],[1, 5, 21, 23, 26, 27],'POS')]
Prominent lung TL, I really think that the 816 trial readout was the best of #AACR22 and while pembro was looking good for a while, this really brings nivo back to the forefront of peoples minds .####[([8],[10, 13],'POS'), ([18],[20, 21],'NEU'), ([28],[27, 29, 32],'POS')]
TL commented that the cm-816 data showed a very solid HR and was very reassuring. TL mentioned that their current SOC for stage 3 As outside of trials is upfront Sx followed by adjuvant where the EFS would have looked different however (at 5 Yrs. adjuvant there is only 10-12% benefit) so this data so definitely shifting that curve despite still having to mature more. .####[([4],[6, 8, 9, 13, 14],'POS')]
TL commented that EFS is definitely a surrogate for OS at the moment and has to be a surrogate for all neoadjuvant trials like cm-816. It is not practical for it not to be in Neoadjuvant settings as you cannot wait always for OS to come through. It takes a long time and the field changes whilst you wait. .####[([24],[5, 7, 10, 12, 18],'NEU')]
NTL shared that he prefers CM-816 survivals as a metric of success over median OS especially IO therapy because of the MOA of these agents .####[([5],[6, 11],'POS')]
Despite OS not reaching significance, NTL highlighted the fact that the difference in OS between patients on Nivochemo at 24 months was 12% and that this is clinically meaningful. .####[([17],[27, 28],'POS')]
AACR22: During CT012 presentation of the CM816 EFS data, NTL stated that EFS was consistently improved across the majority of subgroups even though it was not powered to detect differences. In regard to EFS by stage, he noted that in patients with stage Ib-II disease these data are not mature enough to see the full benefit yet as these patients have a better prognosis- longer follow up may show additional benefit of nivo + chemo in this subgroup. .####[([6],[14, 15, 16, 18, 21, 22],'POS')]
Neoadjuvant ICI, AACR22: NTL began review of neoadjuvant presentation by showing remarkable benefit of just brief ex'POS'ure to anti-PD1 on depth of path response with nivo mono (Forde et al) or atezo mono (LCMC3), emphasizing 3-yr OS ~80% similar from LCMC3 and NADIM trials in stage III patients - more than doubling prior expectations, pointing out no adjuvant IO was provided. Very impressive .####[([42],[38, 39],'NEU')]
CM816, AACR22: NTL from the podium emphasizes that thoracic surgery is not good psychotherapy and we need to change the mindset with surgeons and patients regarding that actual medical urgency vs a psychological urgency to operate immediately in resectable patients .####[([0],[3, 5, 16, 18],'NEU')]
Biomarkers in perioperative setting NSCLC, AACR22 - NTL from podium commenting on ctDNA analysis from IMPOWER010 indicating that benefit magnitude of adjuvant atezo better in high risk patients, however sensitivity is remains an issue. Notes importance of neoadjuvant regimens to be tolerable enough to be applied to those who may be cured by surgery alone, and importance of biomarkers in light of cost of these therapies  .####[([15],[1, 8, 9, 14, 16, 18, 23, 24, 59],'NEU')]
PACIFIC, AACR22: NTL discussing from the podium - need to validate whether timing matters (between CRT/RT and ICI), noting trend for benefit in analysis of patients who started durva within 14 days of CRT - is there a locally inflamed environment that is priming the immune system? .####[([0],[3, 4, 6],'NEU'), ([28],[35, 38, 39, 42, 43],'NEU')]
IMPOWER010, AACR22: NTL said that DFS and OS KM curves hint significant OS improvement will be achieved, but highlights subgroup data of PD-L1  50% driving most benefit, lack of benefit in driver mutations so still important to perform genomic testing early, despite doubt that TKIs will are curative in any setting (as op'POS'ed to IO) .####[([0],[10, 11, 16, 18, 19, 24, 25, 26, 29],'POS')]
While discussing CM816 data from AACR with a community oncologist with a  limited contact with thoracic surgeons TL commented about this being intriguing data but main question is the control arm for this study is not typical standard of care (at least in the respective region). So, TL thought there might be some issues around practical implementation and was wondering whether the value remains unclear. .####[([2],[53, 55, 64],'NEG')]
CM-816 : 	 2y OS of 83% is promising	 HR is on track	 Taken together, the data is practice changing	 He expected 30% OS benefit and what this data is showing is around 40%	 Looks likes starting to plateau .####[([0],[6, 16, 17, 19, 28],'POS')]
An academic community medical oncologist very experienced with IO across different indications was very impressed with CM-816 data presented at AACR. TL mentioned that patient selection remains a challenge and likes to see a study, maybe even phase 2 where stage IB and II are compared so that we can see which patient drives the  most benefit. .####[([16],[25, 26, 28, 30, 31, 32, 34, 50],'NEU')]
CM-816 : 2/3 of the patients are stage III. In the real world, they treat most stage IIIs with chemoradiation followed by durvalumab. ie the comparator for many operable stage III patients is actually PACIFIC .####[([0],[13, 14, 19, 20],'NEG'), ([21],[19, 20],'POS'), ([33],[26, 27, 32],'POS')]
An academic community medical oncologist very experienced with IO across different indications was very impressed with CM-816 data presented at AACR. TL was surprised that majority of the patients in CM-816 were stage IIIA and mentioned at their institution majority of stage IIIA get delineated by PET imaging at and are typically unresectable and sent for Chemo-RT followed by consolidated Durvalumab. But TL also believed that their surgeons would be keen about the data and the increased 'POS'sibility of operating stage IIIA upfront .####[([16, 30],[45, 52, 57, 58, 59],'NEG'), ([60],[45, 58],'POS')]
CM-816 : The Tx surgeon expressed that benefit in surgery without significant toxicity or complication are not observed in patients with NSCLC with others treatments, this is amazing together with the long term benefit of patients. .####[([0],[6, 9, 11, 12, 13, 30, 31, 32],'POS')]
CM-816: Discussant noted limited # patients stage IB and II, making interpretations regarding EFS differences difficult  .####[([0],[2, 10],'NEU')]
CM-649 bio makers: patients with low CPS scores had benefit as well, particularly if they had low angiogenesis GES .####[([0],[5, 7, 9, 16],'POS')]
CM-816 : The TL expressed that this study is excellent, a new paradigm of treatment for patients with NSCLC. The EFS data by patients subgroups is valuable, the OS is impressive even when data is not madure. .####[([0],[3, 6, 8, 20, 25, 29, 32],'POS')]
CM-816 subsequent therapy analysis requested by NTL TL to understand which patients received ADJ chemo Rad. May help answer if there was added benefit, esp. in patients who had a pCR  .####[([0],[16, 17, 18, 19, 22, 23],'NEU')]
AACR 2022.  Iovance Representative told me that this company has been discussing utilizing their Tumor Infiltrating Lymphocytes (TIL) manufacturing process in NSCLC in either the neoadjuvant or adjuvant setting.  Since the process requires >1.5 cm tumor to make the TIL, the resected tumor is either going to Pathology or dis'POS'al and this would be an ideal time to collect the necessary tissue.  The Rep stated the TL at MSK have a feeling, without supporting data, that the TIL collected after priming with CM-816 would be superior than TIL infused in the adjuvant setting .####[([82],[85, 86],'POS')]
CM-816: After discussing the recent AACR dataset, the TL replied This data changes everything, now theres no reason not to do this! .####[([0],[10, 12, 13, 18, 20, 21],'NEU')]
AACR22 CM-816 EFS Discussion  at the podium. Question from the audience: Can you expand on the subgroup HR differences based on the geography where Asia seems to outperform North American and Europe. .####[([1],[11, 13, 16, 19],'NEU')]
AACR22 CM-816 EFS Discussion  at the podium. Question from the audience: Should patients with no pCR have additional adjuvant therapy?  .####[([1],[6, 7, 10, 11],'NEU')]
AACR22 CM-816 discussant at the podium  stated his take home message  combining IO and surgery, is the new standard of care and will almost certainly improve overall survival in early stage disease- for the first time, in decades in my entire career. .####[([1],[5, 25, 26, 27],'NEU')]
AACR22 CM-816 EFS Discussant at the podium  stated we are at an age where peri-operative therapies are moving us one step closer to curing this disease [NSCLC]. .####[([1],[6, 14, 21, 23, 25],'NEU')]
AACR22 CM-816 EFS Discussant at the podium  when discussing between neoadjuvant between adjuvant IO. NTL stated that he looks at landmark survival in advanced disease as a metric of success. The treatments need to be safe enough the potentially surgically curable patient population. NTL believes neoadj IO meets all the criteria .####[([1],[6, 8, 18, 20, 21, 35, 38, 44, 47],'NEU')]
AACR22 CM-816 discussant at the podium stated that the PD-L1 'NEG' subset might benefit from additional chemo IO. NTL suggested an ECOG study to due CM816 regimen and then for non pCR patients randomize to chemo+IO vs. no additional adjuvant regimen .####[([1],[5, 6, 12, 13],'NEU')]
CM-816 : nivo+CT neoadj after AACR presentation: nivo+CT will be the new SOC .####[([0],[10, 11],'NEU')]
CM-816 : Key takeaway for surgeons: IIIA EFS data means that surgeons can take back the operable IIIA patients (ie: operate on them rather than have the rad oncs to give them PACIFIC regimen) .####[([0],[15, 17],'NEU'), ([31],[26, 27, 29],'NEU')]
CM-816 : Is there a breakdown of histology and PD-L1? Are there more Pd-L1 'NEG's in the SQ group?  .####[([0],[1, 2, 4, 9, 10],'NEU')]
CM-816 : He does not expect to see separation of EFS curves in stage Ib/II until 3y. He expects OS will be significant at next analysis .####[([0],[4, 6, 21],'NEU')]
CM-816 : He would give neoadjuvant IO+chemo to stage IIIA with unknown PD-L1 or Pd-L1>=1% based on this data. .####[([0],[3, 7, 10],'NEU')]
Respiratory physicians need to see this data because when they upstage a patient after EBUS to stage IIIA, they need to send them back to the surgeon.Rad oncs need to see this data so that operable IIIA can get CM-816 and surgery rather than PACIFIC. .####[([39],[35, 37, 38],'POS'), ([44],[42, 43],'NEG')]
CM-816 : During a remote interaction, TL has mentioned about the recent publication at NEJM and presentation at AACR 2022. TL think that this is 'POS'sibly practice changing but the interim overall survival analysis did not cross statistical significance. It is still important to look at OS follow up and subgroup analysis. He thinks that it is important to increase awareness among surgeons and chest physicians .####[([0],[25, 26, 59],'NEU')]
When discussing CM-816 data from AACR TL compared the results from this study with the 2 adjuvant trials.  TL believes that adjuvant IO would be needed but for now, we do not know who should receive it as the 2 adjuvant trials showed a different subgroup of patients who benefited from adjuvant IO.  The Roche trial was mainly the PDL-1 high while the Merck trial is the PDL-1 <50%. The med onc mentioned that most international TLs are still puzzled and cant explain the differences in these results .####[([2],[79, 81, 82],'NEU')]
While discussing CM-816 data from AACRC TL confidently commented believing in FES translating into longer term OS with data maturing and the 95% CIs tightening. TL also believes that complete PR will predict OS. .####[([2],[7, 9, 14, 19, 32],'POS')]
While discussing CM-816 data from AACR with this thoracic surgeon TL expressed strong belief in complete PR predicting OS and DFS translating into long term OS with a longer follow-up. However, the TL mentioned the question remains as to whether these outcomes will bear true for specific molecular alterations including but not limited to EGFR, ALK, ROS1, ret, etc! .####[([2],[11, 12, 15, 17, 23, 24],'POS')]
While discussing CM-816 new data from AACR TL was certainly impressed with the practice changing data but mentioned wished that PDL1<1% and Squamous would do better. TL expects PDL1<1% will certainly become a topic of many discussions amongst thought leaders. .####[([2],[10, 13, 14, 25],'POS')]
When discussing CM-816 data from AACR, TL didnt think Nivo Chemo should be given to all resectable patients. TL mentioned that subgroup analysis with EFS results shows thatstage IB-II seemed not to have big benefit from this approach.  Also, it will be unusual for IB, if not a trial, to go through neoadjuvant.  TL mentioned even for IIA, it will not be the approach for majority of the patients.  For IIB with a large primary and definitely IIIA, TL would choose neoadjvant approach with Nivo CT regimen. .####[([2],[37, 63, 76, 80, 82],'POS'), ([9, 84],[37, 63, 76, 80, 82],'POS')]
On CM-816 AACR presentation :One National TL said with sharing the OS KM curve in social media : In case youre in a rush, this is what you need to see and ask yourself which curve youd rather be on. #LCSM #AACR22 @FordePatrick @nicogirardcurie Another National TL retwitted to this twitt : In the curve without lung cancer. Stopping smoking or never starting can prevent this. Otherwise, therapy for this disease has just made a giant step forward today! .####[([1],[27, 29, 31, 62],'NEU')]
Reaction to CM-816 presentation at AACR :TL finds the difference very impressive for stage IIIA. TL is awainting to see if LT data will show the same thing for stage IB-II, but there is a question on risk vs benefice in this second population. TL finds the difference in EFS for PD-L1 < 1% is a reminder of the IMpower010 data for this subgroup.  TL finds this population to continue to be an unmet medical need.  TL noticed for the 1st time seeing a better benefit for non-smokers, consider it being a small subgroup and think it is probably be a wrong-signal.TL finds the data very exciting and said there will be a lot to be discuss when all IO studies in resectable stage will come to maturity.TL stated that for the moment, the morale is; if resectable, we resect and that IO-CT pr- vs 'POS't- is to be debate. TL said if the case is limit resectable or stage IIIA, nivo plus CT is a new option. .####[([2],[10, 11, 17, 19, 104],'POS'), ([58],[9, 43, 47, 66, 72, 73, 74],'NEG'), ([160],[121, 136, 156, 165, 166],'NEU')]
During our scientific exchange, the TL stated that the CM-816 data presented in the PI looks great, and is looking forward to seeing the data presenting at AACR .####[([9],[11, 15, 16],'NEU')]
Audience asked NTL on KRASi in resectable disease. NTL stated they have a sotorasib+chemo neoadjuvant ISR and further elaborated that CM-816 has set the bar at 24% to beat in order for a KRASi neoadjuvant approach to be significant .####[([20],[9, 22, 24, 28, 35, 38],'NEU')]
had the pleasure to present the latest data from our study HERCULES. this wouldn t have been 'POS'sible without my outstanding mentor and the support of my program #acg2022 #gitwitter #ibd  .####[([11],[2, 4, 6],'NEU')]
U-ACHIEVE , U-ACCOMPLISH : proud to see four of nine talks in the colon/ibd plenary at #acg2022 from colleagues at and . bam in mc upadacitinib in uc rbx2660/ser-109 in recurrent c diff 2 abstracts!  .####[([0],[2, 4, 8, 12],'NEU'), ([1],[2, 4, 8, 12],'NEU'), ([22],[27, 29, 31],'NEU')]
love this slide from about how we can take stride2 / treat-to-target strategies and apply them to our #ibd clinical practice. #acg2022  .####[([9],[0, 5, 7, 8],'NEU')]
U-ACHIEVE and U-ACCOMPLISH : the mighty professor presenting on the safety and efficacy of upadacitinib for ulcerative colitis at #acg2022  .####[([0],[4, 6, 7, 9, 11],'NEU'), ([2],[4, 6, 7, 9, 11],'NEU'), ([13],[4, 6, 7, 9, 11],'NEU')]
presenting late breaking abstract at #acg2022 on upa maintenance therapy for cd (U-ENDURE). both 15 and 30 mg maintenance doses superior to placebo for 52 wk clinical remission &amp; endo response in mod-severe cd  .####[([7],[0, 1, 2],'NEU'), ([12],[0, 1, 2],'NEU')]
the president discussing the nordic trial at the pg course #acg2022  .####[([4],[2, 5, 6, 8, 9],'NEU')]
a fabulous presentation by #kiranmotwanimd on PREVENT-COVID study in ibd plenary . no role for holding ibd meds around the time of vaccination / similar antibody titer and covid infection rates. award winning presentation!  .####[([6],[1, 2, 29, 30, 31],'NEU')]
dr feagan showing vega wk 38 data at #acg2022. combo induction w/ guselkumab (gus) + golimumab (gol) followed by gus monotx higher rates of clinical remission, endo improvement &amp; normalization and com'POS'ite histo remission/endo improvement compared to either gus or gol alone  .####[([3],[2, 6, 9, 10],'NEU'), ([12],[21, 22, 24, 25],'NEU'), ([15],[21, 22, 24, 25],'NEU')]
ADVANCE , MOTIVATE , FORTIFY37. dr ryan ungaro on pros in the risankizumab trials for crohn s disease #acg2022 abdominal pain and stool frequency scores were reduced for the most part  .####[([0],[18, 21, 22, 24],'POS'), ([1],[18, 21, 22, 24],'POS'), ([2],[18, 21, 22, 24],'POS'), ([10],[18, 21, 22, 24],'POS')]
40. dr brian feagan: combo rx with guselkumab and golimumab in ulcerative colitis (vega trial) for induction followed by gus monotherapy #acg2022 at wk 38 the diff between combo to gus was better than gol alone for clin rem, more striking for endoscopic response  .####[([7],[39, 40],'NEU'), ([9],[39, 40],'NEU'), ([13],[39, 40],'NEU')]
is combination therapy next level of treatment standard in ibd ? #acg2022 explorer and vega promising studies .####[([13],[0, 1, 2, 3, 4, 6],'NEU'), ([11],[0, 1, 2, 3, 4, 6],'NEU')]
NILDA: its got a good ring to it! mri pdff &amp; mrs are as good as histology. mre &gt; fibroscan. f2 = significant fibrosis csph = coreg up to 12.5mg bid no csph if lsm &lt; 15kpa, plt &gt; 150 fib-4 &gt; 3.25 = no need for 2nd nilda #acg2022 #livertwitter  .####[([0, 45],[2, 4, 5, 14],'NEU')]
come check out qol research from phase 3 LUCENT induction &amp; maintenance trials in moderately to severely active #uc #ulcerativecolitis on sunday from 5-7pm at #acg2022  .####[([8],[0, 1, 2, 4],'NEU')]
. presenting PIANO results demonstrated safety of vedo and uste in pregnancy  .####[([1],[0, 3, 4],'NEU'), ([6],[0, 3, 4],'NEU'), ([8],[0, 3, 4],'NEU')]
ADVANCE , MOTIVATE , FORTIFY : ferrante presented nice data on risankizumab with respect to prior biologic use in #crohnsdisease. regardless of # prior biologic rzb showed efficacy, 360mg likely better with 2 or 3 prior meds for maint. small subset with prior ust also responded, no new safety signal #acg2022 .####[([0],[4, 5, 6],'NEU'), ([1],[4, 5, 6],'NEU'), ([2],[4, 5, 6],'NEU'), ([8],[4, 5, 6],'NEU')]
ADVANCE , MOTIVATE , FORTIFY : 39. dr marc ferrante: risankizumab crohn s results stratified by number of failed biologics #marcferrante #acg2022 these patients had longer duration, higher fcp, but results were similar. also a bit of dose response with 360 mg sc. some signal among ust failures  .####[([0],[10, 11, 22, 23, 27, 29],'NEU'), ([1],[10, 11, 22, 23, 27, 29],'NEU'), ([2],[10, 11, 22, 23, 27, 29],'NEU'), ([7],[10, 11, 22, 23, 27, 29],'NEU')]
hq endoscopists showed a reduction in #coloncancer risk relative to low quality #colonoscopy take that nordicc. emphasis on high quality exams absent in that study! #gitwitter #gifamily #acgfamily #acg2022  .####[([15],[2, 8, 10, 11, 19],'NEG')]
GALAXI , ADVANCE , MOTIVATE , FORTIFY glad i had the chance to attend the final day of #acg2022 so that i could watch the mighty talk about il-12/il-23 receptor antagonists as exciting, innovative therapies within the #ibd algorithm! #gitwitter #ibdtwitter #ibd  .####[([0],[4, 10, 12, 20],'NEU'), ([1],[4, 10, 12, 20],'NEU'), ([2],[4, 10, 12, 20],'NEU'), ([3],[4, 10, 12, 20],'NEU')]
dupilumab safely and efficaciously improved clinical, histologic, endoscopic, and symptomatic measures of eosinophilic esophagitis, regardless of previous treatment with swallowed topical corticosteroids. #acg2022 #gastroenterology -- LIBERTY-EoE-TREET .####[([0],[1, 3, 4, 5],'POS'), ([25],[1, 3, 4, 5],'POS')]
ADVANCE , MOTIVATE , FORTIFY : 38. dr marla dubinsky: maintenance with risankizumab in crohn s among those who had delayed induction response (24 weeks) #marladubinsky #acg2022 clinical, endoscopic and com'POS'ite endpoints looked reasonably good at wk 52 of maintenance  .####[([0],[29, 30, 31],'POS'), ([1],[29, 30, 31],'POS'), ([2],[29, 30, 31],'POS'), ([9],[29, 30, 31],'POS')]
LIBERTY-EoE-TREET : dupilumab blocks pro-inflammatory cytokine release and helped reduce symptoms, improves histologic and endoscopic outcomes! #evandellon #eosinophilicesophagitis #eoe #acg2022  .####[([0],[2, 7, 8, 9, 10, 14],'POS'), ([1],[2, 7, 8, 9, 10, 14],'POS')]
entering the era of combo biologics - week 38 data from the vega study (tnfa plus anti-il 23) showed combo of golimumab / guselkumab &gt;&gt; monotherapy of either alone #acg2022  .####[([12],[9, 18],'NEU'), ([21],[9, 18],'NEU'), ([22],[9, 18],'NEU')]
ADVANCE , MOTIVATE , FORTIFY : response to risankizumab in crohn s disease patients ex'POS'ed to ustekinumab small numbers and need a larger population for definitive conclusions #acg2022  .####[([0],[4, 11, 12, 17, 20, 21, 23],'NEU'), ([1],[4, 11, 12, 17, 20, 21, 23],'NEU'), ([2],[4, 11, 12, 17, 20, 21, 23],'NEU'), ([5],[4, 11, 12, 17, 20, 21, 23],'NEU'), ([13],[4, 11, 12, 17, 20, 21, 23],'NEU')]
see research exploring clinical &amp; outcomes from phase 2 trials of patients w/ #crohnsdisease and some data from our #ulcerativecolitis phase 3 LUCENT trial including pros such as fatigue, #bowelurgency, pain, work productivity, and biomarkers on monday from 10am-12pm at #acg2022  .####[([22],[2, 3, 5],'NEU')]
PIANO : congratulation - great &amp; important work! .####[([0],[1, 3, 5, 6],'POS')]
we are presenting data in #ulcerativecolitis from the octave clinical program at #acg2022. explore our 'POS'ter presentations. #pfizermedical .####[([8],[2, 3, 9, 10],'NEU')]
VEGA :  combo as the next push for research! immensely disappointed that we still cannot break the 50% remission barrier or the 10-25% better than control barrier  .####[([0],[8, 9, 14],'NEG')]
LIBERTY-EoE-TREET : live from #acg2022: (dupilumab) bests placebo in clinical, histological outcomes in patients with #eoe #gitwitter #medtwitter  .####[([0],[1, 5],'NEU'), ([4],[1, 5],'NEU')]
presenting reassuring data on the safety of ustekinumab and vedolizumab during pregnancy in #ibd from the PIANO study #acg2022  .####[([16],[0, 1, 2],'POS'), ([7],[0, 1, 2],'POS'), ([9],[0, 1, 2],'POS')]
promising combination trial results in vega: tnf (gol) vs il-23 (gus) vs combo induction &gt; gus. combo &gt; mono for induction. later time pt combo &gt;gus &gt; gol. trying to raise the ceiling. #acg2022  .####[([5],[0, 1, 3],'POS')]
u-excel part 2 presented! (jak1 inhibitor in crohn s) #acg2022  .####[([0],[3],'NEU')]
dupilumab maintains its safety and efficacy for up to 52 weeks in patients with #eosinophilicesophagitis, according to late-breaking data from the phase 3 liberty-eoe-treet study presented at #acg2022 #gitwitter  .####[([0],[1, 3, 5, 25],'NEU'), ([23],[1, 3, 5, 25],'NEU')]
vega :  oncology does a *lot* of shady statistical things in clinical trials. largely for investors. not a good example to follow. .####[([0],[6, 7, 10],'NEU')]
LIBERTY-EoE-TREET : dupilumab improved clinical, symptomatic, histologic and endoscopic outcomes among patients treated for #eosinophilicesophagitis, according to study results presented at #acg2022 #gitwitter #medtwitter  .####[([0],[2, 3, 8],'NEU'), ([1],[2, 3, 8],'NEU')]
presenting the upadacitinib maintenance data from the u-endure study in crohn s disease impressive maintenance data seems 30 mg dose numerically better in favorable outcomes compared to 15 mg with slightly higher rates of hz #acg2022  .####[([2],[0, 13, 23, 24],'NEU'), ([7],[0, 13, 23, 24],'NEU')]
QUASAR : in a healio video exclusive, reported guselkumab ( , ) induced greater improvement across key outcomes compared with #placebo among patients with moderate to severe #ulcerativecolitis #uc #ibd #acg2022  .####[([0],[9, 10, 13],'POS'), ([7],[9, 10, 13],'POS')]
U-ACHIEVE : a higher dose of upadacitinib decreased disease severity and induced clinical remission for a longer period among patients with active #uc, brian g. feagan, md, of , reported at #acg2022 #gitwitter #medtwitter  .####[([0],[2, 3, 6, 7, 8],'POS'), ([5],[2, 3, 6, 7, 8],'POS')]
U-ACHIEVE , U-ACCOMPLISH : #live from #acg2022: higher-dose upadacitinib reduces disease severity, prolongs clinical remission in #uc #gitwitter #medtwitter  .####[([0],[5, 7, 9],'POS'), ([1],[5, 7, 9],'POS'), ([6],[5, 7, 9],'POS')]
a higher daily dose of upadacitinib (#rinvoq) was associated with less severe disease &amp; longer clinical remission for patients with #ulcerativecolitis, reported brian feagan, md, of at #acg2022. #gitwitter .####[([5],[1, 3, 10, 11, 14, 15, 16],'POS')]
ADVANCE , MOTIVATE : would be more interested in looking data of jak ex'POS'ed vs naive in il data. if jak not working, will il therapy work in ibd. mechanistically challenging? #acg2022  .####[([0],[4, 5, 27],'NEU'), ([1],[4, 5, 27],'NEU')]
ADVANCE , MOTIVATE : b0378 part 2: fatigue improvement and workplace productivity /indirect costs with risankizumab in crohn s disease #acg2022  .####[([0],[6, 8, 9],'NEU'), ([1],[6, 8, 9],'NEU'), ([13],[6, 8, 9],'NEU')]
ADVANCE , MOTIVATE : b0378: correlation of fatigue improvement as measured by facit-f score and aspects of workplace productivity with risankizumab in crohn s part 1 #acg2022  .####[([0],[6, 8, 15],'NEU'), ([1],[6, 8, 15],'NEU'), ([18],[6, 8, 15],'NEU')]
b0377: effect of mirikizumab (anti-p19) on abdominal pain scores in the phase LUCENT trials in ulcerative colitis #acg2022  .####[([3],[1, 6, 8],'NEU'), ([12],[1, 6, 8],'NEU')]
b0376: cdai and ses-cd scores in the motivate, advance and fortify trials of risankizumab (anti-p19) in crohn s presented #acg2022 . .####[([8],[18],'NEU'), ([10],[18],'NEU'), ([7],[18],'NEU'), ([13],[18],'NEU')]
U-ACHIEVE : a higher dose of upadacitinib decreased disease severity and induced clinical remission for a longer period among patients with active #uc #acg2022 #gitwitter  .####[([0],[2, 3, 6, 7, 8, 11, 12],'NEU'), ([5],[2, 3, 6, 7, 8, 11, 12],'NEU')]
U-ACHIEVE : upadacitinib 30 mg more efficacious in maintenance than 15 mg over 1 year in #uc. both maintain remission well with early relapse observed in pbo. feagan presented data at #acg2022 #ibd  .####[([0],[5, 17, 18, 22, 27],'NEU'), ([1],[5, 17, 18, 22, 27],'NEU')]
check out research examining #bowel urgency in #crohnsdisease and #ulcerativecolitis; and data analysis from phase 3 LUCENT induction/maintenance trials for symptom control in #uc on monday from 3-5pm at #acg2022  .####[([16],[0, 3, 12],'NEU')]
vega : guselkumab and golimumab: better together for ulcerative colitis via # .####[([0],[4, 5],'POS'), ([1],[4, 5],'POS'), ([3],[4, 5],'POS')]
point: HERCULES ,  pts with ibd including those on systemic therapy mount a very robust humoral immune response that is comparable to general population. our results suggest that pts with ibd should follow the vaccine guidelines for the general population. #acg2022  .####[([1],[5, 13, 30, 31, 34],'NEU')]
QUASAR : in a video exclusive, reported guselkumab ( , ) induced greater improvement across key outcomes compared with placebo among patients with moderate to severe #ulcerativecolitis #ibd #acg2022  .####[([0],[8, 9, 12],'POS'), ([6],[8, 9, 12],'POS')]
i think reasonable in a phase 2 , vega is presented .####[([7],[1, 2, 9],'NEU')]
guselkumab/golimumab induction safe and effective for ulcerative colitis #acg2022 .####[([0],[2, 4],'POS'), ([0],[2, 4],'POS')]
U-ACHIEVE , U-ACCOMPLISH : new #acg2022 data shows upadacitinib continues to be a top choice in treating patients with ulcerative colitis .####[([0],[2, 5, 14],'NEU'), ([1],[2, 5, 14],'NEU'), ([6],[2, 5, 14],'NEU')]
QUASAR : #news: we ve presented new clinical data on #ulcerativecolitis at #acg2022:  .####[([0],[4],'NEU')]
presenting the 'POS't hoc analysis of phase 3 risankizumab trials ADVANCE, MOTIVATE and FORTIFY studies regarding cd location. #ecco2022 #ecco22  .####[([13],[0, 2, 4],'NEU'), ([11],[0, 2, 4],'NEU'), ([10],[0, 2, 4],'NEU'), ([8],[0, 2, 4],'NEU')]
presenting the results from phase 3 ADVANCE, MOTIVATE and FORTIFY studies on risankizumab treatment for mod-sev cd. #ecco2022 #ecco22  .####[([9],[0, 13],'NEU'), ([7],[0, 13],'NEU'), ([6],[0, 13],'NEU'), ([12],[0, 13],'NEU')]
presenting "integrated summary of tofacitinib safety data from the global octave and riveting clinical trials. #ecco2022  .####[([10],[0, 1, 6, 13],'NEU'), ([12],[0, 1, 6, 13],'NEU'), ([4],[0, 1, 6, 13],'NEU')]
presenting the safety data from the global octave and riveting clinical trials of tofacitinib in uc. #ecco22 #ecco2022  .####[([7],[0, 10, 11],'NEU'), ([9],[0, 10, 11],'NEU'), ([13],[0, 10, 11],'NEU')]
remo panaccione presents an integrated analysis of the safety of tofacitinib for the treatment of #ulcerativecolitis, combining data from the octave and riveting trials #ecco2022 #gitwitter #ibd  .####[([20],[2, 5, 8, 13],'NEU'), ([22],[2, 5, 8, 13],'NEU'), ([10],[2, 5, 8, 13],'NEU')]
stunning data from phase 2a VEGA trial at #ecco2022 combination guselkumab + golimumab - 83% clinical response at week 12 combo biologic also better for clinical remission, endoscopic and histologic endpoints reassuring short-term safety &amp; look forward to longer-term data  .####[([5],[0, 6, 15, 25, 26, 31],'POS'), ([10],[0, 6, 15, 25, 26, 31],'POS'), ([12],[0, 6, 15, 25, 26, 31],'POS')]
#ecco2022 with results of VEGA study - combo #guse + #goli vs mono #gus vs mono #goli combo outperforms mono in remission , response , endoscopic improvement no new safety signals ; one serious infection combo-therapies can we de-escalate later ?  .####[([4],[18, 21, 24, 33, 34],'NEU')]
#ecco2022 op36 proof of concept study comparing guselkumab vs golimumab vs guselandgoli in active uc. significantly higher remission rates at w12 for combo (46%) .####[([1],[6, 15, 16],'NEU'), ([7],[6, 15, 16],'NEU'), ([9],[6, 15, 16],'NEU'), ([11],[6, 15, 16],'NEU')]
bruce sands presents results through week 12 of the phase 2a proof-of-concept VEGA rct examining the efficacy &amp; safety of combination induction therapy with guselkumab &amp; golimumab in participants with moderately-to-severely active #ulcerativecolitis #ecco2022 #ibd #gitwitter  .####[([12],[2, 14, 18],'NEU'), ([24],[2, 14, 18],'NEU'), ([26],[2, 14, 18],'NEU')]
dr. silvio danese talks to about the galaxi study. #ecco22  .####[([7],[3],'NEU')]
presenting the absence of any predictive sign of anti-tnf response based on whole blood #trem1 in both SERENE uc and #serence cd #ecco2022  .####[([17],[0, 5, 9],'NEU')]
efficacy and safety of mirikizumab as induction therapy in mod-sev uc, the phase 3 lucent-1 study, presented by geert d haens. #ecco2022 #ecco22  .####[([14],[0, 2, 16],'NEU'), ([4],[0, 2, 16],'NEU')]
nearly two-thirds of patients respond to mirikizumab treatment at 12 weeks in lillys first-in-class ulcerative colitis phase 3 lucent-1 study - feb 18, 2022 #ecco22  .####[([18],[4, 13],'NEU'), ([6],[4, 13],'NEU')]
#geertdhaens "efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active uc: results from the phase 3 lucent-1 study". #ecco2022  .####[([22],[12, 15, 17],'NEU'), ([5],[12, 15, 17],'NEU')]
#ecco2022 another anti -p19 molecule for #uc d haens with phase 3 lucent-1 mirikizab includes histoendoscopic remission and bowel urgency ( ) as secondary end points  .####[([12],[14, 15, 21],'NEU'), ([13],[14, 15, 21],'NEU')]
#ecco2022 #op24 guselkumab efficient for induction and maintenance in active #crohns. galaxi study, complex design with a "reference" arm with ustekunumab (not compared, underpowered) .. .####[([11],[3, 7, 13],'NEU'), ([2],[3, 7, 13],'NEU'), ([20],[14, 18],'NEU')]
danese concludes: guselkumab induction followed by sc maintenance achieved high rates of clinical efficacy at week 48 (note, the ustekinumab arm served as a reference, rather than a comparator). safety of guselkumab was consistent w/ that seen in other indications #ecco2022 #ibd  .####[([2, 31],[1, 7, 8],'NEU'), ([19],[21, 24],'NEU')]
up next, silvio danese presents week 48 data from the phase 2 galaxi 1 trial, investigating the efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active #crohn s disease #ecco2022 #gitwitter #ibd  .####[([12],[4, 15, 17, 19],'NEU'), ([21],[4, 15, 17, 19],'NEU')]
efficacy and safety of guselkumab induction therapy in pts with moderately to severely active uc: phase 2b quasar study results through wk 12. #ecco2022  .####[([17],[18, 19],'NEU')]
axel dignass presents data from the phase 2b quasar study, examining the efficacy and safety of guselkumab induction therapy in patients with moderately to severely active #ulcerativecolitis #ecco2022 #gitwitter #ibd  .####[([8],[2, 3, 10, 12, 14],'NEU')]
#ecco2022 w reinisch with results of Divergence2 #filgo in cd-pf small sample size , proof of concept refractory group of patients small signals of potential efficacy needs a large phase 3 programme?  .####[([6],[4, 16, 25, 27, 30],'NEU')]
walter reinisch presents data from the phase 2 Divergence2 trial, examining the efficacy and safety of filgotinib for treatment of perianal fistulising #crohns disease #ecco2022 #ibd #gitwitter  .####[([8],[2, 3, 4, 10],'NEU')]
#ecco2022 op10 : comparative efficacy of biologics for endoscopic healing (eh) #cd 'POS't-hoc 4 pivotal trials #ifx &amp; ada superior to vdz &amp; #ust for eh at 1yr biological-na ve ileum: no differences colon: #ifx &amp; ada superior to vdz &amp; #ust limitations  .####[([1],[2, 3, 14],'NEU'), ([17, 35],[18, 19, 36, 37],'POS'), ([20, 38],[18, 19, 36, 37],'NEG')]
#ecco2022 op10 #antitnfs remain more efficient in achieving mucosal healing in both ileum and colon in #crohns as compared to ust and vdz. meta analysis from rcts. .####[([1],[3, 4, 5, 7],'POS')]
silvio danese presents data from the u-achieve trial on the effects of maintenance therapy with upadacitinib on abdominal pain, bowel urgency, and fatigue in patients with moderately to severely active #ulcerativecolitis #ecco2022 #gitwitter #ibd  .####[([6],[2, 3],'NEU'), ([15],[2, 3],'NEU')]
stefan schreiber presents 'POS't-hoc analyses of the selection trial, which assessed use of filgotinib as induction and maintenance therapy for #ulcerativecolitis. read the main trial results here: #ibd #gitwitter #ecco2022 .####[([7],[2, 3, 4, 21, 26],'NEU'), ([13],[2, 3, 4, 10, 21, 26],'NEU')]
crispr-based in vivo genome editing in humans well tolerated, CRISPR-ATTR shows consistent and durable ttr reductions over 4-6 mo #aha2022  .####[([9],[7, 8, 10, 11, 13, 15],'POS')]
transform-hf summary results from #aha22 shows commendable efficacy in pts .####[([0],[5, 6, 7],'POS')]
prominent trial: pemafibrate reduced triglycerides, vldl-c, remnant cholesterol, and apociii by 20 to 30%, pemafibrate did not reduce cv event rates in diabetes, mild-to-moderate hypertriglyceridemia, low hdl-c, and well-controlled ldl-c #aha2022  .####[([2, 14],[3, 23, 25, 28],'POS')]
ironman summary results at #aha22 provided 'POS' outlook towards the future .####[([0],[5, 6, 7],'POS')]
catch up on day 1 updates from #aha22, results from transform-hf, dcp, ironman trials and more. watch my #accesspoints video with dr .####[([10],[0, 8, 16],'NEU'), ([12],[0, 8, 16],'NEU'), ([11],[0, 8, 16],'NEU')]
no difference between chlorthalidone vs hctz in cv outcomes or bp control in pragmatic trial in va patients. dr. and dr. areef ishani discuss late breaking results #aha2022 url here:  .####[([3],[0, 1, 2],'NEU')]
follow-up of the ischemia-extend trial over a median 5.7 years showed initial invasive strategy vs initial conservative strategy resulted in no difference in all-cause mortality with nearly twice the number of deaths #aha22  .####[([3],[5, 9, 10, 18, 20, 21],'NEU')]
a strategy of torsemide vs furosemide yielded no significant difference in death or hf hospitalization in pts hospitalized for hf #aha22 download full slideset for transform-hf here:  .####[([3],[6, 7, 8, 9],'NEU'), ([5],[6, 7, 8, 9],'NEU')]
precision care strategy results in the precise trial were that 70% reduction of the com'POS'ite of death, non-fatal mi or catheterization without obstructive cad, compared to usual testing at 1 year #aha22 download full slideset here:  .####[([6],[3, 11, 16, 24, 26, 27],'POS')]
do the results from respect-epa confirm or substantiate the results of reduce-it? dr. hiroyuki daida and i discuss the findings #aha22 url here:  .####[([4],[2, 5, 7, 9, 17],'NEU'), ([11],[2, 5, 7, 9, 17],'NEU')]
radial artery improves mace outcomes thru 15 years vs right internal thoracic artery or svg in cabg pts, rapco trial shows #aha22 download full slideset for the rapco trial here:  .####[([18, 27],[0, 1, 2, 4, 8, 12, 20],'POS')]
what a privilege to present #ironman at #aha22 thanks to all the investigators for your support and commitment  .####[([5],[2, 3, 4, 9],'NEU')]
bright-4 trial: bivalirudin with prolonged 'POS't-pci infusion in stemi reduces all cause death or barc 3-5 bleeding vs heparin monotherapy, less stent thrombosis with bival #aha22 download full slideset here:  .####[([0],[9, 12],'POS'), ([2],[9, 12],'POS')]
if you don t look for it, you won t find it. results from ironman support incorporating the assessment of iron deficiency into regular clinical practice. watch my interview with dr. paul kalra #aha22 url here:  .####[([14],[15, 16],'POS')]
will CRISPR-ATTR based in-vivo genome editing in humans be the next breakthrough for attr-amyloidosis? watch my interview with dr. gillmore and dr. lebwohl here #aha22 url here:  .####[([1],[10, 11, 14],'NEU')]
immediate ecmo cannulation (without venting strategy) in rapidly deteriorating or cardiogenic shock due to stemi did not improve clinical outcomes, shows ecmo-cs trial. watch full interview here #aha22 url here:  .####[([21],[16, 17, 18, 19, 20],'NEU')]
radial artery vs right internal thoracic artery/svg? which is better for long term 'POS't cabg? the rapco trials seal the deal! watch dr and professor david hare discuss here #aha22 url here:  .####[([16],[18, 20],'POS')]
prominent summary results at #aha22  .####[([0],[1, 2],'NEU')]
bivalirudin with high dose infusion in stemi vs heparin, is there a winner? bright-4 trial answers the question. watch my interview with dr gregg stone here #aha22 url here:  .####[([0],[2, 3, 4],'NEU'), ([13],[15, 17],'NEU')]
conservative vs invasive strategy, is either better on the long-run? long term data from the ischemia trial over 5.7 years of follow up are in - dr hochman and i discuss results of the ischemia -extended trial #aha22 url here:  .####[([15, 34],[10, 11, 12, 30, 31],'NEU')]
#originalresearch simpub #aha2022: in this #rct immediate implementation of ecmo-cs in patients with cardiogenic shock did not improve clinical outcomes compared with an early conservative strategy which allowed downstream use of... #circaha22 #ahajournals  .####[([9],[16, 17, 19, 20, 23, 24, 25],'NEG')]
precision-care strategy to guide management in stable cad. is it worth the hype? dr pamela douglas and i discuss results from the precise trial #aha22 url here:  .####[([22],[18, 19],'NEU')]
radial artery vs right internal thoracic artery/svg? which is better for long term 'POS't cabg? the rapco trials seal the deal! watch dr and professor david hare discuss here #aha22 download full slideset here:  .####[([16],[18, 20],'POS')]
host-exam extended study showed clopidogrel monotherapy significantly reduced risk com'POS'ite of all-cause death, nonfatal mi, stroke, readmission b/c of acs, &amp; barc type 3 bleeding in event-free pts under dapt for 12 6 mths after pci w/ des #aha22  .####[([0],[1, 2, 3],'NEU')]
in a randomized trial, the incidence of cardiovascular events was not lower in patients with diabetes, htg, and low hdl cholesterol levels who received pemafibrate, although tg, vldl cholesterol, remnant cholesterol, and apo c-iii levels decreased. #aha22  .####[([24],[7, 8, 10, 11],'NEG')]
drs. steve nissen, luke laffin, and i discuss results from the sport trial live from #aha22. low dose rosuvastatin is superior to any of the 6 dietary supplements in pts at risk of ascvd #accesspoints  .####[([11],[7, 8],'NEU'), ([18],[20, 21],'NEU')]
invasive strategy superior to conservative. reduction in incidence of mi and need of revasc in pts over &gt;80yrs. no effect on survival or cause of death. results from after eighty study #aha22 download full slideset here:  .####[([29],[26, 27],'NEU')]
glp-1 receptor agonists &amp; semaglutide are game changers and can really change the course of heart disease. watch my interview w/ dr. matthew budoff as we discuss results of the stop randomized control trial #aha22 url here:  .####[([4],[6, 7],'POS'), ([30],[26, 27],'NEU')]
#originalresearch simpub #aha2022 #circaha22: acetazolamide added to loop diuretics likelihood of successful decongestion similarily in patients with hfref, hfmref and hfpef. data from the advor trial. #ahajournals  .####[([4],[9, 11, 13],'NEU'), ([24],[21],'NEU')]
best-cli shows bypass to be superior to endovascular revasc in pts with critical limb ischemia and a saphenous vein available as conduit with respect to primary outcome: male and all cause mortality! also less amputations and reinterventions with bypass! #aha2022  .####[([0],[1, 19, 25, 26],'NEU')]
administration of iv fdi associated with lower risk of recurrent hf and cv death. fewer saes and no-increase related to infection w/ iv fdi, resulted from ironman trial #aha22 download full slideset here:  .####[([26],[6, 7, 17],'NEU')]
stop randomized control trial shows no significant reduction in plaque volumes associated with semaglutide #aha22 download full slideset here:  .####[([0],[5, 6, 7],'NEG')]
in results from swap-5, pts with stable cad pre-treated w/ticagrelor, use of cangrelor associated with no sig difference in pk/pd profiles after discontinuation of drug infusion, indicates absence of ddi. #aha22  .####[([3],[0, 1, 19],'NEU'), ([13],[14, 16, 17, 18],'NEU')]
should you give dual antiplatelet therapy, aspirin, or clopidogrel? watch my interview with dr. hyo soo kim as we discuss the results of the 6yr follow-up host-exam extended study #aha22 url here:  .####[([26],[9, 11, 19, 21],'NEU')]
lots of #heartsuccess here at #aha22. dr. and i discuss transform-hf, ironman and pro-hf url here:  .####[([10],[9],'NEU'), ([11],[9],'NEU'), ([13],[9],'NEU')]
in a randomized BEST-CLI trial of patients with limb ischemia, those assigned to bypass surgery as compared with endovascular therapy as an initial strategy had fewer adverse limb events or all-cause death at a median of 2.7 years. #aha22  .####[([3],[7, 10, 11, 14, 16, 17, 19, 25, 26, 28],'POS')]
SWAP-AC study showed increased p2y12 reactivity but reduced thrombin generation, which translated into no differences in platelet-mediated global thrombogenicity b/w dpi and ticagrelor- &amp; prasugrel, but not clopidogrel-, based dapt #aha22  .####[([0],[2, 5, 11],'NEU')]
immediate ecmo cannulation (without venting strategy) in rapidly deteriorating or cardiogenic shock due to stemi did not improve clinical outcomes, shows ecmo-cs trial #aha22 download full slideset here:  .####[([21],[15, 16, 17, 19, 20],'NEG')]
dcp summary results from #aha22  .####[([0],[1, 2],'NEU')]
phase 2 dose-ranging nova trial shows no significant difference in the rate of 'POS't-op af with botulinum toxin vs placebo #aha22 download full slideset here:  .####[([3],[6, 7, 8],'NEU'), ([16],[6, 7, 8],'NEU')]
admired colleagues, will you still recommend fibrates to a child with triglycerides on 3.000 mg/dl? (obviously along the insulin resistance treatment although the child is not overweight) .####[([6],[2, 3, 4, 5],'NEU')]
strong-hf changes everything we do after admission for hf. i mean everything! look at how they did it&gt; more not less care. how are we going to do this? #aha22  .####[([0],[1, 2, 11],'NEU')]
agree -- there is no way strong-hf can be replicated w cardiologists. #aha22 question is should slightly different models be tested in outcomes trials or do we accept maximal med therapy as a surrogate i ask b/c it might be more than just meds that led to benefits  .####[([6],[0, 4, 5, 7, 8, 9, 19, 39],'POS')]
CRISPR-ATTR summary results at #aha22  .####[([0],[1, 2],'NEU')]
my latest study-of-the-week on : the dcp trial presented here at #aha22 was awesome .####[([5],[7, 11, 12],'POS')]
a couple of thoughts on tongxinluo a traditional chinese med tested in stemi p pci. the drug reduced macce by 36% 30 d cardiac death by 30% 30-d stemi compl by 20% total death by 23% a) who cares how it works (see also sglt2i) b) how many trials did sac/val require? #aha22 .####[([5],[17, 19, 25, 30, 34],'POS')]
wow #aha22 were going to have to talk about tongxinluo -"a traditional chinese med which consists of herbs and insects" in cts-ami, a large rct, the drug led to a clinically significant statistically robust decrease in macce in pts w stemi 'NEU' martians are impressed! .####[([9],[27, 30, 31, 32, 34, 36, 43, 44],'POS')]
this seems like a strong rebuke of expert opinion on the preference of chlorthalidone over hctz no diff in outcome, higher ae w chlorthalidone --&gt; practicing docs prefer hctz. ?wisdom in everyday practice #aha22  .####[([13, 23],[4, 5, 11, 14, 16, 19],'NEG')]
lipoprotein is similar to ldl cholesterol but contains apolipoprotein. a trial, OCEAN-DOSE tested the effects of an oligonucleotide drug targeting apo mrna on lipoprotein concentrations in patients with cvd. #aha22  .####[([11],[2, 12],'NEU'), ([0, 8, 23],[2, 12],'NEU'), ([8],[2, 12],'NEU'), ([17],[2, 12],'NEU')]
ecmo-cs study #aha22 #lbct cardiogenic shock: rct immediate ecmo vs early conservative tx: no rct to date &gt;72% men shock due to stemi in most no difference in endpoint in circulation now  .####[([0],[13, 25, 26, 28],'NEU')]
#aha22 #lbct #cts ami study novel trial looking at supplement use of tomgxinfuo in #stemi t is used and approved in for stemi since 1996 124 3777 pts: t vs placebo- no diff in baseline characteristics signif in death/1o endpoint with use of t! &amp; 30d events  .####[([12],[31, 32, 35, 36],'NEU')]
late getting to #aha22 and transform-hf study which is rumoured to be amazing even with dst, but i blame today is wear red day and i am bringing these shoes today as well #gored #shoefie #hearts  .####[([5],[2, 9, 10, 11, 12],'NEU')]
rapco #aha22 conclusions use radial graft: associated with better outcomes in cabg it is &lt;10% first rct in #cabg  .####[([0],[3, 4, 6, 7, 8, 9],'POS')]
sport trial #aha22 #lbct examined statin supplements placebo single center, ldl&gt;70-189 ascvd risk &gt;5% statin only drug to ldl(1/2 had 40% ldl 5 mg rosuva) tg or cholesterol, statin had no effect on hscrp but only 4 week duration only statins ldl tg tc  .####[([0],[4, 8, 15, 16, 19, 29, 30, 31, 35, 39],'NEU')]
questions that remain #rapco #aha22. #lbct  .####[([3],[0, 2],'NEU')]
strength of this study rapco #aha22  .####[([4],[0, 1],'NEU')]
#transformhf presented by furosemide torsemide in hf #aha22 2859 pts randomized 12-month f/up no difference in all-cause / regardless of medication #lbct  .####[([4],[13, 14, 16],'NEU'), ([3],[13, 14, 16],'NEU')]
major congratulations $arwr for hitting a home run on 3 major world-changing #ascvd targets at #aha22: olpasiran - lp(a), apoc3, and angptl3. #rnai is now the hottest drug modality in town .####[([16],[0, 10, 11],'POS')]
#aha22 #lbct ironman aim: to evaluate longer-term effects of intravenous fe on cve in patients w/ #hf lvef&lt;45%, transferrin sat&lt;20% or ferritin&lt;100 g/l rct fe uc lower risk for heart failure + cardiovascular death with fe  .####[([2],[3, 5, 6, 7, 26, 27],'NEU')]
#lbct #aha22 #prominent pemafibrate triglyceride but will it events? 10,497 patients (66.9% w/ cvd) + dm no difference in cv events but adverse renal events and venous thromboembolism should we even tg in dm on statins  .####[([2],[8, 21, 23, 25],'NEU')]
the ecmo-cs trial showed that use of va-ecmo early among patients with rapidly deteriorating or severe cardiogenic shock did not result in superior outcomes compared with initial conservative care. read more: #aha22 #cardiotwitter  .####[([1],[3, 12, 13, 15, 16, 19, 20, 22, 24, 26, 27, 29, 30],'NEU')]
yes triglycerides matter. but the treatment does not involve medication #aha22 .####[([1],[2, 7, 8],'NEU')]
congratulations et al on this study! COACH is such an important trial! #aha22 .####[([6],[0, 10],'NEU')]
no both men and women. but not enough women in my opinion. 300 (26%) were women in ironman #aha22  .####[([17],[7, 11],'NEU')]
i was surprised about chlortalidone vs hctz in dcp!!!! #aha22  .####[([8],[2],'NEU'), ([4],[2],'NEU')]
#originalresearch simpub #aha2022 #circaha22: in the host-exam extended study, clopidogrel monotherapy had lower risk of thrombotic and bleeding events compared w/ aspirin monotherapy among patients w/o clinical events for 12mo after des  .####[([6],[10, 12, 13, 19, 22],'NEU'), ([9],[10, 12, 13, 19, 22],'NEU')]
breaking news: first data from best-cli bring surgical bypass into the forefront of discussion for patients with high-quality great saphenous vein - #bestcli #aha2022  .####[([5],[0, 1, 13],'NEU')]
rosuvastatin (5 mg daily) ldl-c sig. more than placebo, fish oil, cinnamon, garlic, turmeric, plant sterols &amp; red yeast rice in individuals w/ 10-yr risk for #ascvd based on findings from sport presented at #aha22 &amp; published in . #jacc  .####[([31],[29, 32, 36],'NEU'), ([0],[29, 32, 36],'NEU')]
ironman - ambulatory and inpatients with hf lvef&lt;45% - ferric derisomaltose results - numerically hf /cv by around the 18% (0.07) [covid sensitivity analyses 24% (0.047)] well-done to the ironman team #aha2022  .####[([0, 29],[11, 26],'NEU')]
vital-af #aha22 update: check out supersar lakotah hardie presenting on ac prescriptions in acutely-precipitated af, mentored by ! congratulations, lakotah!  .####[([0],[8, 15, 17],'NEU')]
dr presents the results of the sport trial. rosuva 5mg/d lowered ldl significantly more than 6 dietary supplements commonly used for cholesterol health. in fact no supplement lowered ldl-c more that placebo and garlic supplement actually raised ldl. #aha22  .####[([6],[1, 3],'NEU'), ([8],[10, 12, 27],'POS')]
fantastic discussion of the RESPECT-EPA trial by . #aha22 still a role to consider epa to address residual risk in secondary prevention patients .####[([4],[0, 1],'NEU')]
notably in this short term sport trial, no increase in musculoskeletal or 'NEU'rological symptoms or worsening glycemia with rosuva 5. all participants with rosuva 5 had ldl lowering (coin toss for supplements), 50% had ldl&gt;40% reduced with rosuva 5. #aha22  .####[([5],[7, 8],'NEU'), ([18, 23, 37],[35],'POS')]
RESPECT-EPA shows trend for benefit for #epa (no mineral oil control) with 21% reduction in primary outcome, borderline significance. trial may have been underpowered. increase in afib &amp; gi sz but not bleeding. #aha22  .####[([0],[1, 15, 16, 17, 23],'NEU')]
dr david preiss presents cv outcomes from empa-kidney. #sglt2i . in ckd patients, empaglifozin conferred similar reduction in primary outcome among patients with or without baseline cv disease. fewer cv deaths than expected. #aha22  .####[([7],[3, 13, 14, 17, 18],'NEU'), ([12],[3, 13, 14, 17, 18],'NEU')]
some additional slides from RESPECT-EPA including patient flow-diagram, baseline characteristics, study limitations, and concluding thoughts #aha22  .####[([4],[1, 7, 8, 9, 13],'NEU')]
discussant of the diurectic comparison trial, transform-hf. i know it was a va trial, but 97% men?!! we need women in trials to ensure results are generalizable to this half of the population. #aha22 . #wherearethewomen  .####[([6],[23, 24, 26],'NEU')]
dr discusses the prominent trial of pemafibrate. #aha22 . its about this specific drug not a strategy for tg lowering. but we have studied other fibrates for similar outcomes in past and gotten same results. here are her thoughts:  .####[([3],[1, 22, 26, 27, 32, 33],'NEU'), ([6],[1, 22, 26, 27, 32, 33],'NEU')]
dr presents the results from the transform-hf trial which shows that torsemide had similar comparative effectiveness as furosemide for all-cause mortality &amp; hospitalizations in #heartfailure patients in this pragmatic trial. #aha22  .####[([6],[1, 9, 13, 14],'NEU'), ([11],[1, 9, 13, 14],'NEU'), ([17],[1, 9, 13, 14],'NEU')]
so excited to see two of my idols #womenincardiology, present in the #lbctsession with dr aruna pradhan presenting the long awaited prominent trial of pemafibrate, with then as the discussant of this trial. cant wait! #aha22  .####[([21],[0, 1, 3, 17],'NEU'), ([24],[0, 1, 3, 17],'NEU')]
transform-hf findings from #aha22 suggest no real difference in deaths/hospitalizations in #heartfailure pts taking either torsemide or furosemide. future work should now focus on appropriate dosing of diuretics &amp; medication adherence, researchers said .####[([0],[1, 4, 13, 32],'NEU'), ([15],[1, 4, 13, 32],'NEU'), ([17],[1, 4, 13, 32],'NEU')]
now, dr presents dcp trial comparing chlorthalidone with #hctz in va patients with hypertension. #aha22 thread 1/3  .####[([3],[0, 2, 5],'NEU'), ([6],[0, 2, 5],'NEU')]
dr aruna pradhan presents the prominent trial of pemafibrate. here are the background slides for rationale of trial. #aha22 . thread 1/5  .####[([5],[3],'NEU'), ([8],[3],'NEU')]
concluding slide of transform-hf, with discussion by . #aha22  .####[([3],[0],'NEU')]
concluding thoughts in transform-hf by discussant at #aha22  .####[([3],[0],'NEU')]
excuse me, dr was moderator of prominent trial. with as discussant. triple #womenincardiology powerhouse on stage today for this trial! #aha22  .####[([6],[0, 1],'NEU')]
and here are the results of dcp, there was no difference in bp or major cv outcomes with chlorthalidone compared to hctz. there has more hypokalemia with chlorthalidone. #aha22 2/3  .####[([6],[14, 19, 24],'NEU'), ([18, 27],[14, 19, 24],'NEU')]
concern for increased renal adverse events &amp; vte with pemafibrate. and prominent concluding slides. now published in . #aha22 thread 5/5  .####[([11],[0, 2, 15],'NEU'), ([9],[0, 2, 15],'NEU')]
ironman : can t wait to hear present #aha22  .####[([0],[3, 5, 6],'NEU')]
dr eric broni presents his study on cumulative weight, adipokines, and prevalent hypertension from aric study. #aha22  .####[([14],[3],'NEU')]
sport trial #aha22 #lbct examined statin supplements placebo single center, ldl&gt;70-189 ascvd risk &gt;5% statin only drug to ldl(1/2 had 40% ldl 5 mg rosuva) tg or cholesterol, statin had no effect on hscrp but only 4 week duration only statins ldl tg tc  .####[([0],[4, 8, 15, 16, 19, 29, 30, 31, 35, 39],'NEU')]
questions that remain #rapco #aha22. #lbct  .####[([3],[0, 2],'NEU')]
strength of this study rapco #aha22  .####[([4],[0, 1],'NEU')]
"#transformhf presented by furosemide torsemide in hf #aha22 2859 pts randomized 12-month f/up no difference in all-cause / regardless of medication #lbct  .####[([4],[13, 14, 16],'NEU'), ([3],[13, 14, 16],'NEU')]
major congratulations $arwr for hitting a home run on 3 major world-changing #ascvd targets at #aha22: olpasiran - lp(a), apoc3, and angptl3. #rnai is now the hottest drug modality in town .####[([16],[0, 10, 11],'POS')]
#aha22 #lbct ironman aim: to evaluate longer-term effects of intravenous fe on cve in patients w/ #hf lvef&lt;45%, transferrin sat&lt;20% or ferritin&lt;100 g/l rct fe uc lower risk for heart failure + cardiovascular death with fe  .####[([2],[3, 5, 6, 7, 26, 27],'NEU')]
#lbct #aha22 #prominent pemafibrate triglyceride but will it events? 10,497 patients (66.9% w/ cvd) + dm no difference in cv events but adverse renal events and venous thromboembolism should we even tg in dm on statins  .####[([2],[8, 21, 23, 25],'NEU')]
the ecmo-cs trial showed that use of va-ecmo early among patients with rapidly deteriorating or severe cardiogenic shock did not result in superior outcomes compared with initial conservative care. read more: #aha22 #cardiotwitter  .####[([1],[3, 12, 13, 15, 16, 19, 20, 22, 24, 26, 27, 29, 30],'NEU')]
 yes triglycerides matter. but the treatment does not involve medication #aha22 .####[([1],[2, 7, 8],'NEU')]
 congratulations et al on this study! COACH is such an important trial! #aha22 .####[([6],[0, 10],'NEU')]
 no both men and women. but not enough women in my opinion. 300 (26%) were women in ironman #aha22  .####[([17],[7, 11],'NEU')]
 i was surprised about chlortalidone vs hctz in dcp!!!! #aha22  .####[([8],[2],'NEU'), ([4],[2],'NEU')]
#originalresearch simpub #aha2022 #circaha22: in the host-exam extended study, clopidogrel monotherapy had lower risk of thrombotic and bleeding events compared w/ aspirin monotherapy among patients w/o clinical events for 12mo after des  .####[([6],[10, 12, 13, 19, 22],'NEU'), ([9],[10, 12, 13, 19, 22],'NEU')]
breaking news: first data from best-cli bring surgical bypass into the forefront of discussion for patients with high-quality great saphenous vein - #bestcli #aha2022  .####[([5],[0, 1, 13],'NEU')]
rosuvastatin (5 mg daily) ldl-c sig. more than placebo, fish oil, cinnamon, garlic, turmeric, plant sterols &amp; red yeast rice in individuals w/ 10-yr risk for #ascvd based on findings from sport presented at #aha22 &amp; published in . #jacc  .####[([31],[29, 32, 36],'NEU'), ([0],[29, 32, 36],'NEU')]
ironman - ambulatory and inpatients with hf lvef&lt;45% - ferric derisomaltose results - numerically hf /cv by around the 18% (0.07) [covid sensitivity analyses 24% (0.047)] well-done to the ironman team #aha2022  .####[([0, 29],[11, 26],'NEU')]
vital-af #aha22 update: check out supersar lakotah hardie presenting on ac prescriptions in acutely-precipitated af, mentored by ! congratulations, lakotah!  .####[([0],[8, 15, 17],'NEU')]
dr presents the results of the sport trial. rosuva 5mg/d lowered ldl significantly more than 6 dietary supplements commonly used for cholesterol health. in fact no supplement lowered ldl-c more that placebo and garlic supplement actually raised ldl. #aha22  .####[([6],[1, 3],'NEU'), ([8],[10, 12, 27],'POS')]
fantastic discussion of the RESPECT-EPA trial by . #aha22 still a role to consider epa to address residual risk in secondary prevention patients .####[([4],[0, 1],'NEU')]
notably in this short term sport trial, no increase in musculoskeletal or 'NEU'rological symptoms or worsening glycemia with rosuva 5. all participants with rosuva 5 had ldl lowering (coin toss for supplements), 50% had ldl&gt;40% reduced with rosuva 5. #aha22  .####[([5],[7, 8],'NEU'), ([18, 23, 37],[35],'POS')]
RESPECT-EPA shows trend for benefit for #epa (no mineral oil control) with 21% reduction in primary outcome, borderline significance. trial may have been underpowered. increase in afib &amp; gi sz but not bleeding. #aha22  .####[([0],[1, 15, 16, 17, 23],'NEU')]
dr david preiss presents cv outcomes from empa-kidney. #sglt2i . in ckd patients, empaglifozin conferred similar reduction in primary outcome among patients with or without baseline cv disease. fewer cv deaths than expected. #aha22  .####[([7],[3, 13, 14, 17, 18],'NEU'), ([12],[3, 13, 14, 17, 18],'NEU')]
some additional slides from RESPECT-EPA including patient flow-diagram, baseline characteristics, study limitations, and concluding thoughts #aha22  .####[([4],[1, 7, 8, 9, 13],'NEU')]
discussant of the diurectic comparison trial, transform-hf. i know it was a va trial, but 97% men?!! we need women in trials to ensure results are generalizable to this half of the population. #aha22 . #wherearethewomen  .####[([6],[23, 24, 26],'NEU')]
dr discusses the prominent trial of pemafibrate. #aha22 . its about this specific drug not a strategy for tg lowering. but we have studied other fibrates for similar outcomes in past and gotten same results. here are her thoughts:  .####[([3],[1, 22, 26, 27, 32, 33],'NEU'), ([6],[1, 22, 26, 27, 32, 33],'NEU')]
dr presents the results from the transform-hf trial which shows that torsemide had similar comparative effectiveness as furosemide for all-cause mortality &amp; hospitalizations in #heartfailure patients in this pragmatic trial. #aha22  .####[([6],[1, 9, 13, 14],'NEU'), ([11],[1, 9, 13, 14],'NEU'), ([17],[1, 9, 13, 14],'NEU')]
so excited to see two of my idols #womenincardiology, present in the #lbctsession with dr aruna pradhan presenting the long awaited prominent trial of pemafibrate, with then as the discussant of this trial. cant wait! #aha22  .####[([21],[0, 1, 3, 17],'NEU'), ([24],[0, 1, 3, 17],'NEU')]
transform-hf findings from #aha22 suggest no real difference in deaths/hospitalizations in #heartfailure pts taking either torsemide or furosemide. future work should now focus on appropriate dosing of diuretics &amp; medication adherence, researchers said .####[([0],[1, 4, 13, 32],'NEU'), ([15],[1, 4, 13, 32],'NEU'), ([17],[1, 4, 13, 32],'NEU')]
now, dr presents dcp trial comparing chlorthalidone with #hctz in va patients with hypertension. #aha22 thread 1/3  .####[([3],[0, 2, 5],'NEU'), ([6],[0, 2, 5],'NEU')]
dr aruna pradhan presents the prominent trial of pemafibrate. here are the background slides for rationale of trial. #aha22 . thread 1/5  .####[([5],[3],'NEU'), ([8],[3],'NEU')]
concluding slide of transform-hf, with discussion by . #aha22  .####[([3],[0],'NEU')]
concluding thoughts in transform-hf by discussant at #aha22  .####[([3],[0],'NEU')]
excuse me, dr was moderator of prominent trial. with as discussant. triple #womenincardiology powerhouse on stage today for this trial! #aha22  .####[([6],[0, 1],'NEU')]
and here are the results of dcp, there was no difference in bp or major cv outcomes with chlorthalidone compared to hctz. there has more hypokalemia with chlorthalidone. #aha22 2/3  .####[([6],[14, 19, 24],'NEU'), ([18, 27],[14, 19, 24],'NEU')]
concern for increased renal adverse events &amp; vte with pemafibrate. and prominent concluding slides. now published in . #aha22 thread 5/5  .####[([11],[0, 2, 15],'NEU'), ([9],[0, 2, 15],'NEU')]
ironman : can t wait to hear present #aha22  .####[([0],[3, 5, 6],'NEU')]
dr eric broni presents his study on cumulative weight, adipokines, and prevalent hypertension from aric study. #aha22  .####[([14],[3],'NEU')]
aha sfrn #cardiometabolic fellow from stands in for 1st author eric broni to present our study from mesa about #adipokines &amp; risk of incident #vte. #aha22  .####[([17],[3, 13, 23],'NEU')]
prominent trial main results. pemafibrate did not reduce major cardiovascular outcomes, no benefit in any subgroup. #aha22 thread 4/5  .####[([0],[2, 3, 6, 7, 10],'NEU'), ([4],[2, 3, 6, 7, 10],'NEU')]
prominent trial. here are baseline characteristics slides, 96% on background statins. and the change in tgs &amp; tgrls. #aha22 . thread 3/5  .####[([0],[4, 13],'NEU')]
prominent trial. here are design slides. #aha22 thread 2/5  .####[([0],[4],'NEU')]
more slides about transform-hf by . #aha22  .####[([3],[0, 1],'NEU')]
 late-breaking science: dcri faculty presents primary results of the transform-hf trial 1 5 minutes from now in main event i #aha22  .####[([9],[4, 5, 6],'NEU')]
PROGRESSIVE-AF first-line ablation initial aad for afib shows lower progression to persistent afib 1.9% 7.4% lower af burden better 3 yr qol by 2 scores hospitalisation 5.2% vs.16.8% rrr 69% cardioversions ns #aha22  .####[([0],[7, 8, 15],'POS')]
NODE-301 : rapid #aha22 phase 3 study etripamil nasal ca channel block in svt at primary endpoint = psvt conversion to nsr at 30 min effective: by 30min 64.3% converted 31.2% placebo er avoided in pooled analysis:22% placebo 14% etripamil: nnt 13 to avoid er safe:ae mild  .####[([0],[1, 23, 31],'NEU')]
enhance-af decision aide #digital #tool designed for low #healthliteracy pts using #designthinking teaches pts iteratively about #oacs afib for stroke risk shows better decision making explaining #oac need in afib takes time, pt education;may factor in #pharmoequity #aha22  .####[([0],[1, 5, 21, 22, 23],'POS')]
nova phase 2 dose finding study of #botox for prevention of 'POS't-op #afib finds no significant difference in the two #botox doses placebo trend toward 125 unit dose effect in pts isolated cabg or age&gt;65 #aha22  .####[([0],[14, 15, 16],'NEU')]
sport important for #publichealth rosuvastatin 5 mg ldl-c more than placebo, fish oil, cinnamon, garlic,turmeric, plant sterols,&amp; red yeast rice ldl-c 37.86% w rosuva 5mg c/w placebo p&lt;0.001 similar adverse event rates #evidencebasedmedicine #aha22  .####[([0],[1, 30, 31],'NEU')]
best-CLI : #aha22 #clti many amputation events happened early on in this study, with high major amputation rate 10+% at 6 months in endo group &amp; 1% mortality w/in 30 days of endo &amp; if patients did not have adequate saphenous vein no dif b/w sx &amp; endo  .####[([0],[3, 37, 39, 40],'NEU')]
CTS-AMI : tongxinluo txl chinese herb (10 active ingredients that affect no reflow,endothelial fxn ) rct of stemi in despite 5 hour dtbt primary endpoint met 36% rrr of 30d mortality driven by cv death reduction w few strokes/mi no safety issues found #aha22  .####[([0],[22, 23, 24],'NEU')]
 cv death did not reach significance in either AFFIRM-AHF or ironman &amp; the com'POS'ite endpoints also missed being significant (hf hospitalizations/cv death) p=.07 in #ironman &amp; p=.06 in #affirm #aha22  .####[([10, 24],[3, 13, 18],'NEU'), ([8],[3, 13, 18],'NEU')]
RESPECT-EPA secondary prevention #epa 1800mg/d non mineral oil controls shows non significant p=.05 trend for benefit for #epa with 21% in primary outcomes, underpowered w ~ 2500 pts(not enough cv events) in afib &amp; gi symptoms but no bleeding #aha22  .####[([0],[5, 9, 10, 11],'NEU')]
stress trial 'NEU' 30% were neonates w low co subgroup analysis shows trend for benefit in lower complexity operations ,longer cpb, not premature patients pragmatic trial w/in a registry steroids to reduce systemic inflammation after infant heart sx?answer still yes #aha22  .####[([0],[2, 11, 16, 19, 22],'NEU')]
ecmo-cs 'NEU' #rct of immediate ecmo with cs stage d-e conservative rx shows early ecmo implantation no added benefit but 23/127 crossed over to downstream ecmo( one of the primary endpts) complex patients- took 8 yrs to enroll 127 patients  .####[([0],[1, 4, 10, 12, 13],'NEU')]
empa-kidney summary results from #aha22  .####[([0],[2, 3],'NEU')]
COACH cluster randomized~5k pts w acute chf to ehmr30-st risk algorithm (risk score/rapid hf clinic controls no intervention primary outcomes or cv re 12% risk reduction (hr .88) secondary outcomes hf hospitalizations 16%(hr.84) #aha22  .####[([0],[5, 18, 19, 28, 29],'NEU')]
pro-hf quality improvement study tests kccq-12 (4 domains) accuracy b/w clinicians &amp; patient pro delivery kccq-12 implementation 8 questions asked to clinicians &amp; also surveyed pts agreement b/w clinician &amp; pts based on nyha class better clinician prediction of pt health #aha22  .####[([0],[1, 2, 18, 19],'NEU')]
phase 1 cm arm of CRISPR-ATTR in vivo crispr/cas9 gene editor &amp; guide sgrna ntla-2001 based on data circulating precursor ttr protein assoc w better survival 12 patients: median age 75 all men, well tolerated most ae mild 93% ttr by 28d in all pts at .7 &amp; 1 mg/kg dose #aha22  .####[([5],[25, 33, 34],'POS')]
join us now main event i #aha22 #lbts CRISPR-ATTR editing in amyloidosis first-in-human in vivo coach health system intervention for chf pro-hf patient-reported outcome measurement in heart failure clinic ironman: iv ferric hfref  .####[([8],[23, 24],'NEU'), ([29],[23, 24],'NEU')]
dcp open label study for htn chlorthalidone hydrochlorothiazide (95% on 25 mg) in mostly men(97%) in 'NEU' primary outcome hr 1.01 only 1 pre specified subgroup with prior stroke/mi had a significant p value .035 #aha22  .####[([0],[16, 17, 18],'NEU'), ([6],[16, 17, 18],'NEU')]
prominent randomized &gt;10k pts 1/4 women to pemafibrate .2mg bid for high triglycerides 200-499 or hdl &lt;=40 in dm2 (no dm1) placebo 'NEU' primary endpoint hr 1.03 no dif in pre specified subgroups renal adverse,v embolism nalfd #aha22  .####[([0],[22, 23, 24],'NEU'), ([7],[22, 23, 24],'NEU')]
 discusses prominent #aha22 - in the statin era,no cv benefit with fibrates( with ldl controlled- in prominent trial median was 78)  .####[([1, 17],[0, 8, 9, 10],'NEU')]
empa-kidney: among a wide range of patients w/ ckd who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cv causes (vs. placebo) ca. 2022 from #kidneywk #aha22 #nephpearls  .####[([0],[1, 3, 4],'NEU'), ([16],[1, 3, 4],'NEU')]
EMPA-KIDNEY ; DELIVER ; SCORED : sglt2 inhibitors have a role in modifying risk of kidney disease progression &amp; aki in those w/ type 2 dm at cv risk, and also in those w/ ckd or heart failure irrespective of diabetes status, primary kidney disease, or kidney function ca. 2022 #aha22 #kidneywk #nephpearls  .####[([0],[9, 10, 14, 25],'NEU'), ([1],[9, 10, 14, 25],'NEU'), ([2],[9, 10, 14, 25],'NEU')]
DELIVER , SCORED : sglt2 inhibitors have a role in modifying risk of kidney disease progression &amp; aki in those w/ type 2 dm at cv risk, and also in those w/ ckd or heart failure irrespective of diabetes status, primary kidney disease, or kidney function ca. 2022 #aha22 #kidneywk #nephpearls  .####[([0],[8, 9, 13, 24],'NEU'), ([1],[8, 9, 13, 24],'NEU')]
#aha22: read this review of the primary results from the multicenter, randomized ecmo-cs by still no clarification on standardized definitions for escalation of therapy. #cardiotwitter  .####[([12],[3, 6, 7],'NEU')]
 despite being underpowered, and while one can quibble about the p value, looks like it had a real benefit, consistent with both JELIS and reduce-it. the curves appear to separate in a plausible way. good ldl control, and importantly, the average triglycerides were normal! .####[([24],[2, 7, 12, 18],'POS'), ([22],[2, 7, 12, 18],'POS')]
 despite being underpowered, and while one can quibble about the p value, looks like it had a real benefit, consistent with both jelis and reduce-it. the curves appear to separate in a plausible way. good ldl control, and importantly, the average triglycerides were normal! .####[([24],[2, 7, 12, 18],'POS'), ([22],[2, 7, 12, 18],'POS')]
 , my parents are cvd patients and received this from their healthcare provider . how is this not infringing on reduce-it patents. icosapent ethyl does not have a cvd label, vascepa does!  .####[([18],[7, 12, 13, 14, 15, 16, 23],'NEU')]
ORION-9 ; ORION-10 ; ORION-11 : inclisiran and cardiovascular events: a patient level analysis of phase iii trials #aha22  .####[([0],[6, 8, 9],'NEU'), ([1],[6, 8, 9],'NEU'), ([2],[6, 8, 9],'NEU')]
precision : omg! we have a new bp medication after 2 decades ! and for resistant ht - really meticulous study design aprocitentan in #aha22  .####[([0],[3, 5],'NEU')]
BrigHTN : and the aldo synthase inhibitor also #baxdrostat in resistant ht - dose dependent effect #aha22 at this rate we need a #hypertensionjc  .####[([0],[9, 12, 13],'NEU')]
 in the early 2000s there was a lot of talk of the cardio-renal-anemia syndrome and people tried esas in heart failure it was probably all about the iron instead? #aha22 #kidneywk, affirm-ahf .####[([31],[9, 15, 20],'NEU')]
 congratulation to the authors on this investigator initiated study,ECMO-CS. it shows the the complexity of this area where it took 8 years to enroll 122 patients. we clearly need more data to confirm what is best for the cs patient. #aha22 #cardiotwitter .####[([9],[29, 30, 31, 33],'NEU')]
 congrats on your presentation of FOURIER-OLE ! .####[([5],[0, 3],'NEU')]
#aha22 transform-hf: torsemide comparison with furosemide formanagement of heart failure similar efficacy of torsemide versus furosemide strategy for all cause and total in patients hospitalized for hf success of decongestion, disease specific cv or hf outcomes  .####[([1],[10, 31],'NEU'), ([2, 13],[10, 31],'NEU'), ([5, 15],[10, 31],'NEU')]
#aha22 #shep trial chlorthalidone did not major cv outcomes or non-cancer vs hctz at doses commonly used in clinical practice (ctd 12.5mg/hctz 25mg)  .####[([1],[4, 5, 6, 7, 8],'NEU')]
#aha22 ldl-c- effects of inclisiran + usual care vs usual care alone in with recent for an acs: #victorion-inception ongoing trial planned to complete in 2024 assess the effectiveness of inclisiran + usual care for the management of with ldl-c 'POS't-acs  .####[([18],[6, 7, 9, 10, 26, 28, 32, 33],'POS')]
#strong-hf #aha22 rapid up-titration of hf under close follow-up (exam, nt-probnp): is effective full dose at 90d: bb 49%vs4% raasi 55%vs2% mra 84%vs 46% is safe (similar saes) 44% rr hfre all-cause patients qol  .####[([0],[2, 7, 12, 13, 25, 26, 31],'POS')]
#hfpef vs hfmref in EMPEROR-Preserved via sd.anker #aha22 empagliflozin in hfpef&gt;50% cv/ hf (rrr 17%) first hf (rrr 22%) kccq-ccs slope decline egfr rate over time  .####[([4],[20, 21, 23],'NEG'), ([8],[20, 21, 23],'NEG')]
despite the theoretical benefits &amp; prelim data, among patients on hctz, switch to chlorthalidone vs staying on hctz didnt change cv prognosis #aha22 .####[([13],[18, 19, 21],'NEU')]
pemafibrate lowered tg but increased ldl-c leading to an overall *null* apob-effect. resoundingly clear- it s all about apob-lowering for addressing atherogenic lipoprotein-related risk #aha22 .####[([0],[9, 10],'NEU')]
coach: among pts presenting to the ed with acute hf, a point-of-care algorithm (stratifying risk of death for outpt or inpt triage) improved risk for death or cv hospitalization w/in 30d (hr 0.88) #aha22 .####[([0],[14, 22, 23],'POS')]
precise summary results from #aha22  .####[([0],[1],'NEU')]
large empa-kidney meta-analysis highlights safety/efficacy of #sglt2 inhibitors in reducing risk of kidney disease progression, acute kidney injury, cv death &amp; #heartfailure hospitalization in patients w/ #ckd or hf, irrespective of #diabetes status #aha22  .####[([1],[9, 10, 21, 29, 31, 32],'POS')]
an incredible pleasure to present these data on covid-19 in #deliver at scientific sessions. thank you to the entire deliver team, especially for his ever-constant support .####[([10, 19],[1, 4, 12],'NEU')]
Transform-HF: so basically there is no difference! .####[([0],[5, 6],'NEU')]
the best-cli trial showed among pts w/ clti in whom both surgical &amp; endovascular interventions were feasible, #cvsurg #revasc w/ great saphenous venous conduit was superior to endovascular intervention in reducing major adverse limb events or death. #aha22  .####[([1],[13, 27, 30, 31, 32, 34, 36],'POS')]
 Advor: this is beautiful physiology! congratulations my friend! .####[([0],[3, 4],'NEU')]
rcts are the gold standard but they should not go unquestioned esp with an implausible large effect, wide ci &amp; an unknown biological mechanism what active ingredient(s) in tongxinluo (mix of herbs &amp; insects) that can explain a 30% in cv death at 30 day 'POS't ami? #aha22  .####[([28],[10, 14, 15, 16, 22, 41],'NEU')]
 triglyceride lowering w/ #pemafibrate to reduce cardiovascular risk no benefit #aha22 #cardiotwitter #cardioed  .####[([0],[5, 6, 7, 8, 9],'NEU')]
 transform-hf: placebo effect  .####[([0],[1, 2],'NEU')]
transform-hf - a large pragmatic rct of furosemide vs torsemide. no evidence of difference in mortality or hospitalisation. but a great demonstration that pragmatism is an essential &amp; beneficial feature of good rcts. #aha22  .####[([0],[3, 4, 20, 26, 28, 31],'NEU')]
another pragmatic rct dcp result @#aha22 chlorthalidone vs hydrochlorothiazide - no difference in incidence of major cardiovascular outcomes again, an efficient way to get reliable evidence in a broad range of patients  .####[([3],[1, 10, 11, 16, 20, 23, 24, 25],'NEU')]
david preiss presenting results of empa-kidney trial #aha22  .####[([5],[2],'NEU')]
pemafibrate va placebo on top of ldl-lowering treatment in pts with high triglycerides and low hdl-cholesterol in diabetic pts. a debate as long as my career. despite 20-30% reduction in triglycerides, no impact on major cardiovascular events. #aha22  .####[([0],[31, 32, 34, 36],'NEU')]
really important to see this practical transform-hf trial and now we have the data to guide our debates on which loop diuretic: (answer: use what works for your patient and focus on decongestive #gdmtworks- compliment with sglt2i, arni, mra for k sparing). monitor carefully .####[([6],[1, 5],'NEU')]
ecmo-cs in patients with rapidly deteriorating or severe cardiogenic shock, immediate use of #ecmo does not improve outcomes over an initially conservative strategy with bailout ecmo as needed #aha22 #heartfailure #cardiotwitter  .####[([0],[14, 15, 16, 17],'NEG')]
extended f/up of the ischemia-extend trial over a median 5.7 yr demonstrated that an initial inv strategy compared with an initial con strategy resulted in: no difference in all-cause with nearly twice the number of (557) lower risk of cv higher risk of non-cv #aha22  .####[([4],[0, 11, 14, 16, 20, 22],'NEU')]
#originalresearch simpub #aha2022 #circaha22: in this #rct, indobufen + clopidogrel dapt compared with aspirin + clopidogrel dapt significantly reduced the risk of 1-year net clinical outcomes, mainly driven by a reduction in bleeding events without an ... .####[([7],[17, 18, 20],'NEU'), ([9, 15],[17, 18, 20],'NEU')]
early ecmo-cs no better than watch-and-wait approach in #cardiogenicshock the ecmo-cs trial of patients with rapidly deteriorating or severe shock suggests ecmo can be held until hemodynamic status worsens #aha22  .####[([1, 10],[0, 5, 6],'NEU')]
ischemia-extend even with a few more years of follow-up, an initial invasive strategy is no better than a more-conservative approach for improving survival in patients with chronic cad and moderate to severe ischemia #aha22  .####[([0],[4, 5, 8],'NEU')]
decongestion with acetazolamide in acute decompensated #heartfailure across the spectrum of #lvef : a pre-specified analysis from the advor trial #aha22  .####[([17],[13, 14],'NEU'), ([2],[13, 14],'NEU')]
#originalreseach #simpub #aha2022 #circaha22 in valor-hcm myosin inhibition with mavacamten reduced the need for septal reduction therapy at 32 weeks with lvot gradients quality of life, and 'POS' cardiac remodeling #ahajournals  .####[([5],[10, 12, 27, 28, 29],'POS'), ([9],[10, 12, 27, 28, 29],'POS')]
ecmo-cs summary results from #aha22  .####[([0],[1, 2],'NEU')]
"while we were disappointed that we didnot show torsemide was better, i think we ve answered the question," says #aha22  .####[([8],[3, 6, 7, 10],'NEG')]
immediate insertion of ecmo-cs in patients with #cardiogenicshock did not improve clinical outcomes compared with an early conservative strategy #aha22, ecmo-cs .####[([3, 20],[13, 18],'NEU')]
 (empa-kidney) (#empagliflozin) results were presented .####[([0],[4],'NEU')]
 #aha2022 exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: the breast cancer randomized exercise intervention BREXIT study  .####[([18],[1, 4, 15, 16],'NEU')]
acetazolamide &amp; natriuresis in advor good or excellent natriuresis ~ una+ 280 mmol/l #acetazolamide allocation: n=186 or 80.5% vs placebo allocation: n=152 or 65.8% excretion of 115 mmol na+ (corresponding to 6.7 g salt) within 48 hr) #aha22  .####[([4],[5, 7, 13, 19, 28],'NEU'), ([0, 12],[5, 7, 13, 19, 28],'NEU')]
#ironman for a broad range of patients with #heartfailure ( #lvef 45%) and fe deficiency, iv ferric derisomaltose was associated with a risk of admissions for hf and cv #aha22  .####[([0],[3, 18, 21, 23],'NEU')]
hot trials from #aha22 #transform-hf #dcp #prominent #ironman and more accs full coverage of the latest science from american heart associations (aha) scientific sessions 2022 #jacc #heartfailure #cardiotwitter  .####[([4],[9, 11, 15, 22],'NEU'), ([7],[9, 11, 15, 22],'NEU'), ([5],[9, 11, 15, 22],'NEU'), ([6],[9, 11, 15, 22],'NEU')]
transform-hf: torsemide no better than furosemide for hospitalized hf #heartfailure #aha22  .####[([0],[2, 3],'NEG'), ([1],[2, 3],'NEG'), ([5],[3],'NEU')]
With CRISPR-ATTR ,apollo by day 28, all patients achieved #ttr reductions of at least 90% those in the nyha iii 0.7 mg/kg and #nyha i/ii 1.0 mg/kg cohorts achieved 94% and 92% ttr reductions, respectively, at 4 month the nyha i/ii 0.7 mg/kg group had achieved 93% ttr reductions at 6 month #aha22 .####[([1],[8, 13, 28, 34, 45],'NEU'), ([2],[8, 13, 28, 34, 45],'NEU')]
novel CRISPR-ATTR -editing therapy shows promise for patients with transthyretin amyloid #cardiomyopathy #aha22 #heartfailure  .####[([1],[0, 4, 5],'POS')]
ironman for a broad range of patients with #heartfailure ( #lvef 45%) and fe deficiency, iv ferric derisomaltose was associated with a risk of admissions for hf and cv #aha22  .####[([0],[3, 18, 21, 23],'NEU')]
#originalresearch simpub #aha2022 #circaha22: the efficacy and safety of empagliflozin was similar in black and white patients with hf across the range of ef, with a suggestion of enhanced efficacy in black patient.. .####[([9],[5, 7, 11, 29],'NEU')]
#justpublished #aha22 #circaha22 exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: the breast cancer randomized exercise intervention BREXIT study #ahajournals  .####[([20],[3, 17, 18, 21],'NEU')]
strong-hf rapid uptitration of #gdmtworks after acute #heartfailure pays dividends the trial was stopped early due to a greater-than-expected benefit of high-intensity therapy after 1,078 patients (mean age 63 yrs; 39% ) were randomized #aha22  .####[([0],[13, 14, 18, 19, 21, 33],'POS')]
PROGRESSIVE-AF first-line #ablation reduces #afib progression, boosts #qol patient-reported outcomes, including disease-specific and general #qol and symptom burden, also significantly favored an ablation-first strategy #aha22  .####[([0],[3, 5, 6, 19, 20],'POS')]
strong-hf getting patients up to full doses of #gdmt within just 2 weeks of an acute #heartfailure hospitalization improves measures of congestion and clinical outcomes #aha22 just published in  .####[([0],[18, 24, 27],'NEU')]
BrigHTN - phase 2 trial of baxdrostat for treatment-resistant hypertension this aldosterone synthase inhibitor, baxdrostat led to substantial reductions in sbp and dbp in patients with tx-resistant #hypertension #aha22 #cardiotwitter  .####[([0],[15, 17],'POS'), ([6, 14],[15, 17],'POS')]
thrilled to have presented the safety &amp; efficacy analysis of fourier and fourier-ole as a late-breaker at #aha22! monotonic relationship btw lower ldl-c, &lt;20mg/dl, and lower adverse cv events. huge thanks to dr. marc sabatine, and !  .####[([12],[0, 3, 5, 7, 15, 30],'NEU'), ([10, 12],[0, 3, 5, 7, 15, 30],'NEU')]
had so much fun presenting the adjudicated results from the soloist-whf and scored trials! #aha2022  .####[([12],[3, 4],'NEU'), ([10],[3, 4],'NEU')]
the prominent trial presented today at #aha2022 revealed that in patients with diabetes, mild to moderate hypertriglyceridemia and low hdl, pemafibrate did not lower rates of cv disease .####[([1],[3],'NEU'), ([20],[3, 7, 22, 23],'NEU')]
#ecls as circulatory support in cs? results of ecmo-cs out! immediate #ecmo-cs feasible but no improved outcomes in rapidly deteriorating/severe cs (scai d-e) vs early conservative therapy allowing ecmo if worsening hemodynamics  #foamcc #aha2022  .####[([8, 11],[6, 12],'NEU')]
dr piazza presents prevent-hd results comparing prophylactic-dose rivaroxaban vs placebo in ambulatory patients with #covid19 infection. study terminated early due to low event rates with delta &amp; omicron viral variants. #aha22  .####[([3],[2, 5, 17],'NEU'), ([7],[2, 5, 17],'NEU')]
#aha22 extended follow-up of the ischemia-extend demonstrated that an initial invasive strategy vs. an initial conservative strategy resulted in: -no difference in all-cause mortality -lower risk of cardiovascular mortality -higher risk of non-cardiovascular mortality  .####[([5],[2, 6, 17, 20],'NEU')]
#aha22 the OPTION trial: indobufen+dapt is not inferior to aspirin+dapt after coronary drug-eluting stent implantation  .####[([2],[6, 7, 11, 12],'POS')]
#aha22 the PRECISE trial: net clinical effectiveness of the precision strategy with a 70% reduction of the com'POS'ite of death, non-fatal mi or catheterization without obstructive cad, compared to usual testing at 1 year  .####[([2],[4, 5, 6, 20, 27, 30],'NEU')]
join us for the #lbct session this am in main event i featuring several interesting trials including rapco CTS-AMI stress ecmo-cs #patogara, #joannechikwe #accearlycareer #accfit #accic #cardiotwitter  .####[([18],[5, 12, 14],'NEU'), ([20],[5, 12, 14],'NEU'), ([17],[5, 12, 14],'NEU')]
 tct @ aha case based discussions at #aha22 #aha2022 were a huge hit w/4 complex cases in a box w/ excellent discussion: rca cto in a pt w/ prior tavr w/ self expanding valve recalcitrant rca isr tavr in pure ar teer (ice+tee guided) in pt w/ sev smr &amp; tr  .####[([41],[10, 11, 20, 21],'NEU')]
day 1 recap of #aha22: drs. , and review late-breaking science from aha 2022, including transform-hf, dcp, prominent, and ironman. watch it here: #cardiotwitter  .####[([14],[2, 7, 8],'NEU'), ([18],[2, 7, 8],'NEU'), ([15],[2, 7, 8],'NEU'), ([16],[2, 7, 8],'NEU')]
best-cli: the results are in and they re likely practice-altering actagainstamputation #aha22  .####[([0],[2, 9],'POS')]
such a privilege to share the results of transform-hf this morning. so much more to tell including insights on qol, dose &amp; data from ancillary studies slides and lay summary available at: #aha22  .####[([8],[6, 29],'NEU')]
PRECISE trial demonstrates the net clinical effectiveness of the precision strategy with a 70% reduction of death, non-fatal mi or cath without obstructive cad compared to usual testing at 1 year. precise trial presented by #aha22  .####[([0, 31],[2, 4, 5, 6, 33],'POS')]
precise trial presented by today and discussion by #aha22  .####[([0],[2],'NEU')]
demographics (~50% women) table and initial diagnostic tests performed chart below from PRECISE trial, presented by #aha22  .####[([12],[5, 6, 8, 14],'NEU')]
late breaking trials: among patients with stemi undergoing primary pci with radial artery access, bivalirudin reduced 30-day com'POS'ite of all-cause mortality or major bleeding compared to heparin monotherapy, BRIGHT-4 presented by #aha22  .####[([28],[0, 1, 7, 8, 29],'NEU'), ([14],[15],'POS')]
#aha22 - sport trial nutraceuticals ubiquitous and assumed by many pts to be heart healthy. industry sport compared to rosuva and placebo, do they impact biomarkers? 1/  .####[([2, 16],[7, 24],'NEU'), ([19],[7, 24],'NEU')]
 nearly 20 years later in a population on statin, jelis results are confirmed: 19-21% rrr w/ epa 1800 mg. hscrp similar effect in reduce-it, real. magnitude . probably 15-20% rrr af real pcsk9i rrr is 15% 5/5 #aha22 #epa #om3  .####[([23],[10, 12, 20, 21],'NEU')]
RESPECT-EPA estimated 30% rrr. achieved a 21.5% in 1 , 26.5% in 2 endpts. no mineral oil. didnot meet endpoint, underpowered. achieved nearly jelis-like similar ~20% rrr. both groups on statins and ldl-c 80 mg/dl. 4/ #aha22  .####[([0],[1, 16, 17, 18, 19, 23],'NEU')]
u.s. experts favor chlorthalidone over hctz in the first-line treatment of hypertension. yet practicing doctors are approximately 20-fold more likely to choose hctz over chlorthalidone. #aha22 #medtwitter  .####[([3, 24],[2, 8, 13, 18, 19, 21],'NEU')]
1,800 mg epa 46 145 ug/ml (26 150 ug/ml, REDUCE-IT) ldl-c, trigs, hdl-c no change hscrp went down in both 3/ #aha22  .####[([10],[14, 15],'NEU')]
 no surprise, rosuva 5 mg is potent, ldl-c %change 37 good to know: ryr, 6% ish. others nominal 2 - no surprise for rosuva in tc, trigs, hdl-c #aha22 4/ sport trial .####[([30],[0, 1, 20, 21],'NEU'), ([2, 23],[0, 1, 20, 21],'NEU')]
my pi, gregory piazza, presenting prevent-hd trial to evaluate rivaroxaban in reducing the risk of major venous and arterial thrombotic events, hospitalization, and death in medically ill outpatients with covid-19 in late-breaking clinical trial #aha22  .####[([5],[4, 8, 31],'NEU'), ([9],[11, 13],'POS')]
n=199, randomized single blind lipid in sport trial, hscrp, cmp. baseline and at 28 days. 1 risk, age 40-75, ldl-c 70-189, borderline to upper intermediate risk (5-20%, estimated 10 yr event) 1 endpoint: %ldl-c change vs rosuva 2 endpt: biomarkers vs rosuva; vs placebo #aha22 2/  .####[([6],[1, 7, 10, 21, 32],'NEU'), ([36, 41],[1, 7, 10, 21, 32],'NEU')]
happening now at #ress22: prof presenting the box trial: devise-based prevention of fever for up to 36 or 72 hours after ohca .####[([7],[0, 1, 5],'NEU')]
 excited for all four transform-hf,prominent,dcp,sprint! yes, i am that reviewer question to #aha22 pre-#lbct as a common loop diuretic, which do you currently use?  .####[([4],[0, 12, 13, 19, 20],'NEU'), ([5],[0, 12, 13, 19, 20],'NEU'), ([6],[0, 12, 13, 19, 20],'NEU'), ([7],[0, 12, 13, 19, 20],'NEU')]
 sim pub with #aha22 from et al pro-hf trial: comparing nyha class &amp; patient-reported outcomes among patients hospitalized for #hf read more: #ahajournals  .####[([7],[13, 14],'NEU')]
 this is what i am hoping to see, though would be happy if transform-hf is equipotent for mace reduction. recognizing that they are not equipotent on #htn lowering at similar mgs. thoughts ? #aha22 earlier lit:  .####[([13],[5, 7, 8, 11, 15, 19, 23, 24, 29],'NEU')]
 these trial results have great potential to change and improve our practice and patient outcomes. my pre #lbct shots called: torsemide &gt; furosemide chlorthalidone &gt; hctz prominent = ppar-a, not a cvd reducing tx #aha22 which trial ru excited for? transform-hf,dcp .####[([26],[4, 5, 9, 11],'NEU'), ([39],[4, 5, 9, 11],'NEU'), ([40],[4, 5, 9, 11],'NEU')]
 dichotomy for tx of trigs - reduce pancreatitis or cvd risk. ppar- reduce trigs, but do they impact cvd events? with prominent results to be presented, do you think ppar- s in cvd tx are done? #aha22 .####[([21],[17, 19, 22, 25],'NEU')]
 very intriguing results of transform-hf,prominent,dcp,sprint ! those leaning towards yes on cvd impact, please tell me your thoughts! #aha22 .####[([4],[0, 1, 2, 9, 14, 19],'NEU'), ([5],[0, 1, 2, 9, 14, 19],'NEU'), ([6],[0, 1, 2, 9, 14, 19],'NEU'), ([7],[0, 1, 2, 9, 14, 19],'NEU')]
curious about VICTORION-INCEPTION? &lt;30 day 'POS't acs, on max statin, and ldl-c &gt;70. stop by to talk to inclisiran, sirna effect on #pcsk9i #aha22  .####[([2],[0, 13, 16],'NEU')]
 not surprised but would have loved this to be a 'POS' study. #aha22  prominent, ppar-a in triglycerides for cv reduction. 'NEU' .####[([13],[0, 1, 20],'NEU')]
 well then. both my called shots have come up as 'NEU'. that s why we need randomized trials like dcp. will you use ctd over hctz or consider them both equally ? #aha22 .####[([19],[10, 16, 30],'NEU')]
 it is why i love that you and your team embarked on this trial. given my clinical experience with ctd during and after sprint, ctd has been much better at similar doses to hctz to reduce bp. thanks for the trial results and congratulations! #aha22  .####[([23],[16, 17, 20, 22, 27, 28, 35],'POS'), ([19, 24],[16, 17, 20, 22, 27, 28, 35],'POS')]
the dcp trial showed that there are no differences in cardiovascular outcomes between chlorthalidone and hctz among elderly veterans with #hypertension. learn more: #aha22 #cardiotwitter  .####[([1],[2, 3, 7, 11],'NEU'), ([13],[3, 7, 11],'NEU')]
dr. alik farber presents the findings of the best endovascular vs. best surgical therapy in patients with critical limb ischemia best-cli trial: surgery &gt; endovascular if adequate great saphenous vein surgery = endovascular if adequate vein not available #aha22  .####[([20],[3, 5, 12, 13],'NEU')]
"it is important to ask who did not make it into the study and whether this introduces bias." dr. discusses the best-cli trial, including primary and #qol analyses, and highlights remaining questions to continue to improve patient care. #aha22  .####[([21],[19, 22, 31, 35, 36, 37],'NEU')]
join us in 15 minutes in main event i hall for the late-breaking vascular science session, lined up with trial findings: best-cli primary outcomes (dr. alik farber) best-cli #qol outcomes (dr. ) prevent-hd primary outcomes (dr. gregory piazza) #aha22  .####[([31],[0, 12, 13, 15],'NEU'), ([21, 27],[0, 12, 13, 15],'NEU')]
"we need to do a better job in engaging and enrolling patients in clinical trials." dr. discusses the prevent-hd trial. #aha22 "we need and do rcts [to guide clinical practice]!"  .####[([18],[1, 5, 8, 10, 11, 22],'NEU')]
greatly look forward to the presentation of strong-hf congratulations and thank you to the investigators testing via rct the safety, tolerability, and efficacy of the rapid optimization of gdmt for patients with hf #aha22  .####[([7],[0, 2, 5],'NEU')]
in light of RESPECT-EPA, compelled to 'POS't this great paper on borderline significance. please read and then interpret the trial findings. #aha22 interpreting and reporting clinical trials with results of borderline significance | the bmj  .####[([3],[13, 14, 16, 17, 19, 20],'NEU')]
#aha22 oral presentation: effect of mavacamten on diastolic function in patients with obstructive hypertrophic cardiomyopathy: insights from the valor-hcm study .####[([18],[2, 15, 19],'NEU')]
decongestion with acetazolamide in acute decompensated heart failure across the spectrum of left ventricular ejection fraction: a pre-specified analysis from the advor trial. | circulation  .####[([21],[4, 5, 7, 17],'NEG'), ([2],[4, 5, 7, 17],'NEG')]
virtually following the #aha22 in chicago and proud to see brazilian participation in prominent study -  .####[([13],[0, 1, 7, 9, 11],'NEU')]
phase 2 nova study results via #aha22: subgroup analyses suggest rate of 'POS't-op #af, reduced rehospitalization in patients undergoing isolated cabg and patients older than 65 who received 125u of botulinum toxin type a  .####[([2],[9, 12, 14, 18, 19, 23, 27],'NEU')]
#justpublished: #aha22 #circaha22 smartphone-based cardiovascular risk reduction in breast cancer patients [smart-breast]: a randomized controlled trial BREXIT #ahajournals  .####[([16],[13, 14],'NEU')]
 discussed with right afterwards on how this would influence practice. main takeaway from that conversation: keep it simple love that advice. don t overthink it. and i do think this answers a question despite transform-hf being a 'NEU' trial. .####[([34],[0, 8, 37],'NEU')]
day 2 recap of #aha22: drs. , and review late-breaking science from aha 2022, including ecmo-cs, respect-epa, ISCHEMIA-EXTEND, and empa-kidney. watch it here: #cardiotwitter  .####[([18],[7, 8, 19],'NEU'), ([16],[7, 8, 19],'NEU'), ([14],[7, 8, 19],'NEU'), ([15],[7, 8, 19],'NEU')]
today at #aha22, dr. judith s. hochman will present ischemia-extended, the follow-up interim report on the ischemia trial. don t miss it in main event hall ii during the late-breaking science: drugs and strategies in acs and revascularization session!  .####[([9],[8, 11, 13],'NEU')]
really proud moment for me today, presenting 1st time in a featured science session . deeper insight in advor trial with key contributions from among many others. proudly ! tweetorial below!  .####[([17],[6, 11, 12, 13],'NEU')]
must be my hottest #aha in the windy city, beautiful skyline yesterday from navy pier! getting ready for my first lbt . eager to learn results from transform-hf ! some great science on #diuretics this meeting! stay tuned for advor analyses tomorrow  .####[([37],[23, 34, 35],'NEU'), ([26],[23, 34, 35],'NEU')]
if you re at please considering joining us at what s new in ablation where i ll speak about first-line ablation today at 3:30. it s a good preamble for our late breaking presentation progressive-af monday morning at 11am .####[([34],[17, 18, 19],'NEU')]
hearing various wrong conclusions at #aha22 'POS't prominent: "we can ignore tg" "tg doesnt matter" reminder: when tg (esp w/ dm or hdl) focus should be on even more aggressive ldl-c (also as more atherogenic ldl particles), dm rx, weight loss / lifestyle changes  .####[([7],[0, 2, 28, 29, 33],'NEU')]
a patient-risk based health system intervention for acute heart failure care: the comparison of outcomes and access to care for heart failure (COACH) trial written by ! summary and analysis and more #aha2022 coverage below:  .####[([22],[26, 28, 32],'NEU')]
#aha22 ironman on : "building upon the other data we have at hand...correcting iron deficiency could help improve patients well-being and in particular reduce the risk of hospitalization in a broad range of patients .####[([1],[15, 16, 22, 24],'POS')]
 completely agree meaningful difference in cv outcome confirms prior studies reduce-it, JELIS and RESPECT-EPA biological plausible (benefit of high dose epa) .####[([10],[0, 1, 2, 7, 14, 15, 16, 18],'POS'), ([11],[0, 1, 2, 7, 14, 15, 16, 18],'POS'), ([13],[0, 1, 2, 7, 14, 15, 16, 18],'POS')]
one of most fav study led by showing interplay of #sdoh #cac in mesa 5th nov #aha22 zone 1 level 3 2:50 pm in short cac stratifies risk across spectrum of social vulnerability -&gt;guide personalized risk management  .####[([13],[4, 7, 8],'NEU')]
 thanks for the tweet - great results with CRISPR-ATTR for amyloidosis. nice to chat with you in the hallway today. .####[([8],[5, 6],'POS')]
in an analysis of #fourier and fourier-ole, and illustrate the monotonic relationship between lower achieved ldl-c levels, down to &lt;20 mg/dl, and lower adverse cardiovascular events. #aha22 .####[([6],[13, 22, 23, 25],'POS')]
we re live now wrapping up our #aha22 presentation set with phase 2 data SHASTA-2 on our investigational #rnai therapeutic for patients with #severehypertriglyceredemia. learn more here if youre not able to join live:  .####[([14],[4, 9, 24, 32],'NEU')]
#simpub with #aha22 from deliver in #ejhf dapa highly effective in reducing clinical events, even among those already treated with #mra or #arni. sglt2i may be added to other treatments recommended in recent guidelines for #hfmref/#hfpef .####[([4],[8, 9, 11, 26, 30],'POS')]
new DELIVER trial website just launched summarizing publications to date. a glimpse at 3 #aha22 simpub &amp; 2 related articles containing #deliver data to be pub at this meeting. impressively, website entirely homegrown by sole designer:  .####[([1, 21],[5, 6, 7],'NEU')]
another win for iv iron in hf! now with a different iron formulation. ironman now out in with #aha22  .####[([13],[1, 10, 12],'POS')]
congrats incredible wrk by huge team lead by alik farber and matt menard. honor to be part of the effort. results are out best-cli, 2 much to discuss and review in the coming weeks  .####[([23],[0, 1, 27, 29],'POS')]
high concentration mineral oil, corn oil and their constitutive fatty acids do not influence low-density lipoprotein (ldl) oxidation. new data about placebo used in #epa reduce-it trial #lipids  .####[([25],[12, 13, 14],'POS')]
new from + based on &gt;3,000 participants in fourier-ole pcsk9 mab study with ldl-c &lt;20. two questions: is it helpful? -&gt; yes, substantial risk reduction down to ldl-c &lt; 10 (!) is it safe? -&gt; yes, no gradient in risk of adverse events detected #aha22  .####[([9],[20, 23, 41, 43],'NEU')]
sustained improvement in vast majority of pts wks in valor-hcm. published in  .####[([9],[0, 1],'POS')]
 big deal!! valor-hcm mavacamten improves diastolic function within 16 weeks. congrats to all authors!  .####[([2],[0, 4, 6],'POS'), ([3],[0, 4, 6],'POS')]
crucial slide from the sport trial. #cee is the largest dietary supplements market. thats why since 2016 we reviewed &gt;2000 supplements &amp; indicated only &lt;20 with ebm for #safety and #efficacy. thats why we educate on #lifestyle changes &amp; introduced #nutrivigilance! #aha22  .####[([4],[0, 1],'NEU')]
super proud of resident for her #aha2022 'POS'ter presentation- 6mo males from the best-cli registry .####[([13],[7],'NEU')]
 the ironman trial: does iv iron improve outcomes in hf? . #cardiotwitter #medtwitter #heartfailure #anemia #aha22  .####[([1],[3, 6, 7],'NEU')]
findings from RESPECT-EPA study presented at #aha22 suggest benefits of highly-purified epa in reducing #cvd events in japanese patients with chronic #cvcad and being treated with statins. read more: #accintl  .####[([2],[4, 7, 8, 13],'POS')]
 think they informing practice, where currently toresmide is used over furosemide, or pts are switched from furosemide, many discussions around chlorthalidone instead of hctz, and fibrates are the second most prescribed lipid tx after statins. #aha22 .####[([6],[5, 8, 9],'POS'), ([10, 16],[5, 8, 9, 14],'NEG')]
 when you have the most complicated patients with severe inflammation affecting multiple organ systems, using steroids is like throwing a glass of water on a forest fire, and they seem to have less impact." kevin hill, md, ms stress trial results #aha22:  .####[([38],[29, 32, 33],'NEU')]
ironman: intravenous ferric derisomaltose did not not meet primary endpoint in hfref written by ! summary and analysis and more #aha2022 coverage below:  .####[([0],[4, 5, 6, 7, 8, 9],'NEG')]
full results of strong-hf in #aha22 - 1078 randomized to high intensity vs usual - by by d90, higher # in high-intensity group up-titrated to full doses #gdmt - 6-month significant improvement in #heartfailure readmission/all-cause mortality  .####[([3],[0, 24, 29, 30],'POS')]
impressive rct strong-hf data on rapid early titration of #gdmt in heart failure #implementation #aha22  .####[([2],[0, 5, 6],'POS')]
apixaban 2.5 mg bid was non-inferior to vka phenprocoumon in #hemodialysis patients with #af. a small investigator initiated #rct including 97 patients in germany. small trial - consistent with previous small sample size studies. the axadia-afnet 8 study  .####[([0],[5, 6],'POS')]
#aha22 late-breaking rct: best-cli trial comparing surgical vs endovascular revascularization. two cohorts were randomized. one cohort with adequate gsv conduit. another cohort without gsv conduit. male was a key primary outcome .####[([3],[5, 13, 17],'NEU')]
my take on best-cli . highly morbid adverse event rates are very high for all patients with cli. while surgery is best when good gsv conduit is available, any intervention significantly improves qol. how do we prevent patients for developing cli in the first place? #aha22 .####[([3],[10, 11, 29, 30],'POS')]
use of rivaroxaban did not significantly reduce the com'POS'ite endpoint of thrombotic events. there was a 'POS't-hoc reduction in symptomatic events, but event rates were quite low. #aha22  .####[([2],[4, 5, 6, 25, 26],'NEG')]
thankfully, major bleeding was quite rare and no different between rivaroxaban and placebo. there were more crnm and trivial bleeds. #aha22  .####[([10],[0, 1, 4, 5, 7, 8, 18],'POS')]
#justpublished #aha22 #circaha22 : sex differences in characteristics, outcomes and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: insights from dapa-hf and deliver #ahajournals  .####[([12],[9, 10],'NEU'), ([26],[24],'NEU'), ([28],[24],'NEU')]
no benefit of immediate #ecmo in ecmo-cs trial #aha2022. will this change clinical practice? 40% cross-over rate, no venting strategy  .####[([6],[0, 1, 3, 17],'POS')]
just presented as part of the late-breaking clinical sessions at #aha2022: the PRECISE trial confirms that #ccta + #ffrct, supported by the aha/acc guidelines, is recognized as a frontline pathway for patients with suspected #cad. #cardiotwitter #yescct  .####[([12],[14, 19, 25],'POS')]
 congratulations jason!! EARLY-AF very impactful and clinically relevant. .####[([2],[3, 4, 6, 7],'POS')]
. discussing the results from the RESPECT-EPA trial during this afternoon s late breaking science session #aha22  .####[([5],[0, 2, 11, 12],'NEU')]
axadia-afnet 8 study: apixaban 2.5 bid vs. vka in patients with #afib on chronic hemodialysis #aha22 97 in 39 in ttr 51% no difference in ischemic or bleeding events 23% of patients died in the f-u, 11% major , only 1 stroke  .####[([3],[8, 17, 19, 22, 23, 24, 28, 33],'NEU')]
ocean(a)-dose: olpasiran (#sirna) vs placebo in with atherosclerotic cv disease and lp(a) #aha22 olpasiran &gt; #sirna every 12 or 24 weeks marked reduction of lp(a) , as much as 100% a phase 3 trial is about to start  .####[([1, 13],[21, 22],'POS')]
and renal-af finally published #aha22 also underpowered low ttr (44%) bleeding 10x than ischemic events and again high death rates (1 out of 5 in the f-u)  .####[([1],[6, 7, 12, 13, 14, 17, 19],'POS')]
#aha22 featured science presentation: valor-hcm - myosin inhibition in patients with obstructive hcm referred for septal reduction therapy: 32-week active blinded crossover results from valor-hcm trial. data presented by  .####[([4, 24],[1, 3, 27],'NEU')]
ischemia-extend studies: rationale and design. #aha22 #cardiotwitter lbs.06. sun nov 6, 5-6pm  .####[([0],[4],'NEU')]
 presents results of DASH-AF. suggests safety and cost effectiveness of iv sotalol for af. #aha2022  .####[([3],[0, 4, 5, 7, 8],'POS')]
great analysis of transform-hf by - the trial did not address success of decongestion. Transform-hf will not alter practice  .####[([3, 14],[9, 10, 16, 17],'NEG')]
first late breaking trial - transform-hf trial comparing torsemide vs furosemide - showing no change in primary endpt of all cause mortality with both therapies .####[([5],[7],'NEU'), ([8],[13],'NEU'), ([10],[13],'NEU')]
the prominent trial addresses lowering tg for residual cv risk tg (200-499) tx with pemafibrate vs placebo - it showed no difference in primary or secondary endpts  .####[([1],[19, 20, 21],'NEU')]
 ocean (a)-dose trial: olpasiran to reduce lipoprotein(a) in cv disease #aha22  .####[([3],[5],'POS')]
 sex differences in characteristics, outcomes and treatment response with dapagliflozin across the range of ejection fraction in patients with hf insights from dapa-hf and deliver #aha22  .####[([9],[4, 7],'NEU'), ([22],[20],'NEU'), ([24],[20],'NEU')]
 timely provision of primary pci in the setting of stemi saves lives! #aha2022 a chinese medication called txl tongxinluo reduced macce events by 36%; death by 30%; heart attack by 65% at 30days!!! look forward to reading the full manuscript  .####[([18],[19, 20, 21, 33, 34],'POS')]
 ironman trial: i.v. ferric derisomaltose in hfref and iron deficiency, was associated with a lower risk of hospital admissions for hf and cv death #aha22  .####[([0],[11, 14, 15],'POS')]
 COACH trial: acute hf in emergency care uso of a strategy to support clinical decision making and rapid follow-up led to a risk of the com'POS'ite of death from any cause or hospitalization for cv causes within 30 days than usual care #aha22  .####[([0],[12, 13, 17, 19, 40],'NEU')]
come meet prof daida and hear more about RESPECT-EPA at the meet the trialist session now in heart theater ii #aha22  .####[([8],[1, 5, 6, 11],'NEU')]
great to see live #interventional case presentations and expert discussion at #aha22 precursor to best-cli trial tomorrow #ctli tct  .####[([14],[2, 3, 9],'NEU')]
transform-hf: no difference in mortality - furosemide vs torsemide in patients with #heartfailure #aha22  .####[([6],[1, 2],'NEU'), ([8],[1, 2],'NEU')]
prominent- no benefit of pemafibrate despite significant tg lowering and baseline high tg/low hdl. want to learn more? come to in-depth session 11/6 at 3;30 #aha22  .####[([4],[1, 2, 6, 8],'NEG')]
need running shoes or a tardis to get between 50+(!!!) parallel sessions . discussing ecmo-cs trial (early ecmo vs deferred for shock - no difference in mortality, arrest or other mcs at 30-days) #aha2022 #lbct  .####[([13],[22, 23],'NEU')]
ecmo-cs take home: small trial (n=117) in 4 centers, older patients (iqr 60-74y), 39% crossed-over to ecmo, no routine lv venting. implications really initial conservative strategy not worse in older patients without severe shock  .####[([0],[21, 26, 27],'NEU')]
ambitions trial transform-hf with equally ambitious primary endpoint! there is great value even in a 'NEU' trial! congrats and team . we are all proud of you  .####[([2],[4, 5, 10, 11],'POS')]
6 supplements that people commonly take for heart health don t help lower bad cholesterol or improve cardiovascular health, except for statins, according to the sport trial at #aha22, simultaneously published in #jacc. reports:  .####[([25],[8, 16, 17, 18, 30],'NEU')]
#aha22 sport is such an important study! rosuvastatin 5mg is $5 for a 90-day supply and really works!! rip cholesterol supplements .####[([1],[5, 6],'NEU'), ([7],[16, 17],'POS')]
cts-ami: tongxinluo (txl) improves cv outcomes in acute stemi written by ! summary and analysis and more #aha2022 coverage below:  .####[([1],[3, 4, 5],'POS')]
analysis of fourier fourier-ole by shows monotonic relationship between lower ldl levels, down to very low levels (&lt;20 mg/dl), and adverse cv events up to 8.6 years of follow-up. #aha22  .####[([2, 3],[5, 6, 7],'NEU'), ([3],[5, 6, 7],'NEU')]
chlorthalidone did not reduce incidence of major cv outcomes or non-cancer deaths compared to hydrochlorothiazide pragmatic trial performed in va health system #lbct #aha22  .####[([0],[1, 2, 3, 4, 8],'NEG'), ([14],[1, 2, 3, 4, 8, 12],'POS')]
prominent trial in patients w/ #t2dm, mild/mod hypertriglyceridemia, &amp; low hdl + ldl, no difference in incidence of cardiovascular events among those treated with pemafibrate vs placebo #lbct #aha22  .####[([0],[1],'NEU'), ([24],[13, 14, 16],'NEU')]
 presents research examining investigator-reporter vs adjudicated events from soloist-whf and #scored #ahaa22  .####[([8],[0, 2, 6],'NEU')]
fantastic expert commentary to the coach trial by - implications for patients, healthcare provider and healthcare resources allocation. #aha22  .####[([5],[0, 2],'NEU')]
#aha22 late breaking trial COACH : point-of-care algorithm to stratify patients with acute heart failure in emergency dept to support rapid clinical decision and rapid follow-up lower risk of death + cv hospitalization at 30 days .####[([4],[1, 2, 3],'NEU')]
no benefits of pemafibrate at #aha22  .####[([3],[0, 1],'NEG')]
#attr news: today, at the scientific sessions, intellia presented additional interim results from its ongoing phase 1 study CRISPR-ATTR of ntla-2001, an investigational, in vivo #crispr #genomeediting therapy. learn more: #aha22  .####[([18],[8, 14, 22, 28, 29],'NEU'), ([20],[8, 14, 22, 28, 29],'NEU')]
 terrific session but unfortunately times op'POS'ite a certain very long await vascular #rct best-cli . we need to catch up on what we missed!!  .####[([13],[7, 9, 10],'NEU')]
 its not the triglycerides which are the problem. its whats raising them. ir. .####[([3],[0, 1, 7, 8],'NEU')]
#eapci #djangiolillo 1st rct showing feasibility of switching from dapt to dpi, another deliver from the swapers! SWAP-AC #aha22  .####[([17],[2, 4, 5, 7],'POS')]
#eapci #djangiolillo another deliver from the swapers! SWAP-5 #aha22  .####[([7],[2, 3, 4],'NEU')]
results from the PROGRESSIVE-AF, rapid, nova and enhance-af trials presented at #aha22 focus on improving treatment of #afib and supraventricular arrhythmias. read the highlights: #cardiotwitter  .####[([3],[9, 21],'NEU'), ([4],[9, 21],'NEU'), ([5],[9, 21],'NEU'), ([7],[9, 21],'NEU')]
listen to the hottest trials from #aha22 on the go with #eagleseyeview podcast! in this episode, drs. , &amp; discuss highlights from from the meeting, including ecmo-cs, respect-epa, ischemia-extended &amp; empa-kidney .####[([25],[0, 18, 24],'NEU'), ([29],[0, 18, 24],'NEU'), ([26],[0, 18, 24],'NEU'), ([27],[0, 18, 24],'NEU')]
exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: the breast cancer randomized exercise intervention (brexit) study  .####[([17],[0, 14, 15, 16],'NEU')]
pro-hf sub-study: routine kccq-12 assessments in hf improves accuracy of provider assessment of patient health status. written by ! summary and analysis and more #aha2022 coverage below:  .####[([0],[2, 4, 7, 8],'POS')]
in ironman trial intravenous iron improved long-term outcomes for people with heart failure and iron deficiency #aha22  .####[([1],[5, 6, 7],'POS')]
acc medical correspondent and #jacccasereports eic talk key insights and takeaways from transform-hf, crispr-attr and ironman trials presented during #aha22 as part of the latest #accesspoints video. #cardiotwitter  .####[([12],[6, 17, 24, 26],'NEU'), ([15],[6, 17, 24, 26],'NEU'), ([13],[6, 17, 24, 26],'NEU')]
 answers a pivotal question with #lbct #aha22 transform-hf torsemide similar to furosemide in mortality &amp; hosp focus time on app diuretic dosing &amp; prioritize #gdmt #accearlycareer  .####[([8],[9, 10],'NEU'), ([11],[9, 10],'NEU')]
#drishani presenting pragmatic #lbct #aha22 dcp followed by an excellent discussion by dr levy #accearlycareer  .####[([5],[1, 6, 10],'NEU')]
 new #aha22 #lbct interview dr julian gillmore discusses exciting results demonstrating tolerability and efficacy of the ntla-2001 #crispr-cas9-based gene editing therapy in pts with #attr #amyloidosis with cardiomyopathy!  .####[([16],[7, 9, 10, 11],'NEU')]
happening now: hfc s presents late-breaking results of transform-hf at #aha2022!!  .####[([8],[4, 5, 6],'NEU')]
so proud of ms2 kathy recto, presenting this very interesting and important work from the cardia study!  .####[([15],[6, 8, 9, 12],'NEU')]
in press: the patient-reported outcome measurement in heart failure clinic trial: rationale and methods of the pro-hf trial. #aha22 #cardiotwitter #cardiology lbs.02. sat, nov 5, 3-4pm  .####[([16],[4, 5, 11, 13],'NEU')]
in strong-hf trial in aha22 rapid gdmt titration in hfref led to improved clinical outcomes (qol, ntprobnp and reduction in combined hf hosp and death) .####[([1],[10, 12, 13, 14],'POS')]
 congratulation on transform-hf study as it was amongst the top enrolling centers and we are excited to have contributed to the science!!!  .####[([2],[9, 10, 18],'NEU')]
more great #aha22 coverage by the stellar crew: best-cli strong-hf progressive-af brightn nova more on  .####[([12],[0, 1, 3, 13],'NEU'), ([9],[0, 1, 3, 13],'NEU'), ([8],[0, 1, 3, 13],'NEU'), ([10],[0, 1, 3, 13],'NEU'), ([11],[0, 1, 3, 13],'NEU')]
it was an honor to interview dr. pradhan about the prominent trial of pemafibrate for triglyceride reduction at #aha22!  .####[([10],[3, 5, 16],'NEU'), ([13],[3, 5, 16],'NEU')]
breaking news: first data from best-cli bring surgical bypass into the forefront of discussion for patients with high-quality great saphenous vein - #bestcli #aha2022  .####[([5],[0, 1, 13],'NEU')]
we look forward to #aha22 where dr ray will share new clinical data and findings from the 4-year long-term safety and efficacy extension study, orion-3. please join the presentation session on monday, november 7th from 3:00-4:00pm ct at main event iii  .####[([24],[2, 9, 10, 12, 14, 26],'NEU')]
best-cli quality of life analysis: no meaningful clinically important differences in qol metrics between surgery and endovascular in pts with cli, regardless of whether there was an adequate saphenous vein #aha22 #cardiotwitter  .####[([0],[5, 6, 7, 8, 9, 13, 21],'NEG')]
no benefit of apixaban compared to vitamin k antagonists in patients receiving dialysis. less than 100 patients enrolled. will this change for any practice?  .####[([3],[0, 1, 4],'NEG')]
#aha2022: fantastic presentation by of the 'POS' strong-hf trial publication today in cocorico dream team  .####[([7],[2, 10],'NEU')]
first interview with after his #strong-hf lbct which overwhelmingly demonstrated the benefit of protocolized (i.e.mandatory) rapid optimization of gdmt vs usual care 'POS't #heartfailure hospitalization! (1/9)  .####[([5],[8, 9, 11, 22, 24],'POS')]
 all retrospective data. like most trials in ecmo-cs, few are rct s. i am not aware of a rct comparing ecmo alone to ecmo plus iabp but the data we do have is encouraging .####[([7],[3, 4, 5],'NEU')]
 ironman trial was presented #aha22 #cardiotwitter #heartfailure  .####[([0],[2, 3],'NEU')]
breaking news #aha2022 from REVIVED-BCIS2 - also no reduction in sudden cardiac death by pci in revived  .####[([4],[7, 8, 12],'NEG')]
breaking news in chicago nov 6, 2022 with 2 late breaking clinical trials presentations on subanalysis of #advor presented by and (1/5)  .####[([17],[0, 9, 10, 13, 18],'NEU')]
congrats to for his strong-hf to be presented tomorrow .one of the top hf trials  .####[([4],[0, 7, 8],'NEU')]
on further reading, we found advor to be very effective @ (5/5)  .####[([5],[1, 8, 9],'POS')]
 many data on the importance of advor have emerged and even made it into the hfa guidelines to guide decongestive therapy .####[([6],[0, 1, 8, 10, 11, 18],'NEU')]
an important presentation on ai-based adaptive trial optimization on the iris trial, led by , here w our group #aha22  .####[([10],[2, 7, 12],'NEU')]
summary on valor-hcm provided by someone stating about its amazing results#aha22  .####[([2],[3, 6, 9],'POS')]
breaking news with #transformhf - the largest (n=2859) ambulatory #heartfailure diuretic trial to determine if torsemide would be superior to furosemide to reduce all-cause mortality - what a huge accomplishment of et al!!! (1/9)  .####[([15],[13, 16, 18, 22, 24],'NEU'), ([20],[13, 16, 18, 22, 24],'NEU')]
late breaking trialists debrief on Ironman, excellent results, all patients are alive and healthy #aha22  .####[([5],[6, 7, 9, 13],'POS')]
t-minus 5 minutes until moderates a late-breaking session and , director of aortic surgery, will serve as a panelist discussing the use of extracorporeal membrane oxygenation, or ecmo. learn more about our use of ecmo-cs: #aha22  .####[([33],[27, 28, 29],'NEU')]
ironman summary results at #aha22 ferric derisomaltose decreased cvd or hfh but p values were &gt;0.05. this is a 'POS' study  .####[([0],[16, 17, 19],'POS')]
REVIVED-BCIS2 arrhythmia study #aha22 tomorrow at 8am (clocks go back so will be a lie in!) - room n230 - see you there!! free donuts are rumoured. .####[([0],[4, 20, 22],'NEU')]
packed room this morning at #aha22 for the arrhythmia results! In REVIVED-BCIS2 no difference seen in the primary outcome of death or aborted sudden death between pci and omt  .####[([11],[12, 13, 14, 18],'NEU')]
intellia presents updated interim data from the cardiomyopathy arm of ongoing phase 1 study of ntla-2001, an investigational crispr therapy for the treatment of transthyretin (attr) amyloidosis at the american heart association scientific sessions 2022  .####[([15],[1, 2, 4],'NEU')]
 excellent results from the trim (time-restricted intake of meals) trial #rapidfire #aha22  .####[([4],[0, 1],'POS')]
the choice of loop diuretic, between furosemide or torsemide, for decongestion in patients hospitalized with hf may make little difference to survival or readmission risk over the next year, a randomized trial suggests. #aha22 #medtwitter  .####[([6],[17, 18, 19, 32],'NEU'), ([8],[17, 18, 19, 32],'NEU')]
traveling home from #aha22 and want a refresher? or maybe you were busy at #asnkidneyweek and couldnt attend? #dontmissabeat has you covered. in our on-site episode at aha 22, and break down empa-kidney and transform-hf .####[([34],[17, 30, 31],'NEU'), ([32],[17, 30, 31],'NEU')]
#jacchf eic dr. moderating the late breaking session, in depth with transform-hf w/ dr. #aha22 transform-hf #transform #heartfailure #cardiotwitter #cardioed  .####[([11, 15],[3, 7],'NEU')]
another 'NEU' pragmatic trial at #aha2022. no difference in major adverse cv events between chlorthalidone and hydrochlorothiazide in older us veterans with hypertension .####[([2],[1, 3],'NEU'), ([14],[6, 7, 12, 13],'NEU'), ([16],[6, 7, 12, 13],'NEU')]
respect-epa study showed 'POS'sibly beneficial effects of omega 3 fatty acid epa on outcomes of cv death, nonfatal mi, nonfatal ischemic stroke, and unstable angina. #aha22  .####[([0],[2, 3, 4, 13],'POS')]
intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the uk (ironman): modest evidence to support the use of intravenous iron in hfref &amp; id patients. #aha22 should american guidelines follow european?  .####[([14],[15, 16, 18],'NEU')]
congrats to the investigators of for this tremendous effort on best-cli #aha22 with being one of top enrollers for the trial. lots to further learn on how to translate and tailor findings to practice  .####[([10],[0, 8, 24],'NEU')]
baxdrostat significantly and substantially reduced systolic and diastolic #bloodpressure in patients with treatment-resistant #hypertension, based on findings from the brightn study presented at #aha22: #cvprev #cardiotwitter  .####[([0],[1, 3, 4],'POS'), ([19],[14, 21],'NEU')]
 #aha22 #lbct dr &amp; prof discuss the strong-hf results! watch here rapid up-titration of #gdmt under close follow-up is safe and reduces the risk of #hf readmission and all-cause mortality at 180 days! #cardiotwitter  .####[([7],[5, 8, 9, 10],'NEU')]
happening now: and dr. ostadal are participating in meet the trialists: ecmo-cs. a key takeaway: dr. ostadal recommends the pa catheter for patients with cardiogenic shock. important follow-up fact: the #swanganz was invented at . #aha22  .####[([11],[0, 6, 8, 26, 27, 32],'NEU')]
#aha22 reviews bright-4, a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 h 'POS't ppci was superior to unfractionated heparin in patients presenting w/ #stemi undergoing radial access ppci .####[([2],[1, 29],'NEU'), ([11],[4, 7, 9, 29],'NEU')]
ecmo-cs trial reported at #aha22. 117 patients with cardiogenic shock randomised to va ecmo or conservative treatment. no reduction in death, cardiac arrest or need for further mcs within 30 days .####[([0],[2, 17, 18, 20, 21, 22],'POS')]
 very impressive strong-hf trial. lots to unpack. finally we have an evidence base for rapid review in op clinic after hf discharge. .####[([2],[0, 1, 6, 11, 14],'POS')]
 thanks - did many clinicians continue acetazolamide for longer in #advor or do they in real-world practice? .####[([6],[3, 5, 15, 16],'NEU')]
acc medical correspondent dr. discusses points from #aha22s lbct results from the sport trial comparing rosuvastatin &amp; 6 dietary supplements in pts at risk of #ascvd w/ drs. steve nissen &amp; luke laffin as part of #accesspoints. #jacc  .####[([12],[4, 9, 14],'NEU')]
great about ironman trial #aha22 and trials about iron deficiency in #hf  .####[([2],[0, 1, 3, 7, 9],'NEU')]
short #aha2022 interview  dr spoke with dr david preiss about the results of the empa-kidney study! watch here treatment with empagliflozin reduced #ckd progression or cv death! #cardiotwitter  .####[([14],[9, 11, 12, 15],'NEU'), ([20],[21, 25, 26],'POS')]
oh, you prefer ccta for stratifying nonacute chest pain? happily, has your back #aha22: PRECISE strategy based on risk allows clinicians to do less for stable chest pain w/ (bonus: can you spot yael in the photo?)  .####[([14],[19, 20, 21, 22, 23, 25],'NEU')]
dr. prakriti gaba presents her work on long-term efficacy of very low ldl-cholesterol levels with the pcsk9 inhibitor evolocumab: analysis of the fourier and fourier-ole studies, tomorrow :16pm ct, main event iii. #aha22  .####[([24],[3, 7, 8, 10, 11, 12, 13],'POS'), ([18],[3, 7, 8, 10, 11, 12, 13],'POS')]
everyone brace yourselves. best-cli results being presented at #aha22 tomorrow am  .####[([3],[1, 4, 5, 6],'NEU')]
rapco: radial artery grafting is superior to both rita and svg in patients undergoing cabg written by ! summary and analysis and more #aha2022 coverage below:  .####[([0],[1, 2, 3, 5],'POS')]
""risk scores are important for papers but not for patients."" this is something i hear repeatedly from clinicians. coach - an elegant study presented at #aha22 used a risk score for heart failure (applied in the er) to stratify the risk of #heartfailure patients. /1  .####[([18],[0, 23, 26, 28, 29, 40],'NEU')]
aspirin vs. clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: the host-exam extended study  .####[([12],[4, 5, 6, 10],'NEU'), ([0],[4, 5, 6, 10],'NEU'), ([2],[4, 5, 6, 10],'NEU')]
the rapco-sv trial showed that a radial artery bypass graft improves adverse cardiovascular outcomes compared with a saphenous vein bypass graft. read more: #aha22 #cvcabg #cardiotwitter  .####[([1],[3, 6, 8, 10, 12, 13, 19],'POS')]
implementing strong-hf is imperative. must -mobilize whole multidisciplinary team eg md, np, pa, rn, pharmd, social work -be across specialties: pcp, cardiology, etc -organize clinic infrastructure -leverage emr to standardize workflow #aha22  .####[([1],[0, 3, 6, 7, 29],'NEU')]
late-breaking science at #aha22 sheds light on breakthrough strategies in managing and treating #heartfailure. get the highlights from CRISPR-ATTR, coach, pro-hf and ironman trials here: #cardiotwitter #cardioed  .####[([18],[0, 4, 7, 8, 10, 12, 14, 16],'NEU'), ([22],[0, 4, 7, 8, 10, 12, 14, 16],'NEU'), ([19],[0, 4, 7, 8, 10, 12, 14, 16],'NEU'), ([20],[0, 4, 7, 8, 10, 12, 14, 16],'NEU')]
a novel CRISPR-ATTR -based gene-editing technique seems to safely diminish the production of a protein linked to worsening outcomes in patients with transthyretin amyloidosis cardiomyopathy, according to first-in-human data. #aha22 .####[([2],[5, 6, 8, 9, 14],'POS')]
prominent trial of pemafibrate completely 'NEG'! is this the nail in the coffin for triglycerides as a residual risk factor? #aha22 .####[([0],[4, 5],'NEG'), ([3],[4, 5],'NEG')]
transform-hf trials are important for simplicity, cost effectiveness, reflection of real-life setting with diverse representation of the population - #jacchf eic on  #aha22 #cardiotwitter #cardioed  .####[([0],[3, 5, 6, 7],'POS')]
transform hf: a loop diuretic strategy of torsemide vs. furosemide did not lower incidence of all-cause mortality or hospitalization in hf, according to speaking at #aha22  .####[([7],[11, 12, 13, 18],'NEU'), ([9],[11, 12, 13, 18],'NEU')]
the diuretic comparison project (dcp): for hypertensive patients already on hydrochlorothiazide, switching to chlorthalidone does not improve outcomes written by ! summary and analysis and more #aha2022 coverage below:  .####[([10],[8, 11, 15, 16, 17],'NEU'), ([13],[11, 15, 16, 17],'NEU')]
consider the risks of omission consider the risks of *not* doing everything 'POS'sible to initiate/titrate #gdmtworks in an eligible patient, without delay as shown in strong-hf #aha22  .####[([25],[16, 20, 21, 22, 23, 24],'NEU')]
transform-hf: congratulations it is humbling to note that all-cause mortality is 26% at a median of 17 months after a hf hospitalization .####[([0],[4, 6, 8],'NEU')]
excellent presentation by on impact of time restricted eating on physical activity in the TRIM trial. #aha22  .####[([14],[0, 1, 7, 8, 10, 11],'NEU')]
individual patient-level meta-analysis of pivotal rcts from COMBINE-AF shows noacs generally preferable to warfarin across the full spectrum of bmi &amp; body weight. #aha22  .####[([7],[0, 4, 8],'NEU'), ([13],[10, 11, 12, 14, 16, 17],'NEU')]
 at #aha22, talks with healio about findings from the sport study which showed low-dose statin therapy bests six common dietary supplements for ldl lowering. check back for exclusive video!  .####[([9],[12, 13, 14, 15, 17, 18, 19],'POS')]
initial treatment of paroxysmal af with cryoballoon ablation lowered the incidence of af progression by 75% at 3 years vs. antiarrhythmic drugs, according to results of the PROGRESSIVE-AF study #aha22 #cardiotwitter  .####[([3],[8, 10, 22, 23, 24],'NEU'), ([27],[8, 10, 22, 23, 24],'NEU')]
great work by presenting genetic substudy of EAST trial this evening at #aha22  .####[([7],[0, 1, 3],'NEU')]
the sport trial at #aha22, simultaneously published in #jacc, found that statins were "vastly superior" in lowering ldl-cholesterol compared with 6 other supplements studied. has more:  .####[([1],[5, 6, 9, 11, 14, 16, 17],'NEU')]
host-exam: do these results also apply to european and north american patients? #aspirin #clopidogrel  .####[([0],[3, 5, 7, 9, 10, 11],'NEU')]
the conclusion of prevent-hd "is the op'POS'ite from what we believed at the beginning of the pandemic, illustrating one more time why we need and do randomized trials, since they are the only reliable way to guide medical decisions in clinical practice." #aha22  .####[([3],[6, 10, 17, 19, 20],'NEU')]
#drpiazza presenting the results of prevent-hd for rivaroxaban vs placebo w outpatients w covid19. #thrombosis  .####[([5],[1, 3, 11],'NEU'), ([7],[1, 3, 11],'NEU')]
PRECISE a precision diagnostic strategy in patients with suspected cad improves outcomes written by ! summary and analysis and more #aha22 coverage below:  .####[([0],[2, 4, 10, 11],'POS')]
pemafibrate tgs but not cv events in type 2 diabetes, mixed dyslipidemia perspective #aha22  .####[([0],[3, 4, 5, 12],'NEU')]
transform-hf is an important trial benefitting daily clinical practice. .####[([0],[3, 4, 5, 6, 8],'POS')]
i cant keep up with #aha22 at this point. our ischemia-extend coverage is here: sport is here (thanks !) but better yet, go to to find all of our coverage. .####[([10],[9, 12, 13, 15, 16, 19, 20, 27],'NEU')]
lessons learned from prominent study by - very disappointing for our patients. new therapies needed. #aha22  .####[([3],[1, 7, 8, 11],'NEG')]
#aha22 poll time: given the known dangers of gene editing, would it be acceptable to permanently gene edit cv gene targets when CRISPR-ATTR study is just as effective temporary gene targeting drug alternatives exist that provide the same clinical benefit? #crispr #rnai .####[([22],[24, 25, 26, 27, 37, 38],'NEU')]
open access: china tongxinluo study for myocardial protection in patients with acute myocardial infarction (cts-ami): rationale and design... #aha22 #cardiology #cardiotwitter lbs.03 .####[([14],[0, 1, 17],'NEU')]
advor has shown excellent results by far compared to any other trial .####[([0],[2, 3, 4],'POS')]
primary results from transform-hf, presented by at #aha22:  .####[([3],[0, 1, 4],'NEU')]
 reviews the 3 randomized trials presented this morning: , prevent-hd, and improve-dd risk assessment for vte, moving the needle on clinical care  .####[([8],[0, 3, 5],'NEU'), ([10],[0, 3, 5],'NEU')]
 it depends on how you define the 'POS'itivity. however, in the traditional frequentist framework, ironman is not interpreted as a 'POS' trial. authors also may confused bc there is at least 3 different interpretations in the paper (reduced, numerically lower, associated..) .####[([14],[1, 5, 16, 17],'NEU')]
 hypertension experts - interested in your thoughts on this large pragmatic trial of dcp vs hct - lbct at #aha22  .####[([13],[1, 3, 6],'NEU')]
 new fourier and fourier-ole analysis evaluates safety of very low ldl-c levels (&lt; 20 mg/dl) in adults with atherosclerotic cardiovascular disease (#ascvd). press release: #aha22 #cardiotwitter $amgn  .####[([3],[4, 5, 6],'NEU')]
interim results of ischemia-extend, the follow-up to the landmark ischemia trial, were presented over the weekend at #aha22 and published in , helping experts gain long-term perspective on coronary disease management. read more:  .####[([3],[0, 12, 24, 25],'NEU')]
findings from bright-4, option, precise and ischemia-extend trials presented at #aha22 shed light on drugs and strategies for managing #cvacs and #revascularization. get the details:  .####[([2],[8, 16],'NEU'), ([3],[8, 16],'NEU'), ([4],[8, 16],'NEU'), ([6],[8, 16],'NEU')]
 come to our session on the heart and the kidney tomorrow #aha22 and #kidneywk, advor .####[([14],[0, 10],'NEU')]
 agree, great work on transform-hf! congratulations. .####[([4],[1, 5],'NEU')]
 disappointing in a way, but these are the kind of data we need! #kidneywk #aha22, transform-hf .####[([15],[0],'NEG')]
 congrats ! and it comes from a furo lover like me, so... great results with acetazolamide but dont mess with the f. .####[([14],[3, 6, 10, 11, 12],'POS')]
 dude, same effect with one daily dose, would you rather take 1 or 4 pills a day for the same effect? looks good to me, transform-hf .####[([25],[1, 19],'NEU')]
impressively run prominent trial with ~10k patients with dm2+high tg+low hdl-c: 20-30% reduction in tg with pemafibrate but no reduction in cv events or death. venous thromboembolism. disappointing but illuminating nevertheless. #aha2022  .####[([2],[0, 27, 29, 30],'NEU'), ([16],[0, 27, 29, 30],'NEU')]
iron group fared better numerically better in all endpoints but of course statistically not significant. and btw cv mortality too high a bar? #aha22, ironman .####[([24],[8, 12, 13, 14],'NEU')]
 50% stemi, ecmo overloads the lv without venting, shock is one area where device development and new knowledge outstrips slower pace of rct initiation-completion, ecmo-cs .####[([24],[3, 11, 16],'NEU')]
interesting lbct presentation by on the difference in cause mortality and hospitalization with furosemide versus torsemide. transform-hf. #aha2022  .####[([16],[0, 2],'NEU'), ([13],[0, 2],'NEU'), ([15],[0, 2],'NEU')]
presentation RESPECT-EPA #aha22  .####[([1],[0],'NEU')]
one of my favorite trials of #aha2022: sport randomized single-blind trial (1 prev population, n=199) of rosuvastatin 5 mg, placebo, or 6 supplements. 38% in ldl-c, no supplements led to significant change vs placebo. impt data for patients  .####[([7],[8, 9, 26, 30, 31],'NEU'), ([16],[8, 9, 26, 30, 31],'NEU')]
RESPECT-EPA at #aha2022: in open-label rct of 1.8g epa + statin vs statin alone in 2,460 patients w/ chronic cad and epa/aa &lt;0.4, ~22% in 1 com'POS'ite outcome with p=0.05, small but signif risk of af consistent w/ prev fish oil studies  .####[([0],[27, 28, 37],'NEU')]
COACH at #aha2022: stepped-wedge cluster rct in of acute hf risk score tool + specialized early 'POS't-discharge transition clinic death/cv hosp by 12% at 30d / 5% at 20mo. win for implementation science results .####[([0],[11, 32],'NEU')]
#prominent at #aha22 : pemafibrate reduced tg, remnant c, apo-c3, increased ldl-c and apob, no effect on 1 com'POS'ite endpoint. significant risk of renal events and vte .####[([0],[13, 14, 17, 18],'NEU'), ([3],[13, 14, 17, 18],'NEU')]
the prominent trial failed to show that pemafibrate improved cardiovascular outcomes among patients with #diabetes and #hypertriglyceridemia. read more: #aha22 #cardiotwitter  .####[([1],[3],'NEG'), ([7],[3],'NEG')]
diuretics in hospitalised heart failure? torsemide no better or worse than furosemide from late breaking science trials. transform-hf #aha2022 #chicago  .####[([17],[6, 7, 9],'NEU'), ([5],[6, 7, 9],'NEU'), ([11],[6, 7, 9],'NEU')]
remaining questions after transform-hf #aha22  .####[([3],[0, 1],'NEU')]
really interesting 3x null trials on diuretics, dcp hctz vs chlothalidone &amp; fibrates in cvd prevention- all likely to be practice-changing in addressing incompletely evidenced dogma #aha2022  .####[([7],[1, 17, 20],'POS')]
congratulations to our institutional giants for this incredible result in patients with COACH trial #ahf #aha2022  .####[([12],[0, 7, 8],'NEU')]
#blastfromthepast as you read the PRECISION trial results the role of endothelin-1 in hypertension and vascular disease from 2001, by current eic #free #aha22  .####[([5],[3, 7],'NEU')]
 ingenious model of using the pragmatic trial design in cardiac surgery in neonates stress study showed no benefit of routine use of methylprednisolone in cardiac surgery in neonates trial cost was 3 mil , 2000 /enrolled pt  .####[([13],[6, 7, 19, 28],'NEU')]
tomorrow at 930 #aha22 in room n226, i will be talking about triglycerides 'POS't prominent .####[([14],[0, 5, 10],'NEU'), ([12],[0, 5, 10],'NEU')]
 have questions about the prominent trial? we will be doing a deep dive #aha22 in room 230b at 330 pm. send your questions online or live @ .####[([4],[1, 9, 11, 12, 15, 22, 23, 25],'NEU')]
best-cli: revascularization in cli was superior with surgery vs endovascular if there was an adequate great saphenous vein available; no difference if not #aha22 #cardiotwitter #cardiology  .####[([0],[19, 20],'NEU')]
rosuvastatin significantly lowered ldl more than placebo and six commonly used over the counter supplements. as cardiologists we really should use these results of sport trial to have evidence based discussions, said #aha22 #cardiotwitter  .####[([24],[30],'POS'), ([0],[1, 2, 4],'POS')]
decongestion with acetazolamide in acute decompensated heart failure across the spectrum of left ventricular ejection fraction: a pre-specified analysis from the advor trial .####[([21],[4, 5, 12, 13, 17],'NEU')]
really interesting results from the respect-epa trial with commentary by so as we reconcile with reduce-it &amp; jelis, the truth lies somewhere in between- well said! #epalevels  .####[([15],[1, 2],'NEU'), ([17],[1, 2],'NEU'), ([5],[1, 2],'NEU')]
terrific young investigator award session featuring presenting his work on remnant cholesterol and adipokines in mesa study with senior author and expert moderator #aha  .####[([15],[3, 4, 6, 19, 21],'NEU')]
for patients undergoing cabg, use of radial arteries leads to less mace over 15 years compared with using either rita or saphenous vein grafts, according to randomized data from rapco. #aha22  .####[([29],[2, 26, 27],'NEU')]
honored to discuss the prominent trial at #aha22. we need to prioritize medications with demonstrated risk reduction and re-think those without  .####[([4],[0, 2, 18],'NEU')]
 only 14 percent iabp? btw did they count cross overs outcomes under ecmo-cs? this usually means these patients are marinated and in cardiometabolic stage where nothing works. .####[([12],[7, 14, 15, 19, 22, 26],'NEU')]
honoured to have been a part of the all canadian COACH trial presented at the american heart  .####[([10],[0, 12],'NEU')]
interesting day for #heartfailure at #aha22 in chicago. not least with the long anticipated results of the ironman study  .####[([17],[0, 14],'NEU')]
ironman: iv ferric derisomaltose vs. standard of care reduced recurrent heartfailure hospitalizations and cv death by 18% with p = .07. no infection risk #aha22 #cardiotwitter #cardiology  .####[([0],[8, 9, 10, 11, 14],'NEU')]
no difference in outcomes between early ecmo and conservative management group for scai d ecmo-cs! importantly: -no difference in complications -39% eventually received ecmo due to clinical deterioration #aha22  .####[([14],[0, 1, 3, 9, 17],'NEU')]
no attenuation of advor results by lvef per at #aha22 simpub in !  .####[([3],[1, 4],'NEU')]
more data form REVIVED-BCIS2 no difference in all-cause death or sudden death with pci vs omt #aha22  .####[([3],[0, 1, 4, 5],'NEU')]
transform-hf trial: similar efficacy of torsemide versus furosemide for all cause mortality and total hospitalizations in hf hosp pts. #aha22 #cardiotwitter  .####[([0],[2, 3],'NEU'), ([5],[2, 3],'NEU'), ([7],[2, 3],'NEU')]
 it looks like transform-hf studys primary endpoint was all cause mortality, for a trial testing 2 different loop diuretics? and they powered for a 20% relative risk reduction?! that would be more than double the effect size of sglt-2 inhibitors effects in heart failure for acm. .####[([3],[5, 6, 14],'NEU')]
another fibrate fails to show cardiovascular benefit in the prominent trial, pemafibrate did not reduce incidence of the com'POS'ite cardiovascular endpoint. #aha22  .####[([9],[2, 13, 14],'NEG'), ([11],[2, 13, 14],'NEG')]
steep (and such exciting) lowering of lp(a) w/ olpasiran #sirna! as put it . hope is in sight but also short and long term outcomes remain unknown! #aha22 #cvprev  .####[([8],[23, 25],'NEU')]
prominent: pemafibrate reduces triglyceride levels but not cardiovascular events in patients with dyslipidemia and t2dm written by ! summary and analysis, as well as more #aha2022 coverage below:  .####[([0],[17, 19],'NEU'), ([1],[2, 17, 19],'NEU')]
prominent study at #aha22 with and p ridker among authors #lipids  .####[([0],[1, 9],'NEU')]
background and design transform-hf #aha22  .####[([3],[0, 2],'NEU')]
excited to hear the first lbct at #aha22. about to present results to the transform-hf trial!  .####[([14],[0, 2, 10, 11],'NEU')]
pragmatic design of hctz vs chlorthalidone for htn #aha22 dcp trial .####[([9],[0, 1],'NEU')]
congratulations to and team on designing a successful pragmatic rct transform-hf! #aha22  .####[([10],[0, 5, 7, 8],'NEU')]
pemafibrate vs placebo in patients with ascvd and dm on a statin with high tgs - no difference #aha22 prominent .####[([19],[16, 17],'NEU'), ([0],[16, 17],'NEU')]
i difference in outcomes between furosemide and torsemide for the primary outcome of transform-hf #aha22 .####[([13],[1, 10, 11],'NEU'), ([5],[1, 10, 11],'NEU'), ([7],[1, 10, 11],'NEU')]
 also: - increased risk of hypokalemia with ctd vs hct in dcp - intriguing ?chance interaction by history of mi/stroke thanks for tweeting - too much happening at #aha22 and #kidneywk at the same time!! interested in your thoughts too  .####[([11],[13, 26, 33, 38],'NEU')]
no benefit of torsemide on primary endpoint whatever were the pre specified subgroups. similar rates of hospitalisations. on treatment analysis reported similar data for transform-hf. open label rct #transform hf #lbs1 #aha22  .####[([24],[0, 1, 13, 20, 21, 22],'NEU'), ([3],[0, 1, 13, 20, 21, 22],'NEU')]
interesting discussion following the results of dcp. was the study biased to patients responsive to hctz? #aha22  .####[([6],[0, 1, 10],'NEU')]
so proud of presenting pro-hf demonstrating outstanding work at #aha22 quality of life collection in clinic adds value  .####[([4],[3, 5, 6, 7],'NEU')]
more late breaking science started at #aha22 pro-hf trial and gene editing among other . presenting soon  .####[([7],[0, 1, 2, 14, 15],'NEU')]
scott garrison reviewing his two new ongoing chronotherapy trials: bedmed and bedmed-frail. #bloodpressure #aha2022 #chronotherapy  .####[([11],[2, 5, 6],'NEU'), ([9, 11],[2, 5, 6],'NEU')]
bruce neal talking about the population impact of the findings of the landmark SSaSS trial. #bloodpressure #salt  .####[([13],[2, 6, 9],'NEU')]
cincor $cinc pharma announces late-breaking presentation of phase 2 BrigHTN data on baxdrostat in treatment-resistant hypertension at the 2022 american heart association scientific sessions  .####[([9],[3, 4, 5],'NEU'), ([12],[3, 4, 5],'NEU')]
 top 5 clinical trials for day-1 of #aha2022 1 transform-hf (torsemide vs furosemide) 2 dcp (chlorthalideon vs hcz in htn) 3 prominent (pemafibrate in hyper-tg) 4 ironman (iron infusion in hf &amp; anemia) 6 ECMO-CS (va-ecmo in cs) #aha22 #medtwitter #cardiotwitter  .####[([9],[0, 2, 3, 5],'NEU'), ([10],[0, 2, 3, 5],'NEU'), ([12],[0, 2, 3, 5],'NEU'), ([14],[0, 2, 3, 5],'NEU'), ([15],[0, 2, 3, 5],'NEU'), ([21],[0, 2, 3, 5],'NEU'), ([22],[0, 2, 3, 5],'NEU'), ([26],[0, 2, 3, 5],'NEU'), ([34],[0, 2, 3, 5],'NEU')]
sport trial presented by the amazing from showing rosuvastatin 5mg significantly lowered ldl-c compared to supplements commonly used! important study for public health! #drnissen #aha22  .####[([0],[2, 18, 19],'NEU'), ([8],[2, 10, 11],'NEU')]
our interim analysis of the best-cli registry showing high limb and cv events. too many not on optimal cv therapies. lots of work to do! thanks to for leading this! #aha22 #sreekvemulapalli  .####[([5],[1, 2, 7, 11, 12, 18],'NEU')]
RESPECT-EPA trial- borderline significance in the reduction of mace and significant reduction in com'POS'ite coronary events with purified epa. #aha22  .####[([0],[2, 6, 11, 15],'NEU')]
important results! no difference in primary endpoint and hospitalizations with torsemide vs furosemide in transform-hf congrats to and the entire study team for this amazing work!  .####[([14],[0, 2, 3, 6, 15],'NEU'), ([10],[0, 2, 3, 6, 15],'NEU'), ([12],[0, 2, 3, 6, 15],'NEU')]
sapt prasugrel host-exam long-term at #aha22  .####[([2],[3],'NEU'), ([0],[3],'NEU'), ([1],[3],'NEU')]
no difference in the primary outcome in chlorthalidone vs hctz in the dcp trial .####[([12],[0, 1, 4, 5],'NEU')]
 "further motivates us to find systems of care that optimize medical therapy in this vulnerable period," says #aha22; comments from strong-hf study .####[([20],[4, 5, 18, 19],'NEU')]
alik farber presenting #nhlbi funded best-cli trial which showed impressive outcomes #aha22  .####[([5],[2, 8, 9, 10],'NEU')]
pemafibrate lowers triglycerides but does not improve outcomes. no difference between furosemide and torsemide in transform-hf. 'NEG' trials dont make for exciting headlines but are still massively important for advancing the science of cardiovascular medicine. #aha2022 .####[([0],[1, 5, 6, 7],'NEU'), ([11],[8, 9],'NEU'), ([13],[8, 9],'NEU'), ([15],[19, 21, 22],'NEU')]
late breaking featured science at #aha2022 valor-hcm 32-wk data w sustained benefit of mavacamten. 88% severely sympto ohcm no longer srt eligible after 32 wks. simult pub in  .####[([6],[0, 2],'NEU'), ([13],[7, 10, 11],'POS')]
great catching up with and looking forward to late-breaking science presentations from advor by and at #aha22 today!  .####[([12],[0, 1, 5, 6, 10],'NEU')]
congrats to and his stellar prodigies showcasing their latest insights from advor at #aha22 late-breaking science session #heartfailure. very proud of all your accomplishments!  .####[([11],[6, 8, 9, 16],'NEU')]
 urine na has become a routine part of my practice . unfortunately it started as a way to cope with inaccurate in/out data, but it has now become a critical step in my inpatient hf care advor .####[([35],[3, 5, 10, 12, 17, 19, 25, 26, 28, 32],'NEU')]
 among low-risk patients, the tests will likely be 'NEG' for coronary artery disease and patients will go on to do well. as a result, we should be deferring testing in these low-risk people. #aha22 results of the PRECISE trial:  .####[([37],[1, 6, 8, 10, 16, 31],'NEU')]
and now BRIGHT-4 at lbct : showing mortality &amp; c/w heparin! simult pub in  .####[([2],[1, 5],'NEU')]
up next at #aha22, dcris presents on the PRECISE randomized trial make your way to main event ii for this late-breaking science session  .####[([8],[0, 5, 9, 11, 15, 20],'NEU')]
while nova trial did not show difference with botox administration in cardiac surgery, autonomic impact eg heart rate variability would be of interest. excellent presentation by and discussion by #aha2022  .####[([1],[4, 5, 6],'NEG')]
 we know ambulatory salient af is bad. but loop and strokestop study had conflicting results on implications of af diagnoses. esc guidelines: af screening in &gt;75 y/o. 2% af diagnosed during stroke diagnosis. 5% af within 1 yr of stroke diagnosis. #aha2022  .####[([10],[13, 14],'NEG'), ([8],[13, 14],'NEG')]
no clear difference between hctz and chlorthalidone but subset analysis suggested better outcomes for clt in history w prior mi. but w 'NEG' study, subset analyses suspect. great study algorithm w va leading this pragmatic trial #aha2022  .####[([4],[0, 1, 2],'NEU'), ([6],[0, 1, 2],'NEU'), ([14],[11, 12],'POS')]
no win for supplements.. fish oil, cinnamon, garlic, turmeric, plant sterols or red yeast rice!! comparative effects of low-dose rosuvastatin, placebo &amp; dietary supplements on #lipid &amp; inflammatory biomarkers | #aha2022 #cardiotwitter  .####[([19],[15, 16],'NEU')]
stress trial results found the use of methylprednisolone in infants undergoing cardiopulmonary bypass #cvsurg did not improve 'POS't-operative outcomes vs placebo &amp; was assoc. w/ 'POS't-op development of #hyperglycemia warranting insulin. #aha22 #chd  .####[([0],[3, 5, 7, 9],'NEU')]
dcris kevin hill, md, leads off #aha22 day 2 for the dcri as he presents the stress trial in a late-breaking session in main event i  .####[([16],[4, 14, 20, 23],'NEU')]
what will be the rrr for RESPECT-EPA, featuring 1.8 g of vascepa? #aha2022  .####[([6],[7],'NEU')]
nice trial that justifies my decision to treat my own hypertension with hctz. sure, 97% of patients were men given the va population, but i think broadly relevant also, i m sitting next to at #aha22, so can just pay attention when he starts taking a picture  .####[([0],[3, 5, 7],'NEU')]
late breaking #aha2022 early-af attested! #epeeps  .####[([3],[0, 4],'NEU')]
#aha22 late-breaking trials starting with the highly anticipated transform-hf trial comparing torsemide vs furosemide in hf .####[([8],[6, 7],'NEU')]
new #aha22 interview  dr spoke with dr about #lbct data from the #prominent trial! #pemafibrate didnt reduce #cv events in diabetes pts. watch here #cardiotwitter #cardioed  .####[([12],[16],'NEG')]
prominent trial of pemifobrate vs placebo in t2dm with high tg. while tg and related markers were reduced, ldl went way up, resulting in no impact on any outcomes. not surprisingly. #aha22  .####[([0],[24, 25, 28],'NEG')]
icymi: [pemafibrate] did not reduce cv event rates in patients with type 2 diabetes, mild to moderate hypertriglyceridemia, low hdl and well-controlled ldl cholesterol, #aha22 #cardiotwitter  .####[([1],[3, 4, 5, 6, 7],'NEG')]
in the prominent trial, pemafibrate lowered triglycerides but did not cut the incidence of cv events compared with placebo in patients with type 2 diabetes and mixed dyslipidemia #aha22 #cardiotwitter  .####[([2],[4, 5, 6, 7, 9, 10, 12, 14, 15],'NEU')]
no difference in primary com'POS'ite outcome nor it s components between chlorthalidone &amp; hctz. #aha22  .####[([13],[0, 1, 5],'NEU')]
turns out, white older men can use hctz to treat their hypertension just fine. no need to switch to chlorthalidone. #aha22 .####[([7],[0, 2, 3, 6, 9, 11, 13, 14, 17],'POS')]
discussant summary: transform-hf results are unlikely to alter practice, targeting torsemide in certain populations who may most benefit. #aha22  .####[([2],[3, 5, 7, 9, 10, 12, 16, 17],'POS')]
open access: rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (prominent) study. #aha2022 #cardiotwitter #aha22  .####[([19],[0, 9, 10, 13],'NEU')]
conclusions. no difference between chlorthalidone &amp; hctz in this va population. #aha22  .####[([6],[1, 2],'NEU')]
potential limitations and strengths of transform-hf as identified by #aha22  .####[([5],[0, 1],'NEU')]
transform-hf: torsemide no better than furosemide for hospitalized hf the head-to-head battle of loop diuretics indicates that correct dosing rather than drug choice should be the focus. thanks for coverage of this first #aha22 late-breaker .####[([0],[1, 3, 5, 7, 15, 17, 18, 26, 32],'NEU')]
limitations &amp; future opportunities following findings of transform-hf. #aha22  .####[([7],[2, 4, 5],'NEU')]
 great results from ischemia-extended interim analysis: lower risk of cv mortality and higher risk of non-cv mortality with an initial invasive strategy over a median follow-up of 5.7 years. no overall mortality benefit yet. #aha2022  .####[([3],[0, 1, 4, 6, 12, 15, 19, 20, 24, 30],'POS')]
precision dual endothelin receptor antagonist aprocitentan superior to placebo in resistant hypertension written by ! summary and analysis and more #aha22 coverage below:  .####[([0],[1, 2, 6, 8, 10],'POS')]
the traditional chinese herbal medicine tongxinluo added to guideline-directed therapy improves clinical outcomes in patients with stemi, the CTS-AMI study suggests. #aha22 #cardiotwitter  .####[([18],[1, 2, 3, 10, 11, 20],'POS')]
thank you for reporting on the #sport trial showing that only low dose statin lowered cholesterol vs multiple dietary supplements that didn t lower cholesterol. thank you telling viewers that supplements are not regulated by the fda. #aha22 .####[([6],[0, 8, 11, 17, 18, 23, 25, 27, 32, 33],'NEU')]
congratulations and the prominent investigators! outstanding presentation and clinical research for tg lowering in patients with diabetes  .####[([3],[0, 5, 8],'POS')]
improvement in diastolic function with mavacamten is related to better outcomes for patients with hcm #ahajournals #aha22  .####[([5],[0, 2, 7, 9, 10],'POS')]
acc medical correspondent and talk key insights and takeaways from #crispr, #precision, #spyral htn-on, &amp; #host-exam trials presented at #aha22 as part of the latest #accesspoints video .####[([15],[1, 4, 5, 17, 24],'NEU')]
 #aha22 #lbct interview dr gregory piazza spoke with  dr about #prevent_hd watch here #rivaroxaban did not reduce a com'POS'ite of venous and arterial thrombotic events, hospitalisation and death in pts with covid-19  .####[([13],[15, 16, 18],'NEG')]
last day of #aha22 ends with two #breastcancer studies on the main event stage! BREXIT - exercise to prevent anthracycline cv dysfunction in breast cancer smart-breast - cv risk reduction in breast cancer with smart #cardiooncology #cardiotwitter  .####[([14],[18, 19],'NEU')]
the dcris will be featured as a discussant at the #aha22 late-breaking science session on ways to prevent limb loss via prevent-hd .####[([21],[4, 7, 17],'NEU')]
#aha22 disparities in #amyloidosis did you know that 3.4% of black american carry the CRISPR-ATTR mutation (incomplete penetrance)? yet delayed diagnosis &amp; worse prognosis in black vs white w v142i powerful talk by ! #cardioonc  .####[([14],[1, 10, 11, 16, 18, 19, 22, 25, 27],'NEG')]
data from empa-kidney and a new meta-analysis of large sglt2i trials show the drug class reduces ckd progression, cv risk and hospitalization in people with and without #t2d #aha22 #cardiotwitter  .####[([2],[6, 15, 17],'POS')]
#aha22 modern #cardioonc immune checkpoint inhibitor myocarditis- can we identify and treat the highest risk patients? discusses risk, severity grades, other cv dysfunction, and the ongoing ATRIUM trial w abatacept. #cardiotwitter  .####[([26],[9, 11, 16, 20, 25],'NEU')]
one take-home message from first lbct session: anyone on their high horse that: torsemide&gt;&gt;&gt;furosemide or ctd&gt;&gt;&gt;hctz should probably find a somewhat lower horse #aha22 nice presentations by and  .####[([13],[17, 18, 20, 21],'NEU'), ([13],[17, 18, 20, 21],'NEU')]
pemafibrate study for t2dm and high tg or low hdl, 2ndry prevention. #aha22 10000 pts - no diff in standard mace. it did reduce tg but raised ldl a bit .####[([0],[19, 23, 25, 26],'NEU')]
hctz and chlorthalidone is fine. - is also fine. no difference #aha22  .####[([0],[4, 8],'NEU'), ([2],[4, 8],'NEU')]
 no up front mcs altho &gt; 30% of those ended up w worsening shock &amp; got an ecmo-cs downstream .####[([17],[0, 1, 2, 9, 10, 12, 18],'NEG')]
 maybe but it s only looking at one section of the vasculature. the intervention still led to an inflammatory process elsewhere. from the abstract but pemafibrate was associated with a higher incidence of adverse renal events and venous thromboembolism . still clotting risks. .####[([25],[30, 33, 35, 40, 41],'NEG')]
how to improve gdmt in hf? strong-hf #aha2022 #cardiotwitter  .####[([6],[0, 2],'NEU')]
co-moderating #aha2022 late-breaking trials with larry jackson and . thanks for PROGRESSIVE-AF, nova, rapid, enhance-af!  .####[([10],[0, 2, 3],'NEU'), ([11],[0, 2, 3],'NEU'), ([12],[0, 2, 3],'NEU'), ([13],[0, 2, 3],'NEU')]
#epeeps #cardiotwitter pass it on to your patients (english &amp; spanish) sfrn shared decision making tool for systemic ac for af from enhance-af ) .####[([22],[12, 13, 14, 15],'NEU')]
 tomorrow! join us at #aha22 for featured science re: management of patients 'POS't-pci/acs invasive vs. conservative strategy for nstemi in elderly host extended results twilight substudy effects of glp-1 ras on coronary atherosclerosis 2 prevention of nstemi .####[([24],[1, 22, 23, 25],'NEU')]
very proud to have received the paul dudley white international scholar award for our aha #ress22 abstract on ecpr + organ donation. couldn t attend but + t.soumagnac were there to represent the ECMO-CS team!  .####[([33],[0, 1, 4, 11, 31],'NEU')]
 intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the uk (ironman trial). in w/#hfref and iron deficiency, intravenous ferric derisomaltose was associated with hospital admissions for hf and cv death. #cardioclinica #aha2022  .####[([14],[15, 26, 28, 29],'NEU')]
icymi: "i believe the implications of this are building upon the other data we have at hand that correcting iron deficiency can help improve patients wellbeing" #aha22 #cardiotwitter ironman .####[([28],[2, 4, 8, 18, 22, 23, 25],'POS')]
#icymi: in this special episode of #eagleseyeview, drs. , and discuss highlights from day 1 of the #aha22 late-breaking science, including transform-hf , dcp , prominent , and ironman. listen here: #cardiotwitter  .####[([20],[9, 10, 19],'NEU'), ([21],[9, 10, 19],'NEU'), ([22],[9, 10, 19],'NEU'), ([24],[9, 10, 19],'NEU')]
ntla-2001, a CRISPR-ATTR-based genomic therapy, lowered serum ttr in patients with attr-cm by more than 90% #aha22 #cardiotwitter #cardiology  .####[([2],[3, 4, 5, 6, 13, 14],'POS')]
extracorporeal membrane oxygenation in the therapy of cardiogenic shock: results of the ecmo-cs randomized clinical trial | circulation  .####[([12],[9, 13, 14, 15],'NEU')]
pemafibrate fails to lower cvd risk in patients with high triglycerides: prominent the disappointing results are a blow to the triglyceride hypothesis: leading experts offer their take on what s next. thanks for the #aha22 story .####[([0],[1, 3, 5],'NEG'), ([11],[13, 14, 17],'NEG')]
areef ishani presenting dcp #aha22  .####[([3],[2],'NEU')]
don t miss dr. mentz s late-breaking science session where we ll learn if one of two diuretics commonly used to relieve heart failure-related congestion is more effective than another in preventing hospitalizations and death. #aha22 #cardiotwitter transform-hf .####[([37],[6, 8, 12],'NEU')]
presenting our work on lp(a) levels and aspirin from mesa at #aha22  .####[([9],[0, 2],'NEU')]
the PRECISION trial showed that dual antagonism of the endothelin receptor improves blood pressure control in patients with resistant #hypertension. learn more: #aha22 #cardiotwitter  .####[([1],[3, 5, 6, 11, 12, 13, 14, 18],'POS')]
rapid self-administered etripamil improves psvt conversion to sinus rhythm written by ! summary and analysis and more #aha22 coverage below: NODE-301 .####[([19],[0, 1, 3, 4, 5],'POS')]
we are very proud to announce that the results of our phase 3 precision study on resistant hypertension were published simultaneously in and presented at #aha22 in the late-breaking scientific session by  .####[([13],[2, 3, 5, 8, 19, 23, 28, 30],'NEU')]
icymi: olpasiran ... dosed at 75 mg or higher every 12 weeks reduces lp(a) concentration by more than 95% in patients with established atherosclerotic cardiovascular disease, #aha22 #cardiotwitter  .####[([1],[2, 7, 11, 13],'POS')]
congratulations to for presenting a truly practice-changing trial! strong-hf .####[([8],[0, 3, 6, 7],'NEU')]
preventing limb loss through vascular interventions/#cvvte therapies was the focus of the bestcli, best-cli qol, prevent-hd and improve-dd trials presented during #aha22 today! check out the highlights: #cvpac #covid19 #accvascular  .####[([15],[0, 1, 2, 9, 10, 19, 20],'NEU'), ([13],[0, 1, 2, 9, 10, 19, 20],'NEU'), ([17],[0, 1, 2, 9, 10, 19, 20],'NEU')]
commenting on the #aha22 PRECISE findings for s , acc vp said he would not be surprised if these results end up changing the guidelines, but added that having follow-up through 3-5 years would be even better .####[([4],[0, 5, 15, 18, 21, 23, 28],'NEU')]
rapid study: self-administered etripamil is a potential management strategy for patients to self-treat psvt episodes, said james ip, md. #aha22 #cardiotwitter  .####[([0],[7, 8, 10, 12],'NEU'), ([3],[2, 7, 8, 10, 12],'NEU')]
 thank you dr &amp; prof for sharing the insights from strong-hf watch here rapid up-titration of #gdmt under close follow-up is safe and reduces the risk of #hf readmission and all-cause mortality at 180 days! #aha22  .####[([10],[0, 1, 19, 21, 23, 25, 30, 31],'POS')]
#sapt after 12 months with clopidogrel provides a arr of 4.1% vs asa #aha22  .####[([5],[6, 8, 12],'NEU')]
with anthracyclines! published today in  .####[([1],[2],'NEU')]
happening now moderating digital innovations to improve cvd prevention session in main event iii @ #aha22 sharing results of the rct, virtual application-supported environment to increase exercise during cardiac rehabilitation study VALENTINE .####[([30],[15, 16, 19, 29],'NEU')]
the enhance-af clinical trial to evaluate an atrial fibrillation shared decision-making pathway: rationale and study design. #aha22 #cardiotwitter #epeeps lbs.08. mon nov 7, 11am-noon  .####[([1],[2, 3, 5, 7, 9, 10],'NEU')]
completely agree. extremely well designed trial showing af ablation may bend the curve on PROGRESSIVE-AF with implantable loop recorders for af detection (a new gold standard for af rhythm control trials). congratulations to and his coauthors. #aha2022 #nejm  .####[([14],[3, 4, 5, 6, 31, 35],'POS')]
early morning #aha2022, you can meet the congestion team ; advor analyses still to come. bravo !  .####[([9],[10, 11, 13],'NEU')]
 #late-breaking science transform-hf torsemide had similar effectiveness as furosemide all-cause mortality or hospitalization was similar between the 2 groups. diverse population: 37% women &amp; 34% black patients #aha22  .####[([2],[5, 6, 14],'NEU'), ([3],[5, 6, 14],'NEU'), ([8],[5, 6, 14],'NEU')]
is there a winner between bivalirudin vs heparin in #stemi? this individual pt data meta-analysis favors bivalirudin. #bright4 will be presented this evening #carsiotwitter #pci #anticoagulation  .####[([5, 16],[0, 1, 3],'NEU'), ([7],[0, 1, 3],'NEU')]
wow surgery for #clti was associated with lower risk of #male than #ensovascular intervention in patients with #clti who are candidates for both strategies. no difference in #mace. does this change your practice? best-cli #aha22  .####[([33],[0, 1, 5, 7, 8],'POS')]
much awaited late-breaking best-cli, prevent-hd and more coming up! #aha22  .####[([4],[0, 1, 2],'NEU'), ([3],[0, 1, 2],'NEU')]
in prevent-hd, xarelto was not associated with lower risk of com'POS'ite endpoint, although lower risk of secondary endpoints of #vte and #arterial thrombosis. stopped early due to low number of events. #aha22  .####[([1],[2, 4, 5, 7, 8, 10, 11, 13, 14],'NEU')]
qol improves significantly after either open and endovascular intervention for #clti. no clinically significant differences between open vs endovascular best-cli. #aha22  .####[([19],[0, 1, 2],'NEU')]
talk of the day after late breaking transform-hf trial, the one and only dr. managed to chat with him in between sessions (lucky me!). what a legend! #aha22  .####[([7],[5, 6, 20, 21],'NEU')]
we are the problem. underdiagnosis of #pad, underuse of statin and rivaroxaban despite strong evidence. lets do better. #aha22  .####[([9],[12, 13, 14],'NEU'), ([11],[12, 13, 14],'NEU')]
intellia $ntla presents updated interim data from the cardiomyopathy arm of ongoing phase 1 study of ntla-2001, an investigational CRISPR-ATTR therapy for the treatment of attr amyloidosis at #aha22  .####[([19],[2, 3, 4, 11, 18],'NEU')]
in the ironman trial, long-term iv iron supplementation in patients with hf and iron deficiency was safe and reduced risk for recurrent hf hospitalizations and cv death compared with usual care. #aha22 #cardiotwitter  .####[([2],[6, 13, 14, 16, 18, 19],'POS')]
ironman : iron deficiency affects up to 50% of people with heart failure. breaking research presented shows after 2.5 years, iv iron reduces recurrent heart hospitalizations and cardiovascular deaths in people with heart failure. #aha2022 .####[([0],[10, 13, 15, 21, 22, 23, 24, 26, 27, 31],'POS')]
pro-hf: routine collection of kccq data improves clinician assessment of health status in pts with #heartfailure #aha22 #cardiotwitter #cardiology  .####[([0],[1, 2, 4, 5, 6, 7, 8],'POS')]
so excited for the first late-breaking session in just a few minutes! team furosemide or torsemide what about hctz vs chlorthalidone come ton fins out!  .####[([13],[1, 5, 6],'NEU'), ([15],[1, 5, 6],'NEU'), ([18],[1, 5, 6],'NEU'), ([20],[1, 5, 6],'NEU')]
 were working from two very different paradigms. i 'POS'it hdl-c and tg downstream of metabolic functionality will not be equivalent to rx interventions for same outcome. this is why we need to study lmhrs PROMINENT. .####[([34],[9, 11, 12, 14, 17, 19, 20, 21, 24, 31],'NEG')]
POS'ter by et al. at #aha22 impact of 22y cumulative apob on ascvd in cardia - similar risk from trl-p and ldl-p - apob &gt; 0.80mg/dl per year a cut point of increased cv risk prominent trial: trl-p offset by ldl-p (apob slightly ) - 'NEU' result on outcomes .####[([35],[9, 16, 32, 38],'NEU')]
u.s. experts favor chlorthalidone over hctz in the first-line treatment of hypertension. yet practicing doctors are approximately 20-fold more likely to choose hctz over chlorthalidone. #aha22 #cardiotwitter  .####[([3, 24],[2, 8, 9, 11],'POS'), ([5, 22],[12, 13, 14, 18, 21],'POS')]
among older veterans with hypertension, there was no difference in the incidence of major adverse cv events after treatment with hydrochlorothiazide compared with chlorthalidone #acc22 #cardiotwitter  .####[([20],[7, 8, 14, 16],'NEU')]
thank you so much for thoughtful discussion of BRIGHT-4 &amp; highlighting the consistency w ipd-ma presented earlier today. #stemi #anticoagulation #bivalirudin #heparin  .####[([8],[5, 6, 10, 12, 15],'NEU')]
no difference in heart outcomes found in use of two diuretics to treat blood pressure dcp #aha22  .####[([15],[0, 1, 4],'NEU')]
survival after pci/cabg or cons management of stable coronary disease &amp; ISCHEMIA-extend study resulted with no difference all-cause mortality with nearly twice the number of deaths #aha22  .####[([11],[13, 15, 16, 17, 18],'NEU')]
the prominent trial failed to show that pemafibrate improved cardiovascular outcomes among patients with diabetes and hypertriglyceridemia. #aha22  .####[([1],[3, 5, 8, 9, 10],'NEG')]
transform-hf: torsemide vs furosemide in treating patients with hf &amp; torsemide vs. furosemide did not improve long-term outcomes for adults hospitalized with hf, including all-cause mortality and hospitalization #aha22  .####[([0],[5, 8, 14, 15, 16, 17, 20, 22, 23, 24, 25],'NEG')]
#ecmo in the therapy of cardiogenic shock: ecmo-cs rct primary endpoint death from any cause, resuscitated circulatory arrest, and use of another mcs device at 30 days did not differ between the immediate versus conservative groups #aha22  .####[([7],[5, 9, 15, 16, 28, 29, 32, 34],'NEG')]
#sglt2 inhibitors benefit patients regardless of ejection fraction. however, shares pooled data from dapa-hf and #deliver which indicates that women may derive more benefit than men. dapagliflozin #aha22  .####[([26],[1, 2, 3, 19, 22, 23],'POS')]
start all foundational classes of #gdmt and get them to target dosing asap. will strong-hf help impact clinical inertia and finally result clinicians (cardiologists, internists, apps) increasing drug doses until target doses are achieved? #aha22  .####[([14],[15, 16, 17, 20, 21, 26, 33],'NEU')]
hypothesis generating: atrial flow regulation could 'POS'sibly effective with higher bnp, higher lvedp, and higher e/e in patients with hfpef. sham-controlled rct would elucidate this further. PRELIEVE #aha22 .####[([26],[3, 4, 6, 7],'NEU')]
open access: rationale and design of the comparison of outcomes and access to care for heart failure COACH trial: a stepped wedge cluster randomized trial. #aha22 #cardiotwitter lbs.02. sat, nov 5, 3-4pm  .####[([17],[0, 1, 2, 4, 7, 9, 11, 18, 23, 24],'NEU')]
honored to present sex differences in #dapahf and #deliver at #aha22, now #simpub available in . similar benefits of dapagliflozin in and . grateful for the mentorship from and . #sglt2i  .####[([18],[0, 2, 15, 16],'NEU')]
NOVA no significant difference in rate of 'POS't-op af with botulinum toxin vs placebo written by ! summary and analysis and more #aha22 coverage below:  .####[([0],[1, 2, 3],'NEU'), ([10],[1, 2, 3],'NEU')]
icymi: andrade said the findings are an exciting milestone in the treatment of progRESSIVE-AF;early-af. these data show that drugs treat the symptoms; ablation treats the disease, #aha22 #cardiotwitter  .####[([13],[4, 7, 15, 16, 18, 19, 21],'POS'), ([13],[4, 7, 15, 16, 18, 19, 21],'POS')]
tune in at 11 a.m. ct: is presenting results of the PROGRESSIVE-AF study at late-breaker: treating atrial and supraventricular arrhythmia. learn more! #epeeps  .####[([11],[7, 8, 12, 14],'NEU')]
#aha22 ISCHEMIA-extend f-up of #ischemia 5.7yrs demonstrated that (#pci / #cabg vs #gdmt): all-cause mortality cvd mortality noncvd mortality #cad  .####[([1],[6, 12, 13, 14, 15, 16, 17],'NEU')]
 beautiful demonstration that a treatment is more effective when it is prescribed and taken the "just do it" strategy must be changed to "just organize it" great strong-hf .####[([27],[0, 1, 4, 6, 7, 18, 19],'POS')]
news from #aha22: , and dr. alik farber of published/presented the results of best-cli, comparing two treatments for patients with the most severe form of #peripheralarterydisease paper in :  .####[([12],[0, 10, 13],'NEU')]
ironman misses but lends support to iv iron repletion in hf like AFFIRM-AHF before it, this latest rct faced covid-19 challenges, but all signs point to hard benefits of iv fe in #heartfailure #aha22 #jacc  .####[([0],[1, 2, 3, 4, 21],'NEU'), ([12],[23, 24, 26, 27],'NEU')]
attending #aha22? dont miss dr. james ips late-breaking presentation today : "self-administered etripamil for termination of spontaneous paroxysmal supraventricular tachycardia: primary analysis from the rapid study". more information here:  .####[([23],[0, 7, 8, 9],'NEU'), ([11],[10, 13, 19, 20],'NEU')]
PROGRESSIVE-AF: young healthy adults treated with cryoballoon ablation as a first-line strategy saw a 75% reduction in progression to persistent #afib vs drug therapy at 3 years, said . #aha22 #cardiotwitter  .####[([0],[1, 2, 4, 6, 7, 15, 17],'POS')]
at #aha22, we are showcasing results from a pre-specified analysis of deliver phase iii data in heart failure with mildly reduced or preserved ejection fraction. learn what this could mean for heart failure patients:  .####[([11],[4, 5, 8, 9],'NEU')]
tune in at 11 a.m. ct: is presenting results of the PROGRESSIVE-AF study at late-breaker: treating atrial and supraventricular arrythmias. learn more! #epeeps  .####[([11],[7, 8, 12],'NEU')]
ai-powered ccta outperforms usual care when evaluating stable chest pain, late-breaking study confirms PRECISE #ai #cardiology #imaging #cardiotwitter #aha22  .####[([13],[0, 2, 3, 6, 7],'POS')]
ai-powered ccta outperforms usual care when evaluating stable chest pain, late-breaking study confirms PRECISE #ai #cardiology #imaging #cardiotwitter #aha22  .####[([13],[0, 2, 3, 6, 7],'POS')]
bmc studied whether surgical bypass or endovascular therapy, to reduce #cardiovascular risk, results in better outcomes for the millions suffering from chronic limb threatening ischemia. dr. alik farber will present at s #aha22. from : BEST-CLI .####[([34],[1, 3, 9, 11, 12, 29],'POS')]
prevent-hd: in outpatients with #covid19, rivaroxaban vs placebo did not decrease death/hospitalization/thrombotic events #aha22 #cardiotwitter #cardiology  .####[([0],[8, 9, 10],'NEG'), ([5],[8, 9, 10],'NEG')]
a surgical bypass led to better outcomes for certain adults with chronic limb-threatening ischemia (#clti) compared to less-invasive endovascular procedures, according to late-breaking best-cli research: #aha22 #cardiotwitter .####[([23],[5, 6],'POS')]
after evaluating procedures to improve circulation for adults with chronic limb-threatening ischemia (#clti), researchers found a surgical bypass led to better long-term outcomes for some compared to less-invasive approaches BEST-CLI: #aha2022 #cardiotwitter  .####[([29],[4, 20, 21, 22],'POS')]
watching the results of BRIGHT-4 unfold was exciting tonight at #aha22 reduced all cause mortality and bleeding events with bivalirudin compared to heparin 'POS'sible barriers to implementation in clinical practice despite evidence  .####[([4],[0, 7, 11],'POS'), ([22],[0, 7, 11, 20],'NEG')]
today at #aha22 meet the trialist: discussion with empa-kidney trialist with dr david preiss 7 november 1pm cst room: heart theater i  .####[([8],[3, 6],'NEU')]
exciting talk by on the use of ai in predicting bleeding in complex ECMO-CS population. #aha22  .####[([13],[0, 9, 12],'NEU')]
 #ecls-shock ecmo-cs trial lead by will further clarify this issue. bigger cohort &amp; clear venting-strategy. #excited .####[([1],[7, 10, 13, 15],'NEU')]
open access: the prospective randomized trial of the optimal evaluation of cardiac symptoms and revascularization: rationale and design of the PRECISE trial. #aha22 #cardiotwitter lbs.06. sun nov 6, 5-6pm  .####[([20],[0, 3, 4, 8],'NEU')]
 tude 'POS' COACH #aha22 .####[([2],[1],'POS')]
PRECISE: in stable pts with nonacute chest pain, a precision testing strategy vs usual testing reduced 1-year death, mi and cath w/o obstructive disease by 70% #aha22 #cardiotwitter  .####[([0],[15],'POS')]
have questions about today s session on ecmo-cs in the therapy of cardiogenic shock: primary results from the multicenter, randomized ecmo-cs trial? said it best: ask those questions tomorrow during meet the trialists: ecmo-cs. see you there! #aha22  .####[([7, 20, 33],[14, 19, 24],'POS')]
strong-hf at #aha22 rapid-up titration 'POS't discharge hf  .####[([0],[3, 5],'NEU')]
transform-hf #aha22 by does torasemide reduced mortality in hf compared to furosemide?  .####[([0],[5, 6],'POS')]
#aha2022 . great oral 'POS'ter presentation. socioeconomic status, heart failure and aric prediction. way to go dr mathews  .####[([10],[1, 4],'POS')]
 at the session . small trial with 39% crossover from medical therapy to ecmo-cs. but it would seem that early ecmo-cs is not the answer. will lean on the opinions of experts like for treatment if these complex patients .####[([12, 19],[16, 18, 25, 36],'NEU')]
 i was at the CTS-AMI presentation today . this slide seemed to sum it up. amazing results but don t really know how or why txl works. more investigation necessary .####[([4],[5, 14, 15],'POS')]
my pi, gregory piazza, presented a rapid oral presentation today in #aha22 about AF-Alert2, a #cds to antithrombotic therapy in oupatients with atrial fibrillation. our cds prescription of antithrombotic therapy, but no difference in mace at 90 days .####[([13],[8, 31, 32],'NEU')]
my pi, gregory piazza, presented a rapid oral presentation today in #aha22 about AF-ALert2, a #cds to antithrombotic therapy in oupatients with af. our cds prescription of antithrombotic therapy, but no difference in mace at 90 days .####[([13],[8, 30, 31],'NEU')]
my pi, gregory piazza, presented a rapid oral presentation today in #aha22 about AF-Alert2, a #cds to antithrombotic therapy in oupatients with af. our cds prescription of antithrombotic, but no difference in mace at 90 days .####[([13],[8, 29, 30],'NEU')]
ironman was an investigator-initiated study funded by and . we definitely need more studies like it. 7/7 #aha2022 #cardiotwitter .####[([0],[9, 10, 11, 12],'NEU')]
 ecmo-cs mrct on immediate #ecmo vs early conservative therapy (ecmo used for further deterioration) in 117 pts with cardiogenic shock ( 3rd fig) no difference in the 30-day com'POS'ite primary outcome or mortality #foamcc #aha2022 #cardiotwitter  .####[([0],[22, 23],'NEU')]
this is a reminder of our late-breaker session tomorrow at #aha22. we are excited to tell you about the results from our PRECISION study! 3:10pm - 3:20pm (cst)  .####[([22],[13, 15, 16, 19],'NEU')]
a point-of-care tool to support clinical decision-making + rapid outpatient follow-up reduced the risk for death or cv hospitalizations for patients with acute hf presenting to the ed COACH #cardiotwitter #aha22  .####[([28],[11, 13, 24],'POS')]
are we changing how we interpret ironman results! or are we ignoring the lack of statistical significance &amp; using numerically better as "evidence" for iv ferric... administration being better?! published in  .####[([6],[11, 13, 15, 16],'NEG')]
early veno-arterial extracorporeal membrane oxygenation for cardiogenic shock did not improve outcomes vs. a conservative strategy allowing for downstream ecmo-cs in case of further hemodynamic decline #aha22 #cardiotwitter  .####[([19],[9, 10, 11],'NEG')]
 lots of brave things in this strong-hf trial for sure but lots of safety nets!. which highlights the absolute necessity to have real-world systems/staffing in place, to be able to deliver such schedules safely! .####[([6],[2, 9, 13],'POS')]
dr. gregory piazza presents #lbct "rivaroxaban to reduce the risk of major venous &amp; arterial thrombotic events, hospitalization and death in medically ill outpatients with covid-19: primary results of the prevent-hd randomized clinical trial" 11/7, 8:27a ct @ main event i #aha22 .####[([30],[7, 9],'POS')]
first in-human in-vivo CRISPR-ATTR editing of the ttr gene by ntla-2001 in patients with attr cardiomyopathy #genetherapy #heartfailure *mainresult: &gt;90% ttr lowering* but will this translate to clinical outcomes? #aha2022  .####[([3],[25, 27, 28],'NEU')]
COACH trial #heartfailure. : admitted with acutehf *: emergency hf mortality risk grade (ehmrg) score for admit - high risk or discharge + 48hr review in nurse-led hf clinic - low risk results: or cv #moreheartfailurenurses #aha2022  .####[([0],[9, 17, 28, 29],'NEU')]
paulkalra to deliver long awaited ironman trial #heartfailure #parenteraliron #aha22  .####[([5],[2, 3, 4],'NEU')]
today at #aha22 empagliflozin and #cardiovascular outcomes in patients with chronic kidney disease: the empa-kidney trial presented by dr david preiss 6 november 5.26pm cst room: main event i  .####[([14],[6, 16],'NEU')]
 congratulations very important and EARLY-AF study .####[([4],[1, 2],'NEU')]
 sharing the results of this ironman trial important #heartfailure trial. wish i could have seen the lecture #aha22  .####[([5],[0, 2],'NEU')]
so nice to be back at #aha22 in chicago exactly 20 years after my first ever 'POS'ter presentation on REVIVED-BCIS2 (on coronary collateral physiology after recannalisation of ctos). it s a warmer chicago than 2002! looking forward to presenting arrhythmia analysis of 6nov22 8am  .####[([19],[14, 15, 16, 17],'NEU')]
CTS-AMI trial showed benefit tongxinluo in stemi patients in a chinese study. time to revascularization was delayed, but trial held during covid pandemic. tongxinluo has been used for years in china. will be interesting to see if this can be replicated #aha22  .####[([0],[2, 3, 33],'POS')]
 #aha22 sim pub from et al: use it or lose it and location matters! read about clinicians diagnostic accuracy regarding #hf symptomatology as well as patient satisfaction in this pro-hf sub-analysis read more: #ahajournals  .####[([29],[14, 26, 31, 32],'NEU')]
intellia presents updated interim data from the cardiomyopathy arm of ongoing phase 1 study of ntla-2001, an investigational CRISPR-ATTR therapy for the treatment of transthyretin (attr) amyloidosis at the american heart association scientific sessions 2022  .####[([18],[1, 2, 10],'NEU')]
transform-hf are we going to see torsemide trending on twitter? #aha22  .####[([0],[3, 5, 7],'NEU')]
 more and encouraging evidences supporting cryo for first-line af ablation! congrats and EARLY-AF investigators!  .####[([12],[0, 2, 4],'POS')]
transform-hf equal to one gallon furosemide  .####[([0],[1],'NEU')]
transform-hf how about diuretic resistance ? what do you think ? .####[([0],[4, 8],'NEU')]
met our commander in chief , i mean our editor in chief ! proud of all the great work we are doing under your leadership . on transform-hf #medtwitter #cardiotwitter #aha22  .####[([24],[11, 15, 16, 19],'POS')]
 will present data from the ischemia-extend trial about biomarkers of adverse cardiovascular events in chronic coronary disease during today s #aha22 abstract oral session at 3:24 pm ct. see our presentations for today: #cardiotwitter  .####[([5],[1, 10, 11, 12],'NEU')]
unbelievably proud of - 10 yrs ago he got me my first publication as a cmt. a true ironman himself, he s executed this with dedication + excellence whilst holding down a demanding clinical workload - an inspiration 2 all cardiac researchers!  .####[([18],[0, 1, 22, 25],'POS')]
will "fantastic 4" in heart failure today become "fantastic 5", adding iv iron to ace-i or sacubitril/at-1-a, mra, sglt-2 and bb? while waiting for ironman to be presented at #aha2022 tonight, enjoy our discussion with and prof. macdougall  .####[([24],[22, 27, 31, 33],'NEU')]
transform-hf great study - but slides are currently not visible for virtual participants - please double-check! .####[([0],[7, 8, 9, 11],'NEU')]
transform-hf the choice of loop diuretic, between furosemide or torsemide, for decongestion in patients hospitalized with hf may make little difference to survival or readmission risk over the next year, a randomized trial suggests. #aha22 #cardiotwitter  .####[([0],[14, 24, 25],'NEG')]
past acc pres. dr. said transform-hf presented at #aha22 is valuable because it was done in a pragmatic manner, answered a long-standing question in the field &amp; enrolled a diverse patient cohort. read more from :  .####[([5],[19, 21, 22],'NEU')]
results of the transform-hf trial presented at aha 22 indicate there were no significant differences in rate of all-cause mortality or hospitalization with the use of torsemide compared with furosemide in people with heart failure. #aha22 #heartfailure .####[([3],[0, 4, 5, 9, 12, 13, 14],'NEU')]
best-cli it was a fantastic session! glad to help promote it on some!! .####[([0],[6, 8, 9],'NEU')]
 congrats and the transform team. great value in this transform-hf study. .####[([9],[5, 6],'POS')]
today at #aha22, our team is proud to announce a new analysis of our drug candidate SLN360-001 to potentially treat high levels of lipoprotein(a) or #lpa, a key genetic risk factor for #heartdisease. see the analysis here: #silenceisgolden  .####[([16],[6, 8, 10, 11, 35],'NEU')]
very exciting sessions at #aha22! make sure to attend dr. s late-breaking science presentation on the randomized BRIGHT-4 trial, one of the most highly-anticipated clinical trials of the year! #cardiotwitter #cardiology  .####[([17],[24, 25, 28],'NEU')]
so exciting to see my mentor present the result of the COACH trial as a #aha22 lbct! the use of a clinical risk stratification algorithm and rapid outpt f/u for hf patients presenting to the ed resulted in reduced com'POS'ite of death or cv hospitalization at 30-days .####[([11],[8],'NEU')]
late breaking science. paul wang and enhance-af. designed and tested novel decision making tool. it works!! #aha22  .####[([6],[7, 9, 10, 11, 13, 15],'POS')]
 our findings point to edoxaban as a new and, perhaps, better alternative to the current medications and may improve quality of life for these children" #aha22 .####[([4],[2, 7, 9, 10, 11, 14, 15, 18, 19, 21],'POS')]
and now up is empa-kidney #aha22 in main 1 please submit questions on the aha conferences app  .####[([4],[1, 2, 10, 11],'NEU')]
congratulations to presenting an #aha2022 #lbct: PROGRESSIVE-AF demonstrating better outcomes for paf patients randomized to first-line ablation vs anti arrhythmic drugs-published in  .####[([6],[0, 2, 7, 8, 9],'POS')]
 very satisfying to see that the precision strategy - including the PROMISE minimal risk tool, derived as a fellow at and forming the basis of my mhs thesis - improved outcomes vs usual care among stable chest pain patients. #aha2022 .####[([11],[0, 1, 3, 6, 29, 30],'POS')]
treatment with the investigational crispr-attr gene-editing therapy, ntla-2001, led to rapid responses in patients with transthyretin amyloidosis with cardiomyopathy, interim phase 1 results show. #aha22 #cardiotwitter  .####[([4],[8, 10],'NEU')]
strong-hf: probably for the first time, we could show that patients with a preserved ejection fraction have very 'POS' benefits from high-intensity care, mebazaa said. #aha22 #cardiotwitter  .####[([0],[4, 5, 8, 16, 17, 18],'POS')]
extracorporeal membrane oxygenation in the therapy of cardiogenic shock: results of the ecmo-cs randomized clinical trial  .####[([12],[6, 9, 10],'NEU')]
transform-hf in term of mortality in hf! the big headline: 26% mortality hf pts in ~1.5yr regardless of all the gdmt! #aha22 #transformhf22  .####[([0],[8, 9],'NEU')]
APOLLO :silence had the opportunity to connect with inspiring people at #aha22 and discuss how we are developing a new generation of medicines harnessing the bodys natural process of rnai. learn more about our precision engineered medicines here: #silenceisgolden  .####[([0],[6, 8, 13, 17, 30, 31],'NEU')]
NOVA: botulinum toxin did not prevent 'POS'toperative #afib in patients undergoing cardiac surgery vs placebo, according to findings from a phase 2 study. #aha22 #cardiotwitter  .####[([0],[4, 5, 6, 7, 10, 11],'NEG')]
in coach, of found that people with acute hf had improved outcomes when ed clinicians were provided a point-of-care decision support tool. called coach a winning trial that is "cause for celebration." #aha22 .####[([1, 23],[3, 10, 11, 25, 26],'POS')]
#aha22 2022 hf guidelines - prompt-hf recognized as a viable strategy of gdmt uptitration  .####[([5],[6, 9, 10],'NEU')]
1/x i awoke today to multiple messages asking me for my take on the sport ("supplements, placebo, or rosuvastatin study") study presented at #aha2022. my take - sterol and red yeast rice arms have issues around underpowering, small dosage size, and lack of supplement testing. .####[([14],[29, 30, 31, 32, 33, 34, 37, 38, 39, 41, 43, 44],'NEU')]
add data about TWILIGHT #sapt #p2y12i #aha22  .####[([3],[0, 1, 2],'NEU')]
my pi, dr. gregory piazza, presenting the results of our prevent-hd trial as a lbct at #aha22 ! our research group enrolled 628 patients out of 1284 across several us centers!  .####[([10],[5, 7, 8, 24],'NEU')]
while nephrologists busy @ #kidneywk this was presented in chicago #aha22. transform-hf trial. #torsemide vs. #furosemide no difference in 'POS't #chf hospitalization. 26% mortality in 17 months sobering!  .####[([10],[15, 16, 18, 20],'NEU')]
 CRISPR-ATTR technology in vivo trial successfully reduced circulating ttr. game changer #aha22 .####[([0],[5, 6, 9, 10],'POS')]
RESPECT-EPA: amarin highlights key data presented at american heart association 2022 scientific sessions for.. .####[([0],[2, 3, 4, 5],'NEU')]
pro-hf - another example of the critical importance and utility of the ehr in clinical data collection implementing modern clinical interventions #aha22 . kccq as an ehr "vital sign"  .####[([0],[14, 17, 18, 19, 20],'NEU')]
impressive and robust results favoring surgery &gt; endo: 10% arr and 32% rrr for death+male at 2.7 years for clti patients with available ssgsv - no meaningful difference in qol. the effect size is enormous! best-cli #aha2022  .####[([35],[0, 2, 4],'POS')]
#aha22 ISCHEMIA-extend invasive th rapie non better than conservative at 5,7y less cv death more non cv death. the same higher when multi cv desease  .####[([1],[5, 6, 8, 16],'NEG')]
no difference between #torsemide versus #furosemide in reduction of primary or secondary endpoints in the transform-hf trial #aha22  .####[([15],[0, 1],'NEU')]
#aha22 dcp chlorthalidone not better than hydrochlorothiazide on hta  .####[([1],[3, 4],'NEG')]
 olpasiran statistically significantly decreased concentrations of lp(a) with better tolerability but what does that mean for cardiovascular outcomes? #aha2022 #cardiotwitter  .####[([0],[1, 2, 3, 8, 9],'POS')]
 taking the stage at #aha2022 #latebreakingtrials in response to RESPECT-EPA we need more mechanistic and clinical data, ie. those with elevated hscrp or highest delta epa, to determine who will benefit from dual statin and epa therapy #wic  .####[([9],[11, 12, 13, 16],'NEU')]
*scrolling twitter* me: .why is ECMO-CS trending? also me: oh yeah it s #aha22 #phew .####[([5],[0, 1, 6],'NEU')]
design and rationale of a phase 2 study of 'NEU'rotoxin (botulinum toxin type a) for the prevention of 'POS't-operative atrial fibrillation - the NOVA study. #aha22 #cardiotwitter lbs.08. mon nov 7, 11am-noon  .####[([23],[0, 2, 16],'NEU')]
daily rosuvastatin lowered ldl, total cholesterol and serum triglycerides more than placebo and six common over-the-counter dietary supplements, with no supplement lowering ldl more than placebo #aha22 #cardiotwitter  .####[([1],[2],'POS')]
ischemia-extend: no difference in all-cause death in invasive vs conservative groups at 5.7 yrs. cv death higher in conservative, non-cv death higher in invasive. #aha22 #cardiotwitter #cardiology  .####[([0],[1, 2, 4],'NEU')]
early results from ischemia-extend continue to support personalized decision-making between physicians and patients with #heartdisease: #aha2022 #cardiotwitter  .####[([3],[4, 5, 6],'NEU')]
 all patients recieved 3 days of acetazolamide or placebo. thereafter they were free to do whatever the treating physician s found best for their patients. .####[([6],[2, 9, 12, 13, 14],'NEU')]
 we don t have data on what happened with the diuretics after the treatment period. its effect theoretically deminishes over time due to acidosis. but significant acidosis didn t happen in advor. you can use it longer as long as you monitor acid base and electrolytes. .####[([31],[17, 18, 25, 29],'NEU')]
new standard for #heartfailure treatment set by and team: early and fast uptitration of #gdmtworks is feasible, safe and improves outcomes in strong-hf. presented today at #aha22 and simultaneously published in :  .####[([22],[17, 19, 20, 23],'POS')]
p. gabriel steg: BRIGHT-4 is a clear, unambiguous win for bivalirudin at 30 days in stemi pci #aha22 #cardiotwitter #cardiology  .####[([3],[6, 7, 8],'POS')]
"ecmo-cs was a great, hard-to-do study. the researchers are congratulated for pulling this off in this very high-risk patient group," said acc vp dr. about the #aha22 late-breaking trial. read more from :  .####[([0],[3, 9, 11],'POS')]
BRIGHT-4: bivalirudin superior to heparin for 30-day death/major bleeding in stemi pci #aha22 #cardiotwitter #cardiology  .####[([0],[2],'POS')]
interesting data from the CTS-AMI study re: a traditional chinese medicine that may improve outcomes in #stemi pts: more on #tongxinluo #txl, in potentially reducing myocardial no-reflow &amp; reperfusion injury in pts with ami. #cardiotwitter #aha22 #accfit  .####[([4],[0, 13, 14, 23, 24],'POS')]
more data from our advor trial showing acetazolamide added to loop diuretics is beneficial across the full range of lvef. results presented today at #aha22 by . very proud of our team! (1/2)  .####[([4],[13, 20, 21, 26, 27],'POS')]
solid long term results for i.v. iron supplementation in hfref: results from the ironman trial presented at #aha22  .####[([13],[0, 1, 2, 3, 10],'NEU')]
cutting edge science at #aha22 - High safety and effectiveness received  in-human gene editing treatment for CRISPR-ATTR  .####[([16],[6, 7, 9],'POS')]
our 'POS'ter presentation of new aric study suggesting chest pain and dyspnea (even mild stages) were significantly associated w/ subsequent risk of #cvd in long-term f/u (&gt;30 yrs) #aha22 #cvcad #heartfailure #afib  .####[([5],[1, 2, 7, 9, 16, 17, 20],'NEG')]
at #aha22: the longer-acting loop diuretic torsemide does not improve 1y-mortality in comparison with furosemide and when given at discharge after hf hospitalization. huge shout out to and team for conducting this fantastic pragmatic trial!  .####[([6],[8, 9],'POS'), ([14],[8, 9, 12, 13],'NEG')]
no difference in all-cause death (5.7 yes) between initial invasive tx and conservative tx in chronic cad pts w/ mod-severe ischemia, but significantly lower cv death and higher non-cv death in invasive tx group #aha22 ischemia-extend #latebreaking  .####[([35],[4, 22, 23, 25, 29],'POS')]
congrats successful presentation of new aric study pro'POS'ing new prediction model including socioeconomic status for the incidence of #heartfailure #aha22  .####[([5],[0, 1, 2, 4, 7, 8, 10],'NEU')]
 this is great! i ve read of several different recommendations in the past for advor .Are there any guideline recommendations? or expert consensus? .####[([14],[2, 5, 7, 9, 19],'NEU')]
congrats successful presentation of new aric study assessing the association of earlier physical activity index w/ patient prognosis after the incident myocardial infection at #aha22  .####[([5],[0, 1, 2],'POS')]
COACH: implementation of this approach may lead to a pathway for early discharge from the hospital or emergency department and improved patient outcomes, #cardiotwitter #aha22  .####[([0],[20, 21, 22],'POS')]
no significant difference in the incidence of com'POS'ite cvd outcomes between pemafibrate and placebo in pts with dm, htg and low hdl. warning renal adverse outcome &amp; venous thrombosis. #aha22 #latebreaking prominent #nejm  .####[([31],[0, 1, 2, 3, 7, 9, 14, 22, 24, 25],'NEG')]
dr. siddharth patel presents his 'POS'ter efficacy and safety of noacs vs warfarin across the continuous range of body mass index and body weight: insights from COMBINE-af, tomorrow :45pm ct, zone 4, science &amp; technology hall, level 3, board 4079 #aha22  .####[([26],[3, 5, 6, 8],'NEU')]
free to read online during #aha22, from : alerting clinicians to 1-year mortality risk in patients hospitalized with heart failure: the REVEAL-HF randomized clinical trial  .####[([20],[1, 7, 8, 9],'NEG')]
no difference at 2 years for blood pressure control when comparing use of chlorthalidone vs hydrochlorothiazide. #aha #aha22  .####[([13],[0, 1, 9, 10],'NEU'), ([15],[0, 1, 9, 10],'NEU')]
no difference in use of torsemide vs furosemide strategy for 'POS't discharge diuretics pharmaceutical treatment after heat failure hospitalization. #aha #aha22 .####[([5],[0, 1, 2, 3],'NEU'), ([7],[0, 1, 2, 3],'NEU')]
ecmo-cs trial: immediate implementation of va-ecmo in patients with rapidly deteriorating or severe cardiogenic shock did not improve clinical outcomes compared with an early conservative strategy. #aha22  .####[([0],[12, 13, 14, 16, 17, 18, 19],'NEG')]
early use of ecmo-cs devices did not improve outcomes in people with cardiogenic shock #aha22  .####[([3],[6, 7, 8],'NEG')]
sustained, &gt;90% reduction of ttr by CRISPR-ATTR w no severe aes, promising first-in-human data! #cardiotwitter #aha22  .####[([6],[2, 8, 9, 11, 12],'POS')]
torsemide = furosemide as per transform-hf, but benefits in ckd patients? will this alter practice? #aha22  .####[([4],[6, 7, 10, 11, 12],'NEU')]
#aha22 lbcts one liners: 1. transform-hf: torsemide was not superior to furosemide in improving survival among patients treated for decompensated hf. 2. dcp: no differences in cardiovascular outcomes between chlorthalidone and hctz among elderly veterans with htn. .####[([5],[8, 9, 12, 13, 14, 25],'NEG'), ([22],[23, 27],'NEU')]
best-cli: the results are in and they re likely practice-altering actagainstamputation #aha22  .####[([0],[2, 3, 8],'NEU')]
yesterday at #aha22, curtis rambaran, silence vp clinical sciences, presented at a 'POS'ter session about a new analysis of our drug candidate APOLLO to potentially treat high levels of lipoprotein(a) or #lpa. if you missed it, see the analysis: #silenceisgolden  .####[([22],[9, 12, 13],'NEU')]
excellent to see strong-hf presented at #aha22 with improved outcomes of more intensive gdmt care. shout out to our amazing hfbc team that facilities our team at hopkins implementing this type of strategy already!  .####[([3],[0, 8, 9, 11, 12],'POS')]
it was a pleasure to meet at #lbct morning session and discuss the results of the strong-hf trial. truly a game changing trial, showing the huge benefits of rapid up-titration of gdmt in #hf .####[([16],[23, 25, 26],'POS')]
EARLY-AF data supports af ablation as 1st line therapy: significantly lower progression to persistent af significant smaller af burden improvement in qol and symptoms lower rates in healthcare utilization significant reduction in any arrhythmias recurrence #aha22  .####[([0],[9, 10, 11, 23, 24, 25],'POS')]
the results of the COACH trial presented by the utility of a clinical risk stratification algorithm and outpatient follow up for hf-patients presenting to the ed #aha22  .####[([4],[1, 6],'NEU')]
the first late-breaking session is about to begin, many clinical practice changing trials will be presented. transform-hf is the first one on the list #aha22  .####[([16],[5, 6, 7],'NEU')]
the results of the ironman trial have been now revealed. iv ferric derisomaltose (fdi) in heart failure #aha22  .####[([4],[1, 8, 9],'NEU')]
$cinc cincor pharma announces late-breaking presentation of phase 2 BrigHTN data on baxdrostat in treatment-resistant hypertension at the 2022 american heart association scientific sessions  .####[([9],[3, 4, 5],'NEU')]
$cinc cincor pharma announces late-breaking presentation of phase 2 BrigHTN data on baxdrostat in treatment-resistant hypertension at the 2022 american heart association scientific sessions .####[([9],[3, 4, 5],'NEU')]
$cinc cincor pharma announces late-breaking presentation of phase 2 BrigHTN data on baxdrostat in treatment-resistant hypertension at the 2022 american heart association scientific sessions  .####[([9],[3, 4, 5],'NEU')]
our stop team under mentoship!. more is coming to the #yescct and plaque quantification field. #aha22  .####[([1],[5, 7, 13],'NEU')]
novartis presents new data at #aha22 showing long-term sustained efficacy over a 4-year study, ORION-3 of ldl-c lowering treatment. #novartisnews .####[([14],[1, 2, 3],'NEU')]
 will need full force strategy outpatient with innovative digital strategies telehealth and cohesive mid-level app team. if you want to be ..need strength in numbers, strong-hf .####[([25],[4, 5],'NEU')]
 not surprising at all considering upto 65-80% of na reabsorbed in proximal tubule in advor. understanding pathophysiology=desirable outcomes! .####[([14],[0, 1, 17],'NEU')]
intellia presents updated interim data from the cardiomyopathy arm of ongoing phase 1 study  of ntla-2001, CRISPR-ATTR an investigational crispr therapy for the treatment of transthyretin (attr) amyloidosis at the american heart association scientific sessions 2022  .####[([16],[1, 2, 3, 4, 10],'NEU')]
radcliffe &amp; cardionerds : empa-kidney: empagliflozin &amp; cv outcomes... via  .####[([3],[7],'NEU'), ([4],[7],'NEU')]
icymi: tongxinluo in CTS-AMI trial, a traditional chinese medicine, significantly improved both 30-day and 1-year clinical outcomes in chinese patients with stemi, especially reducing cardiac death and severe complications, #aha22 #cardiotwitter  .####[([3],[9, 10, 23, 24, 25],'POS'), ([1],[9, 10, 23, 24, 25],'POS')]
silence therapeutics presents new analysis from sln360 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting  .####[([6],[2, 3, 4],'NEU')]
final results from phase 2 INSTANT trial of inrhythm for the treatment of newly diagnosed and recurrent paroxysmal atrial fibrillation presented at 2022 american heart association scientific sessions  .####[([5],[0, 1, 20],'NEU')]
routine early, expeditious use of ecmo is a common strategy in patients with severe cardiogenic shock, but a less aggressive initial approach may be just as effective, a randomized trial ecmo-cs suggests. #aha22 #cardiotwitter  .####[([30],[28, 29],'NEU')]
$cytk news screener alert: the price is down after the recent publication of GALACTIC-HF 'POS'ted about 7 hours ago . #stocksoftheday #stockalert #stocknews #heart #newclinicaltrialdata  .####[([13],[10, 11, 14],'NEU')]
hls therapeutics highlights key data on the late breaking RESPECT-EPA study presented at the american heart associat  .####[([9],[2, 3, 4, 11],'NEU')]
in this healio exclusive, b. hadley wilson, md, facc, provides his perspective on several late-breaking clinical trials presented at the #aha22 #cardiotwitter, BRIGHT-4, OPTION, ISCHEMIA-extend, ECMO-CS .####[([22],[9, 11, 17],'NEU'), ([23],[9, 11, 17],'NEU'), ([24],[9, 11, 17],'NEU'), ([25],[9, 11, 17],'NEU')]
 were you aware: - sport was powered to detect a 15% decrease in ldl whereas the dose of plant sterols used could only be expected to decrease ldl by 6%? - sport did not test for the monacolin k level of the red yeast rice they used, contrary to recent practice? .####[([4, 31],[33, 34],'NEU')]
#other #lifesciences #somewhatbullish $amrn $hltrf 2022/11/08 00:30 hls therapeutics highlights RESPECT-EPA study data .. .####[([10],[9, 12],'NEU')]
ironman with the bayesian approach and longitudinal ordinal analysis would provide better power and be easier to interpret clinically. forcing a "dichotomous" decision within a null-hypothesis-testing framework with cis 0,66 - 1,02 does not serve us well.. .####[([0],[10, 11, 15],'POS')]
$amrn hls therapeutics highlights key data on the late breaking RESPECT-EPA respect-epa study presented at the american heart association see this insight 45 seconds early at  .####[([10, 11],[3, 4, 5, 13],'NEU')]
ironman: rr 0.82 (0.66-1.02) p=0.07* -27.5% vs. 22% com'POS'ite endpoint -cv death: 21% vs. 24% (p=0.23) *covid sensitivity analysis (march, 2020) for 1 endpoints resulted in rr 0.76, p&lt;0.05 .####[([0],[23, 24],'NEU')]
congratulations! best-cli trial .####[([1],[0],'NEU')]
breaking session strong-hf! #aha22  .####[([2],[0, 1],'NEU')]
we look forward to #aha22 where dr ray will share new clinical data and findings from the 4-year long-term safety and efficacy extension study, orion-3. please join the presentation session on monday, november 7th from 3:00-4:00pm ct at main event iii  .####[([24],[9, 10, 11, 12, 14],'NEU')]
we look forward to #aha22 where dr ray will share new clinical data and findings from the 4-year long-term safety and efficacy extension study, orion-3. please join the presentation session on monday, november 7th from 3:00-4:00pm ct at main event iii  .####[([24],[9, 10, 11, 12, 14],'NEU')]
dr. g. piazza presents rivaroxaban to reduce the risk of major venous and arterial thrombotic events, hospitalization and death in medically ill outpatients with acute, symptomatic covid-19" (prevent-hd) trial: "routine antithrombotic prophylaxis .. not supported." #aha22  .####[([27],[3, 32, 33],'NEU'), ([4],[3, 6, 8],'POS')]
$amarin highlights key data from RESPECT-EPA trial presented at american heart association 2022 scientific sessions for vascepa /vazkepa (icosapent ethyl) and patient care .####[([5],[1, 2, 3, 7],'NEU'), ([16],[1, 2, 3, 7],'NEU')]
proud to be part of this landmark multi-center pragmatic clinical trial and the work represented at #aha22. don t miss the late-breaking science session that will discuss the clinical results and the quality-of-life analyses of the best-cli trial:  .####[([36],[0, 9, 13, 14, 28, 29],'NEU')]
watch and dicuss stress trial results at #aha2022 via  .####[([3],[5],'NEU')]
so we finally have corroboration of REDUCE-IT that everyone has been asking for. its all about the epa. and the mineral oil debate is finally put to rest. epa works .####[([6],[2, 11, 24],'NEU')]
amarin highlights key data from RESPECT-EPA trial presented at american heart association 2022 scientific sessions for vascepa /vazkepa and patient care $amrn  .####[([5],[1, 2, 3, 7],'NEU'), ([16],[1, 2, 3, 7],'NEU')]
$amrn - amarin highlights key data of RESPECT-EPA presented at american heart association 2022 scientific sessions for  .####[([7],[3, 4, 5, 8],'NEU')]
$amrn amarin highlights key data of RESPECT-EPA presented at american heart association 2022 scientific sessions for vascepa /vazkepa (icosapent ethyl) and patient care  .####[([6],[2, 3, 4, 7],'NEU'), ([16],[2, 3, 4, 7],'NEU')]
$amrn amarin highlights key data of RESPECT-EPA presented at american heart association 2022 scientific sessions for vascepa /vazkepa (icosapent ethyl) and patient care stock news alerts in bio .####[([6],[2, 3, 4, 7],'NEU'), ([16],[2, 3, 4, 7],'NEU')]
$amrn amarin highlights key data of RESPECT-EPA presented at american heart association 2022 scientific sessions for vascepa /vazkepa (icosapent ethyl) and patient care  .####[([6],[2, 3, 4, 7],'NEU'), ([16],[2, 3, 4, 7],'NEU')]
$cytk new article : cytokinetics presents new data GALACTIC-HF at the american heart association scientific sessions 2022 get all the latest $cytk related news here :  .####[([7],[1, 4, 5, 6, 14],'NEU')]
$cytk [15s. delayed]: issued press release on november 07, 07:30:00: cytokinetics presents new data at the american heart association scientific sessions 2022 of GALACTIC-HF .####[([23],[4, 5, 11, 12, 13],'NEU')]
$cytk 2022-11-07 07:30 et cytokinetics presents new data for GALACTIC-HF at the american heart association scientific sessions 2022 cytokinetics, incorporated  .####[([9],[5, 6, 7, 16],'NEU')]
$cytk cytokinetics presents new data for GALACTIC-HF at the american heart association scientific sessions 2022  .####[([6],[2, 3, 4, 13],'NEU')]
cytokinetics presents new data for GALACTIC-HF at the american heart association scientific sessions 2022 $cytk  .####[([5],[1, 2, 3, 12],'NEU')]
$cytk cytokinetics presents new data for GALACTIC-HF at the american heart association scientific sessions 2022 stock news alerts in bio .####[([6],[2, 3, 4, 13],'NEU')]
icymi: researchers reported no significant difference between an immediate veno-arterial ecmo compared with a conservative strategy for the primary com'POS'ite endpoint for ecmo-cs & cts-ami #aha22 #cardiotwitter  .####[([22],[3, 4, 20],'NEU'), ([23],[3, 4, 20],'NEU')]
silence therapeutics $sln presents new analysis from sln360 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting -  .####[([7],[3, 4, 5],'NEU')]
ISCHEMIA-extend aha22 survival after invasive or conservative management of stable coronary disease  .####[([0],[2, 6, 7],'NEU')]
impressed by the results of CRISPR-ATTR in-vivo #crispr #geneediting in patients with attr cardiac #amyloidosis corroborating previous results from patients with attr poly'NEU'ropathy. congratulations to julian gillmore et al #aha22 #cardiogenetics  .####[([5],[0, 3, 17, 23],'POS')]
torsemide is similar in efficacy to furosemide in reducing all cause mortality, hf-related and total hospitalization in chf patients- transform-hf trial #aha22 .####[([19],[2, 4],'NEU'), ([0],[2, 4],'NEU'), ([6],[2, 4],'NEU')]
 the same was in the AFFIRM-AHF trial. the lower number of events in the i.v. iron group with a p-value slightly higher than 0.05 and statistically significant result in pre-covid analysis  .####[([5],[1, 25, 26],'NEU')]
 for this one or REDUCE-IT presentation .####[([4],[5],'NEU')]
$sln silence therapeutics plc presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association 2022 annual meeting | marketscreener  .####[([8],[4, 5, 6],'NEU')]
innovent releases results of a phase 3 clinical study CREDIT-1 of tafolecimab ibi306 in chinese patients with non- famili  .####[([9],[0, 1, 2],'NEU'), ([11],[0, 1, 2],'NEU')]
innovent releases results of a phase 3 clinical study CREDIT-1 of tafolecimab ibi306 in chinese patients with non- familial hypercholesterolemia at the american heart association (aha) scirntific sessions 2022  .####[([9],[0, 1, 2],'NEU'), ([11],[0, 1, 2],'NEU')]
$ivbiy innovent releases results of a phase 3 clinical study CREDIT-1 of tafolecimab ibi306 in chinese patients with non- familial hypercholesterolemia at the american heart association (aha) scirntific ses.. .####[([10],[1, 2, 3],'NEU'), ([12],[1, 2, 3],'NEU')]
innovent releases results of a phase 3 clinical study CREDIT-1 of tafolecimab ibi306 in chinese patients with non- familial hypercholesterolemia at the american heart.. $ivbiy  .####[([9],[0, 1, 2],'NEU'), ([11],[0, 1, 2],'NEU')]
ron blankstein: PRECISE important because reducing unnecessary caths is meaningful to pts. at 1 yr we would not expect to see death/mi differences in a low-risk group #aha22 #cardiotwitter  .####[([2],[5, 6, 17, 18],'NEU')]
option: dapt with indobufen and clopidogrel was noninferior to dapt with aspirin and clopidogrel after pci #aha22 #cardiotwitter #cardiology  .####[([1, 9],[7],'POS'), ([3],[7],'POS'), ([5, 13],[7],'POS')]
new analysis of soloist-whf results demonstrates sotagliflozin s significant effect in reducing the risk of hospital readmissions for heart failure. to view the full press release, visit our website: #aha22  .####[([3],[8, 11, 13],'POS'), ([6],[8, 11, 13],'POS')]
check out our teams abstracts at #aha22 1) differential efficacy of mras in #afib 2) #alcohol &amp; cv outcomes in patients with #afib; re-ly af registry  .####[([23],[0, 8, 9],'NEU')]
 so, acetazolamide x 48 hours then followed by loop diuretics or thiazides as maintenance at discharge? .####[([1],[5, 6, 13],'NEU')]
 respectfully, your generation has destroyed medicine by claiming midlevels can play doctor. these patients are the sickest of the sick and deserve a cardiologist. full stop. patient s first.strong-hf .####[([28],[0, 4, 21],'NEU')]
transform-hf #aha2022 'POS't-discharge management with torsemide was not superior to furosemide. all-cause mortality was similar between treatment groups. either furosemide or torsemide are acceptable options for diuresis among patients with heart failure .####[([0],[7, 8, 23],'NEU'), ([5, 21],[7, 8, 23],'NEU'), ([10, 19],[7, 8, 23],'NEU')]
 COACH trial use of a hospital-based strategy to support clinical decision making and rapid fu led to a risk of the com'POS'ite of death from any cause or hospitalization for cv causes within 30 days than usual care. #aha22  .####[([0],[13, 18, 21, 23],'NEG')]
hot off the press, check out these trials from #aha22 transform-hf dcp prominent ironman #cardiotwitter #medtwitter accs full coverage of the latest science from american heart associations (aha) scientific sessions 2022  .####[([10],[3, 4, 7],'NEU'), ([11],[3, 4, 7],'NEU'), ([12],[3, 4, 7],'NEU'), ([13],[3, 4, 7],'NEU')]
does tongxinluo, a chinese herbal medicine, offer benefit in stemi patients? interesting finding in the CTS-AMI trial presented at #aha22 suggest major benefit. what is the working mechanism? and... can we make it vegan? lets dive into this paper once it is published .####[([15],[12, 17, 42],'NEU')]
in this #rct ecmo-cs immediate implementation of va-ecmo in patients with cardiogenic shock did not improve clinical outcomes compared with an early conservative strategy which allowed downstream use of... #circaha22 #ahajournals #medtwitter #cardiotwitter  .####[([3],[14, 15, 16, 17],'NEG')]
 ecmo-cs trial immediate ecmo no-early ecmo 39% of pts need ecmo in no-early ecmo primary endpoints werent significantly different. #ecmo  .####[([0],[2, 15, 17, 18],'NEU')]
 excited to see results of PRECISION! .####[([5],[0, 3],'NEU')]
icymi: researchers reported no significant difference between an immediate veno-arterial ecmo compared with a conservative strategy for the primary com'POS'ite endpoint for study ecmo-cs #aha22 #cardiotwitter  .####[([23],[2, 3, 4, 5, 8, 20],'NEU')]
 implausibly large effect of tongxinluo txl in CTS-AMI? =&gt; needs verification. .####[([7],[9, 10],'NEU'), ([4],[9, 10],'NEU')]
early va-ecmo in adults in ecmo-cs trial with rapidly deteriorating or severe cardiogenic shock was not associated with improved clinical outcomes compared with a conservative approach. #aha22  .####[([5],[15, 16, 18, 20],'NEG')]
congratulations to on his presentation of the COACH ! sadly missing #aha2022  .####[([7],[0],'NEU')]
in infants undergoing heart surgery with cardiopulmonary bypass, the use of the steroid methylprednisolone did not reduce odds of a worse outcome compared with placebo, according to the stress trial #cardiotwitter  .####[([28],[15, 16, 20, 21],'NEG')]
ecmo-cs trial with interesting results #aha2022 .####[([0],[3, 4],'NEU')]
first in-human in vivo CRISPR-ATTR editing of the ttr gene in patients with #attr amyloidosis! presented by julian gillmore at #aha22!  .####[([4],[0, 1, 15],'NEU')]
 its an honour to be part of the team and work with such an amazing group of eps on EARLY-AF! .####[([19],[2, 10, 15],'NEU')]
 fantastic update on CRISPR-ATTR!! .####[([3],[0, 1],'NEU')]
fascinating: today, #aha22 ischemia-extend .####[([3],[0],'NEU')]
soon, #aha22: 15-yr rapco results. on the heels of the 17.7yrs va study on radial conduits in cabg .####[([3],[0, 4],'NEU')]
silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting  .####[([6],[2, 3, 4],'NEU')]
intellia presents updated interim data from the cardiomyopathy arm of ongoing phase 1 study  CRISPR-ATTR of ntla-2001, an investigational crispr therapy for the treatment of transthyretin (attr) amyloidosis at the american heart association scientific sessions 2022  .####[([14],[1, 2, 3, 4],'NEU')]
intellia presents updated interim data from the cardiomyopathy arm of ongoing phase 1 study CRISPR-ATTR of ntla-2001, an investigational crispr therapy for the treatment of transthyretin (attr) amyloidosis at the american heart association scientific sessions 2022  .####[([14],[1, 2, 3, 4],'NEU')]
intellia presents updated interim data from the cardiomyopathy arm of ongoing phase 1 study CRISPR-ATTR of ntla-2001, an investigational crispr therapy for the treatment of transthyretin (attr) amyloidosis at the american heart association scientific sessions 2022  .####[([14],[1, 2, 3, 4],'NEU')]
 did results account for different pharmacokinetics? i.e., were patients who ended up taking furosemide with meals excluded from analysis, or was it not even feasible to account for this? were furosemide qday vs bid considered in the comparison? very fascinating considerations for transform-hf! .####[([42],[34, 39],'NEU'), ([13, 30],[34, 39],'NEU')]
 similar to the high mortality seen in transform-hf, the results are eye-opening in other ways.. all cause mortality 20% after just 2.7 years. acei/arb/arni+bb+mra use was subpar. only 3% sglt2i. another thought: slightly more optimal baseline gdmt in fe group skewed results? .####[([7],[9, 11, 13, 14, 41],'NEU')]
new late-breaking data from #aha22 show ntla-2001, a novel CRISPR-ATTR based gene editing therapy, significantly reduced abnormal transthyretin protein levels in patients with attr amyloid cardiomyopathy .####[([9],[14, 15, 16],'POS')]
super informative and motivating meeting #aha22 great late-breaking science BEST-CLI. great chance meeting my colleagues and mentors at #aha had so much fun presenting our research work #aha22 #bu_vascular_medicine  .####[([9],[0, 1, 3, 7, 22, 23],'NEU')]
novel gene-editing therapy of CRISPR-ATTR shows promise for patients with transthyretin amyloid cardiomyopathy #aha22  .####[([4],[0, 2, 5, 6],'POS')]
intellia presents updated interim data from the cardiomyopathy arm of ongoing phase 1 study, CRISPR-ATTR of ntla-2001, an investigational crispr therapy for the treatment of transthyretin (attr) amyloidosis at the american heart association scientific sessions 2022  .####[([14],[1, 2, 3, 4],'NEU')]
COACH: a two-phase intervention to guide admission vs. discharge reduced death and cv hospitalization in pts presenting to ed for #heartfailure #aha22 #cardiotwitter #cardiology  .####[([0],[9, 10, 13],'POS')]
after patients shared their experience with #heartfailure through a questionnaire, they felt physicians understood their condition better, according to early results from the pro-hf trial: #aha2022 #cardiotwitter  .####[([23],[19, 20],'NEU')]
intellia presents updated interim data from the cardiomyopathy arm of ongoing phase 1 study of CRISPR-ATTR, an investi  .####[([15],[1, 2, 3, 4],'NEU')]
silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting - 'NEU'ro central via brainsights for ios  .####[([6],[2, 3, 4],'NEU')]
silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting  .####[([6],[2, 3, 4],'NEU')]
silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting  .####[([6],[2, 3, 4],'NEU')]
silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting -  .####[([6],[2, 3, 4],'NEU')]
 how about this transform-hf presentation !!!!!!!  .####[([3],[0, 1, 4],'NEU')]
silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting  .####[([6],[2, 3, 4],'NEU')]
$sln reveals findings from early-stage study testing SLN360-001, an investigational short interfering ribonucleic acid in healthy adults with high lipoprotein(a) #silencetherapeutics #sirna #lpa #heartdisease #americanheartassociation #aha2022  .####[([7],[1, 2, 4],'NEU')]
free pmc: rationale and design of the steroids to reduce systemic inflammation after infant heart surgery STRESS trial. #aha22 #cardiotwitter lbs.03. sun nov 6, 8am-9am  .####[([16],[2, 4, 9, 11],'NEU')]
silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the ameri  .####[([6],[2, 3, 4],'NEU')]
congratulations drs. kalra for this exciting and important ironman study! #aha22 scientific sessions!  .####[([8],[0, 5, 7],'NEU')]
$sln silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting  .####[([7],[3, 4, 5],'NEU')]
$sln silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting  .####[([7],[3, 4, 5],'NEU')]
 if only there was a way to lower triglycerides and all other robust markers of cvd without taking meds, prominent trial. .####[([19],[7, 16, 17, 18],'NEU')]
#accpresident dr. gave his perspective on the recent dcp late-breaking trial from #aha22. "in the dcp trial, 45% of participants were from rural areas. thats important." :  .####[([8, 15],[2, 4, 9, 10, 16],'NEU')]
icymi: prominent trial, pemafibrate did not reduce cv event rates in patients with type 2 diabetes, mild to moderate hypertriglyceridemia, low hdl and well-controlled ldl cholesterol, #aha22 #cardiotwitter  .####[([3],[5, 6, 8, 9],'NEG'), ([1],[5, 6, 8, 9],'NEG')]
$sln - silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting  .####[([8],[4, 5, 6],'NEU')]
$sln new article : silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting get all the latest $sln related news here :  .####[([9],[1, 5, 6, 7],'NEU')]
-elevated lipid and lipoprotein levels were not associated with reduced coronary reactivity in prominent trial - in a stepwise regression model, oxldl (p = 0.03), homocysteine (p = 0.04) and triglycerides (p = 0.018) were significant predictors of cfr. .####[([13],[6, 7, 9, 10],'NEG')]
silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting  .####[([6],[2, 3, 4],'NEU')]
$sln [15s. delayed]: issued press release on november 05, 10:30:00: silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting  .####[([16],[4, 5, 12, 13, 14],'NEU')]
$silence therapeutics plc [15s. delayed]: issued press release on november 05, 10:30:00: silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting  .####[([18],[6, 7, 14, 15, 16],'NEU')]
$a - - silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting .####[([9],[5, 6, 7],'NEU')]
silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting  .####[([6],[2, 3, 4],'NEU')]
$sln silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting 45 seconds delayed. .####[([7],[3, 4, 5],'NEU')]
silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein at the american heart association 2022 annual meeting $sln  .####[([6],[2, 3, 4],'NEU')]
$sln silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting stock news alerts in bio .####[([7],[3, 4, 5],'NEU')]
$sln silence therapeutics presents new analysis from SLN360-001 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting  .####[([7],[3, 4, 5],'NEU')]
in #aha22s ironman, long-term iv iron supplementation was safe &amp; risk for recurrent hf hospitalizations. acc pres. said: "this trial is another in the puzzle to show us that iron replacement in hf pts is important."  .####[([2],[3, 6, 8],'POS')]
like if the manuscript rejected. just do not consist, just change the journal, transform-hf .####[([13],[0, 5, 9, 10],'NEU')]
icymi: mentz said clinical time should be spent ensuring patients with hf are prescribed the right dose for their loop diuretic and prioritizing therapies proven to improve clinical outcomes of transform-hf . #aha22  .####[([30],[3, 26, 27, 28],'NEU')]
 diuretics being symptomatic control this transform-hf trial result makes perfect sense. .####[([5],[6, 7],'NEU')]
data from the prominent trial at #aha22 indicate the incidence of cv events was not lower among patients who received pemafibrate than those who received placebo .####[([3],[7, 14, 15],'NEG'), ([20],[7, 14, 15],'NEG')]
while at #aha22, learn more about orion-3: our newly released, 4-year safety and efficacy study of leqvio .####[([6],[3, 8, 9],'NEU'), ([16],[3, 11, 13],'NEU')]
great to meet at #aha2022. congratulations on the successful coach trial and publication in nejm. happy to introduce this trial to the korean society of cardiology as a publication committee member .####[([9],[8, 15, 17],'POS')]
 esc tv on the road to #aha22, get the best of what was presented on transform-hf and ironman in a nutshell!  .####[([15],[13],'NEU')]
congrats and the pro-hf team at ! new #simpub #aha22: routine outpatient kccq collection improves clinician health status assessment what will it take for kccq to be a "vital sign" in hf care?  .####[([3],[0, 9, 10, 17],'NEU')]
while at #aha22, learn more about orion-3: our newly released, 4-year safety and efficacy study of leqvio .####[([6],[3, 4, 8, 9],'NEU')]
